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Model of fatigue and its relations based on the data of this study (significant effect with p < 0.05) (Figure 3a, chapter 7)
MAASTRICHT FATIGUE MODEL (MF MODEL)
active
everyday
social
support
age
marital
status
job
stage of
breast cancer
chemotherapy
regimen
*
hb
**
number of
chemotherapy
treatments
***
general
fatigue
physical
symptom
distress
psychological
symptom
distress
depression
F1
physical
distress
F2
psychological 
distress
alone more physcial distresswith job less physical distress
+ (1,2,3,4,5)+(1,2,3,4,5)
+ (4,5)
(4,5)
(1,2)
- (4)
- (1)
active
everyday
social
support
age
marital
status
job
stage of
breast cancer
chemotherapy
regimen
*
hb
**
number of
chemotherapy
treatments
***
general
fatigue
physical
symptom
distress
psychological
symptom
distress
depression
F1
physical
distress
F2
psychological 
distress
alone more physcial distresswith job less physical distress
+ (1,2,3,4,5)+(1,2,3,4,5)
+ (4,5)
(4,5)
(1,2)
- (4)
- (1)
alone more fatigue
with job less fatigue
-
0
0
0
0
0
+
§
+
+
 total effect (sum of indirect effects) of the variable on general fatigue
 relation on general fatigue found during adjuvant chemotherapy, 
   after completion of adjuvant chemotherapy no relationship is found 
 relation on general fatigue found after completion of adjuvant chemotherapy, 
   during adjuvant chemotherapy no relationship is found
 relation on general fatigue found in each measurement 
 relation on general fatigue found during as well as after adjuvant chemotherapy
 latent variable
 indicator and observed variable
 observed variable
§ relation on general fatigue is significant in the first and second measurement
+, -, 0 or text direction of relationship
* at the first measurement patients received their first treatment of adjuvant 
   chemotherapy and therefore this variable is not included in the first measurement
** the level of Hb was only obtained during adjuvant chemotherapy  
*** the variable ‘number of chemotherapy treatments’ was only measured after 
   completion of adjuvant chemotherapy
Model of fatigue and its relations based on the data of this study (significant effect with p < 0.05) (Figure 3b, chapter 7)
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INTRODUCTION
Cancer population
In the Netherlands, 28% of the people who died in 2003 died of cancer. Cancer
is the second most frequent cause of death after cardiovascular diseases [1].
Cancer occurs particularly in elderly people. At diagnosis two-thirds of all new
cancer patients are older than 60 years [2].
In the future, not only the proportional increase of the ageing population
will increase the demand for health care in cancer patients, but so will the
better survival of cancer patients. The five-year survival in male and female
cancer patients increased from 30% and 45% in the seventies to 45% and 60%
respectively in 2001 [2]. Other reasons for an increase in the number of persons
with the diagnosis ‘cancer’ are earlier diagnosis and screening as well as
improved treatments for patients [2]. 
Since the early 1990s breast cancer has been the most frequently
occurring malignancy in women in the Netherlands. Yearly, a third of all new
female cancer patients (11,000) suffer from breast cancer and about 3500
women die because of it. Because of the growth of the elderly population, the
incidence rate of breast cancer patients is expected to be 17,000 in 2015 [2].
Most breast cancers (90%) are operable. Sixty percent of patients with operable
breast cancer receive a type of adjuvant therapy. More than half of these
patients receive adjuvant chemotherapy. Adjuvant chemotherapy is then part of
the standard treatment in a large subset of breast cancer patients [2]. 
Cancer-related fatigue 
Fatigue is a major concern in patients with cancer [3]. The National Comprehensive
Cancer Network (NCCN) reported that fatigue affects 70% to 100% of patients with
cancer [4]. Everyone experiences fatigue on a daily basis. Although fatigue is
normally relieved by a good night’s sleep, this is often not the case for patients
with cancer, for whom it may become a chronic and unpleasant sensation [5].
Cancer-related fatigue is different from typical fatigue of everyday life. It is more
rapid in onset, more energy draining, more intense, more severe, more
unrelenting and it lasts longer [6]. Little is known about fatigue, despite the high
prevalence and its profoundly negative effect on patients’ quality of life [7].
Fatigue is a multicausal, multidimensional and complex concept [8-10], and it is
difficult to define or describe [9, 11-13]. The definition used in this dissertation
is that of the National Comprehensive Cancer Network (NCCN). The NCCN
convened a panel of experts in the field of fatigue, who defined cancer-related
fatigue as ‘a distressing, persistent, subjective sense of tiredness or exhaustion
9
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related to cancer or cancer treatment that is not proportional to recent activity
and interferes with usual functioning’ [4] (p. MS-2). Important characteristics of
cancer-related fatigue in the NCCN definition are the subjectivity of the sensation
and the interference with usual functioning [7]. 
Factors related to fatigue
Although fatigue can be a symptom of the disease itself, it can also be expected
to accompany cancer treatment [14]. Patients with cancer who are receiving
chemotherapy may experience a variety of side effects such as pain, nausea,
vomiting, hair loss, weight changes, fatigue, and anxiety, with fatigue being one
of the most commonly reported side-effects [7]. A common perception is that
more chemotherapy treatments lead to greater fatigue. Results from several
studies [15-17], however, vary in this respect. Between two cycles of adjuvant
chemotherapy the experience of fatigue is fluctuating [18]. After completion of
chemotherapy fatigue is still experienced [19-22]. It is not known when, after
completion of chemotherapy, the fatigue can be regarded as normal fatigue.
There is no clear overview in the literature of the intensity of fatigue in breast
cancer patients throughout chemotherapy treatment cycles, between two cycles
of chemotherapy and after completion of chemotherapy. 
Not only treatment factors are expected to influence fatigue. The actual
mechanisms that produce fatigue are unknown [5, 23]. The most reasonable
approach is to consider multiple factors [24]. There is evidence that age, a
demographic factor, influences the experience of fatigue [25]. In the literature,
anemia, a disease/physical factor, has been characterized as a major contributor
to fatigue [26, 27]. Physical symptom distress, such as pain, influences fatigue
too [19, 22, 28]. That fatigue and depression are related is beyond doubt, but the
interpretation of this relation is, however, complicated [29]. The symptoms of
fatigue and depression may overlap. In addition, fatigue is one of the key
symptoms of depression and may be the result of depressed mood. It is not clear
whether psychological symptom distress cause fatigue or vice versa. Nowadays,
the importance of social relationships and social support for an individual’s well-
being is common knowledge. Social support is expected to have buffer effects,
which means that social support protects people from the deleterious effects of
stress [30]. The author of an early study [31] had already reported that the
uncertainties and fears experienced by a person diagnosed with cancer are likely
to result in an enhanced need for social support. Komproe et al. [30] reported
that many researchers have underlined the relationship between social support
and physical and psychological well-being. Coping also seems an important
factor. McHaffie [32] reported that how well a person copes is central in
10
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determining his or her well-being, no matter how ill he or she is. The daily lives
of almost every individual are filled with stressful experiences which require some
form of coping. The impact of each varies, because people switch between their
many roles and because these roles are changing [32]. Individuals with cancer
must deal with the treatment process and its side-effects, as well as the
uncertainty of the disease course. They must adapt to the changes in physical
functioning and other negative life changes that are inevitably imposed by the
disease [33]. Distinct coping behaviours and thought can influence outcomes
[34], such as fatigue. 
Figure 1 presents an expected simplified model of fatigue and its related
factors, the research model. 
11
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Variables
Fatigue
Intensity of fatigue (I)
Intensity of fatigue (II)
Interference of fatigue with activities in daily living
Treatment factors
Type of chemotherapy
Type of surgery
Radiotherapy
Having radiotherapy at the measurement point
Number of days of radiotherapy the patients had had at the time of measurement
Number of days between the last day of radiotherapy and the time of measurement
Time aspect
Number of days between the operation and the first treatment of chemotherapy
Number of treatments at each measurement point
Demographic factors
Age (in years)
Marital status
Having children
Education
Having a job
Disease/physical factors
Stage of breast cancer
Hemoglobin level (measured in mmol/l)
Physical symptom distress
Psychological symptom distress
Psychological symptom distress
Depressive symptoms
Social support
Coping
13
Introduction
Operationalisation
The Multidimensional Fatigue Inventory (MFI-20) was used to assess the intensity of fatigue.
This 20-item self-report questionnaire, specially designed for cancer patients, consists of five scales based on 
different dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue.
Each subscale consists of four items.
The Shortened Fatigue Questionnaire (SFQ) is an instrument to determine the intensity of the patient’s 
bodily fatigue. The SFQ was used as a diary. The questionnaire consists of four questions: ‘I feel tired’, ‘I tire easily’,
‘I feel fit’ and ‘I feel physically exhausted’, each with a seven-point answer scale.
The revised Piper Fatigue Scale (revised PFS) is an instrument to measure subjective fatigue.
This 22-item questionnaire consists of four subscales. In this study one subscale was used: the behavioural/severity 
subscale.This subscale (6 items) reflects the degree to which fatigue interferes with activities of daily living.
Patients were treated with one of the following adjuvant treatments: CEF (cyclophosphamide, 4-epi-doxorubicin 
and 5-fluorouracil), CAF (cyclophosphamide, doxorubicin and 5-fluorouracil), 4-epi-doxorubicin,
4-epi-doxorubicin/taxotere, CA (cyclophosphamide and doxorubicin) and CMF (cyclophosphamide, methotrexate 
(oral administration from day 1 to day 14 or intravenous) and 5-fluorouracil).
Patients underwent a mastectomy or a lumpectomy with or without lymph nodes excision.
Yes or no
-
-
-
-
-
Married/living together, single, divorced and widow
Yes or no
Educational level ‘low’, ‘middle’ and ‘high’
Yes or no
The TNM (tumour-node-metastasis) clinical classification is used to report the anatomic extent of breast cancer.
-
The Rotterdam Symptom Checklist (RSCL) is an instrument to determine the quality of life of cancer patients.
Patients were asked to indicate the degree to which they had been bothered by physical symptoms (23 items) on 
a four-point Likert-scale (categories: not at all, a little, quite a bit and very much).
The Rotterdam Symptom Checklist (RSCL) is an instrument to determine the quality of life of cancer patients.
Patients were asked to indicate the degree to which they had been bothered by psychological symptoms (7 items) 
on a four-point Likert-scale (categories: not at all, a little, quite a bit and very much).
Depressive symptoms were assessed by using the Center for Epidemiological Studies Depression Scale (CES-D).
Patients indicated their experience of the symptoms responding “rarely or none of the time” (0); “some or little of 
the time” (1); “occasionally or a moderate amount of time” (2); and “most or all of the time” (3). High scores 
indicate more symptoms. The range of scores is 0 to 60, with a cut-off of 16 for a depressive syndrome.
Social support was assessed with the SSL12-I. The SSL12-I consists of three subscales with each four items:
‘everyday social support’, ‘social support in problem situations’ and ‘esteem support’.
The Utrecht Coping List (UCL) was used to assess coping. Four coping styles can be distinguished from the short coping 
list: ‘active coping’ (5 items), ‘social support seeking’ (5 items), ‘avoiding’ (3 items), and ‘palliative coping’(2 items).
This dissertation discusses the following research questions:
1 To what extent do breast cancer patients receiving adjuvant chemotherapy
experience fatigue (chapter 3)?
2 How does the experience of fatigue change over the course of time
(chapter 3, 4, 5 and 6)?
3 To what extent do treatment factors, demographic factors, disease/physical
factors, physical and psychological symptom distress, social support,
coping influence fatigue (chapter 7)?
Patients and methods
One hundred and seventy-five breast cancer patients with an indication for
adjuvant chemotherapy, treated in six hospitals, mainly in the south of the
Netherlands, were included in this study if they met the following criteria: (1) had
no metastasis of disease or other malignancy, (2) had not been treated with
cytostatic drugs before, (3) were planned to be treated with outpatient adjuvant
chemotherapy, (4) did not have a chronic disease (like hypertension, kidney disease,
heart problems, Diabetes Mellitus etc.) or a poor psychological state (such as
diagnosed with a depression), (5) did not use morphine or narcoleptics, (6) were not
deaf, (7) had to be 18 years or older, and (8) could speak and understand Dutch. 
Patients were interviewed at least four times. Patients were also asked to
report their experience of fatigue in a diary on a daily basis between the third
and fourth treatment with adjuvant chemotherapy. 
Table 1 presents the operationalisation of the variables used in the present
study. Medical data were collected from charts and were gathered after the
interviews.
AIMS AND OUTLINE OF THIS DISSERTATION
This dissertation starts with a literature review, chapter 2. The aim of this literature
review is to evaluate the prevalence and course of fatigue in patients with breast
cancer receiving adjuvant chemotherapy and to examine factors relating to fatigue. 
Chapters 3, 4 and 5 focus on the course of fatigue in breast cancer patients.
These chapters constitute an entity, but can be read separately. Each chapter has
been published or accepted for publication. A certain overlap is therefore
inevitable. The purpose of these studies (chapters 3-5) is to investigate the course
of fatigue during as well as after adjuvant chemotherapy in an attempt to circumvent
the major weaknesses of previously published studies. Patients were studied directly
14
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before, during or after infusions at the first, third and fifth cycle of chemotherapy,
and 4 and 12 weeks after the completion of chemotherapy. The Multidimensional
Fatigue Inventory (MFI-20) 35 was used to assess the course of fatigue. This
questionnaire consists of five subscales based on different dimensions: general
fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue. 
Chapter 3 covers the courses of general and physical fatigue. In addition,
the prevalence of fatigue in breast cancer patients both during and after
receiving adjuvant chemotherapy is determined. The purpose of chapter 4 is to
determine the course of fatigue in relation to cognitive symptoms (scale ‘mental
fatigue’) as well as the motivation to start any activity (scale ‘reduced
motivation’) as a result of chemotherapy. In this chapter the relationship between
these subscales and depressive symptoms is also studied. Chapter 5 includes a
description of the course of the activity level, and discusses the extent of the
interference with daily living activities.
Chapter 6 examines the course of fatigue between two cycles of adjuvant
chemotherapy in breast cancer patients. The experience of fatigue of each day,
from the day of administration until the day of the next infusion, is described.
The hypothesis that the maximum fatigue score occurs in the first four days after
treatment was tested. 
The purpose of chapter 7 is to test a model of variables that influence
fatigue in breast cancer patients both during and after adjuvant chemotherapy.
The associations between different variables, other than fatigue, were also
examined. Eventually, a ‘chemotherapy-fatigue model’ was developed. 
This dissertation concludes with a general discussion in chapter 8.
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Chapter 2
Fatigue in patients with breast
cancer receiving adjuvant
chemotherapy: 
a review of the literature
Nynke de Jong, MSc, RN, Annemie M. Courtens, PhD, RN, Huda Huijer Abu-
Saad, FEANS, PhD, RN, & Harry C. Schouten, MD, PhD
Updated version of the article published in: Cancer Nursing 2002; 25(4): 283-297.
ABSTRACT
The aim of this literature review was to evaluate the prevalence and course of
fatigue in patients with breast cancer undergoing adjuvant chemotherapy and
to examine factors relating to fatigue. Fatigue is one of the most common side
effects of chemotherapy. High and fluctuating prevalence rates of fatigue have
been found not only during but also after adjuvant chemotherapy. The intensity
of fatigue seems to be stable throughout the treatment cycles, despite the
common perception that more chemotherapy treatments lead to greater fatigue.
The first two days after a chemotherapy treatment seem to be the worst period. 
The influence of factors such as pain, impaired quality of sleep, and
depression are found to be highly consistent across several studies, although it
is often not clear whether it is the symptoms that cause the fatigue or vice versa.
The outcomes of the studies indicate that several symptoms are interrelated in
a network of symptoms. Factors such as changes in weight, menopausal symptoms,
coping, social support, and biochemical changes have been mentioned in the
literature as potentially contributing to fatigue. Results have been conflicting
and need further study.
Keywords: fatigue, breast cancer, chemotherapy
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Chapter 2
INTRODUCTION
The most common symptom of illness, whether mental or physical, is fatigue. It
is often the first indication of the presence of some abnormality and affects the
totality of an individual [1]. Fatigue is a major concern in patients with cancer
[2]. It is becoming increasingly realized that quality of life in patients with
cancer is affected by fatigue and is becoming more visible as a result of longer
cancer survival [3]. In a recent study in the Netherlands, patients with cancer
(suffering from various types of cancer) stated that fatigue had a greater effect
on their daily life than pain [4]. The National Comprehensive Cancer Network
(NCCN) reported that fatigue affects 70% to 100% of patients with cancer [5]. 
Everyone experiences fatigue on a daily basis. Although fatigue is
normally relieved by a good night’s sleep, this is often not the case for patients
with cancer, for whom it may become a chronic and unpleasant sensation [6].
Although fatigue can be a symptom of the disease itself, it can also be expected
to accompany cancer treatment [7]. Ream et al. [8] reported that it is recognized
that patients with cancer frequently become fatigued when undergoing
treatment, notably chemotherapy. Patients with cancer who are receiving
chemotherapy may experience a variety of side effects such as pain, nausea,
vomiting, hair loss, weight changes, fatigue, and anxiety, with fatigue being one
of the most commonly reported side effects. 
In the Netherlands, breast cancer is the most prevalent form of cancer in
women [9]. One third of the new cases of cancer in women concerns breast
cancer. About 60% of the patients with breast cancer, who underwent an
operation, received adjuvant systematic therapy. More than half of these patients
received chemotherapy [9]. 
The purpose of this article is to critically review the literature with respect
to fatigue in patients with breast cancer who are receiving adjuvant
chemotherapy. 
This study addressed the following questions: 
• To what extent do patients with breast cancer who are receiving adjuvant
chemotherapy experience fatigue?
• How does this change in the course of time?
• What are the factors relating to fatigue?
Published articles were found by means of a CD-ROM search of MEDLINE
(1989 to April 2006): using the search terms fatigue, breast cancer and
chemotherapy. The snowball method was used for additional literature. 
21
A review of the literature
THE CONCEPT OF FATIGUE
Fatigue is a multicausal, multidimensional and complex concept [10-12], and it
is difficult to define or describe [11, 13-15]. Many disciplines are interested in the
concept of fatigue, including medicine, psychology, physiology, nursing science
and ergonomics [11, 16]. No widely accepted definition of fatigue exists, and the
concept has been associated with many other terms such as tiredness, exhaustion,
weariness, malaise, weakness, and asthenia [11, 17]. In addition, differences in
cultural values, meanings of words and concepts, and translation problems have
influenced the meaning of fatigue [18]. The concept is used at different levels: as
a symptom, a diagnosis and a syndrome [11]. 
Despite complexities and difficulties, Ream and Richardson proposed the
following definition of fatigue for nursing purposes based on a concept
analysis: “Fatigue is a subjective, unpleasant symptom which incorporates
total feelings ranging from tiredness to exhaustion creating an unrelenting
overall condition which interferes with individuals’ ability to function to their
normal capacity” [19] (p. 527). To supplement this general definition of fatigue,
NCCN recently convened a panel of fatigue experts to define cancer-related
fatigue. The panel defined cancer-related fatigue as “A distressing, persistent,
subjective sense of tiredness or exhaustion related to cancer or cancer
treatment that is not proportional to recent activity and interferes with usual
functioning” [5] (p. MS-2). This definition emphasizes the unusual character of
cancer fatigue, which differentiates it from the type of fatigue that healthy
individuals may experience. Fatigue in patients with cancer is more severe,
more distressing, and less likely to be relieved by rest. Compared with the
definition proposed by Ream and Richardson [19], it seems to be the unusual
character of fatigue that is specific for patients with cancer. Holley [20] also
reported the unusual character of cancer-related fatigue. She reported that
cancer-related fatigue had a more rapid onset and was more energy-draining,
more intense, longer lasting, more severe, and more unrelenting than typical
fatigue [20]. Important characteristics of cancer-related fatigue in the NCCN
definition are the subjectivity of the sensation and the interference with usual
functioning. These characteristics correspond with the definition proposed by
Ream and Richardson [19]. 
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PREVALENCE AND COURSE OF FATIGUE IN PATIENTS WITH BREAST CANCER
WHO ARE RECEIVING CHEMOTHERAPY
The literature search resulted in the identification of a number of publications
reporting on patients with breast cancer who were receiving or had received
adjuvant chemotherapy. This section is divided in two parts: (1) studies were
fatigue was measured during, during and after, pre and after receiving
chemotherapy; and (2) fatigue measured after completion of chemotherapy.
Table 1 presents an overview of the methodological details of these studies, and
Table 2 presents sample characteristics, main results, and limitations of the
studies.
Fatigue during, during and after, pre and after receiving chemotherapy
Studies with timing of measurements adjusted to the different cycles of
chemotherapy 
Sitzia and Huggins [21] studied side effects in patients with breast cancer 
(n = 52) who were receiving 6 cycles of cyclophosphamide, methotrexate and
5-fluorouracil (CMF). Data were collected after each treatment cycle using the
reliable and valid Worthing Chemotherapy Questionnaire 75 (WCQ-75). This
self-reporting questionnaire features a list of 61 problems. The incidence of
fatigue was approximately 90%, and fatigue severity remained stable
throughout the treatment cycles. The strengths of this study include the use of a
homogeneous group of patients with breast cancer who were receiving only
chemotherapy without radiation therapy and the use of a valid and reliable tool. 
Berger [22] described patterns of fatigue in 72 patients with breast cancer
receiving CMF, doxorubicin and cyclophosphamide (A/C), or cyclophosphamide,
doxorubicin and fluorouracil (CAF). The Piper Fatigue Scale, a reliable and valid
multidimensional subjective fatigue measure established for patients with cancer,
was used to measure fatigue 48 hours after each treatment and at treatment cycle
midpoints during 3 cycles. Berger’s results showed that fatigue levels 48 hours
after each of the first 3 chemotherapy cycles were not significantly different over
time. Donovan et al. [23] reported that fatigue severity in women with early stage
breast cancer increased significantly from the start of chemotherapy to the middle
of chemotherapy but did not increase significantly from the middle of
chemotherapy to the end of chemotherapy. The common perception that fatigue
increases with time as patients receive further courses of chemotherapy is not
supported by the studies of Berger [22] and Donovan et al. [23], which confirms
the findings of Sitzia and Huggins [21]. Jacobsen et al. [24] found similar results
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Author n Design Measuring instrument
Studies assessing fatigue during, during and after or pre and after receiving chemotherapy
Blesch et al. (1991) 77 Cross-sectional, descriptive, Visual Analogue Scale (VAS)*
correlational, comparative (2 groups) Rhoten Fatigue Scale*
Rhoten Fatigue Checklist*
Greene et al. (1994) 86 Longitudinal, descriptive, Self-care diary (SCD)†
comparative (3 groups)
Longman et al. (1996) 307 Cross-sectional, descriptive Side Effects Checklist†,‡
Hoskins (1997) 93 Longitudinal, descriptive Treatment Recovery Inventory (TRI) †,‡
Longman et al. (1997) 53 Longitudinal, descriptive Side Effects Checklist†,‡
Berger (1998) and 72 Longitudinal, descriptive Piper Fatigue Scale (PFS)*
Berger and Farr (1999)
Sitzia and Huggins (1998) 52 Longitudinal, descriptive, Worthing Chemotherapy Questionnaire
retrospective 75 (WCQ-75)†
Wyatt and Friedman (1998) 46 Longitudinal, descriptive, Symptom Measure†
comparative (2 groups)
Jacobsen et al. (1999) 108 Longitudinal, descriptive, Fatigue Scale from the Profile
correlational, comparative (2 groups) of Mood States (POMS-F)*
Fatigue Symptom Inventory (FSI)*
54 Longitudinal, descriptive, Memorial Symptom Assessment
correlational Scale (MSAS)†
Jacobsen et al. (1999) 146 Cross-sectional, descriptive, POMS-F*
correlational FSI*
Multidimensional Fatigue Symptom 
Inventory (MFSI)*
Berger and Higginbotham (2000) 14 Longitudinal, descriptive, PFS*
prospective, correlational Symptom Experience Scale (SES)†
Schwartz (2000) 31 Longitudinal, descriptive, VAS*
comparative (2 groups)
Berger and Walker (2001) 60 Longitudinal, descriptive, PFS*
correlational, prospective
Haghighat et al. (2003) 112 Cross-sectional, descriptive Cancer Fatigue Scale (CFS)*
Tchen et al. (2003) 220 Cross-sectional, descriptive Functional Assessment of Cancer
correlational, comparative (2 groups) Therapy-Fatigue subscale (FACT-F)*
Bennett et al. (2004) 109 Cross-sectional, descriptive FACT-F*
Boehmke (2004) 120 Longitudinal, descriptive, McCorkle Symptom Distress Scale (SDS)‡
correlational, prospective Rhodes Adapted Symptom Distress Scale (ASDS) ‡
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* Fatigue measuring instrument.
† Side effect checklist; fatigue is one of the side effects in the checklist.
‡ Self-developed measurement instrument.
¥ Postsurgery, a designated point in time after medical treatment had started,
to allow for the appearance of treatment-related side effects.
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Multidimensional 
or unidimensional Timing of measurements No. of measurements
Uni While actually receiving chemotherapy 1
Uni and/or radiation therapy
Multi
- On days 2 and 5 after the first 2 cycles 4
- Unknown¥ 1
- 7-10 days/1 month/2 months/3 months/6 months/ 1 year after surgery 6
- Unknown/6-8 weeks/3 months after surgery 3
Multi 48 hours and midpoints of first 3 cycles 6
- After each treatment cycle (6 cycles) 6
- 6 weeks/3 months/6 months after surgery 3
Uni Before the start of chemotherapy/between the 3
second and third cycles/between the third
Multi and fourth cycles
- Before the start of the first 4 cycles 4
Uni During or after treatment 1
Multi
Multi
Multi 2 days before treatment 3/days 1-4 after treatment 6
Uni 3/days 5-10 after treatment 3/days 11-21 after treatment 
3/3 weeks after treatment 4/2 months after treatment 4
Uni Every day over 3 cycles of chemotherapy Diary
Multi Fatigue was measured during chemotherapy at 6 6
collection points: three encompassed 4 days at each 
of the chemotherapy treatments 1, 2 and 3 and 
three encompassed 3 days at the midpoints of cycles 
1, 2, and 3
Multi After three cycles of chemotherapy or at least 2 weeks 1
after completion their treatment
Uni While receiving adjuvant chemotherapy 1
or neoadjuvant chemotherapy
Uni Most women had completed adjuvant treatment with 1
chemotherapy and or radiation, the remainder had to 
complete adjuvant treatment
Timing is divers
- On the day of the first dose of chemotherapy; at the nadir of the 3
- chemotherapy cycle; and at the end of the first cycle of chemotherapy
+ Two subscales were used: the vitality and mental health subscales.
§ Health-related quality of life scale with energy/fatigue subscale.
# CT, chemotherapy; RT, radiotherapy.
$ Two subscales were used: the vitality and the bodily pain subscales.
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Author n Design Measuring instrument
Studies assessing fatigue during, during and after or pre and after receiving chemotherapy
Donovan et al. (2004) 134 Longitudinal, descriptive, FSI*
correlational, comparative (2 groups)
Jacobsen et al. (2004) 80 Longitudinal, descriptive, FSI*
correlational, prospective,
comparative (2 groups)
Andrykowski et al. (2005) 288 Longitudinal, descriptive, POMS-F*
comparative (2 groups) FSI*
Memorial Symptom Assessment Scale (MSAS)†
Fatigue Catastrophizing Scale (FCS)*
Mar Fan et al. (2005) 206 Longitudinal, descriptive, FACT-F*
prospective, comparative (2 groups)
Nieboer et al. (2005) 885 Longitudinal, descriptive,, SF-36+
prospectivecomparative (2 groups)
Studies assessing fatigue after completion of chemotherapy
Berglund et al. (1991) 448 Cross-sectional, descriptive, Symptom list†,‡
comparative (2 groups)
Beisecker et al. (1997) 21 Longitudinal, descriptive Semistructured interview‡
Leddy (1997) 142 Cross-sectional, descriptive, Fatigue Experienced Scale*
comparative (2 groups)
Andrykowski et al. (1998) 176 Longitudinal, descriptive, correlational, PFS*
retrospective, comparative (2 groups) Chalder Fatigue Scale*
Symptom Experience Report (SER)†,‡
Broeckel et al. (1998) 120 Cross-sectional, descriptive, POMS-F*
correlational, comparative (2 groups) FSI*
MFSI*
Lindley et al. (1998) 86 Cross-sectional, descriptive Symptom Distress Scale (SDS)†
Mast (1998) 109 Cross-sectional, descriptive, correlational Revised version of the SDS†
Woo et al. (1998) 322 Cross-sectional, descriptive, correlational PFS*
Gaston-Johansson et al. (1999) 127 Cross-sectional, descriptive, correlational PFS*
VAS*
Bower et al. (2000) 3910 Cross-sectional, descriptive, correlational, Rand 36-Item health Survey§
comparative (2 groups)
Okuyama et al. (2000) 134 Cross-sectional, descriptive, correlational Cancer Fatigue Scale (CFS)*
Curran et al. (2004) 74 Longitudinal, descriptive, FATIGUE-D*
comparative (3 groups)
Bower et al. (2006) 763 Longitudinal, descriptive RAND SF-36$
* Fatigue measuring instrument.
† Side effect checklist; fatigue is one of the side effects in the checklist.
‡ Self-developed measurement instrument.
¥ Postsurgery, a designated point in time after medical treatment had started,
to allow for the appearance of treatment-related side effects.
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Multidimensional 
or unidimensional Timing of measurements No. of measurements
Multi CT + RT# group: first, third, and final cycles CT + RT group: 6
of chemotherapy and at the first, fifteenth, and final 
visits for radiotherapy
RT group: at the first, fifteenth, and final visits for RT group: 3
radiotherapy
Multi First clinic visit for CT or RT† and last 2
visit for CT or RT
Uni Before adjuvant therapy and a post-treatment 2
Multi assessment at the conclusion of an initial course
- of adjuvant chemotherapy or radiotherapy
Multi
Uni After at least three cycles of chemotherapy were completed, 3
1 and 2 years later
- Before and 1, 2 and 3 years after chemotherapy 4
- 2-10 years after primary therapy 1
- Shortly after completion of adjuvant chemotherapy/6 months later 2
Uni < 10 years after treatment 1
Multi 2-54 months after completed breast cancer treatment; 2
Multi initial assessment for benign breast problems group
Uni unknown/4-6 months later
Uni Average of 471 days after treatment 1
Multi
Multi
- 2-5 years after treatment 1
Uni 1-6 years after treatment 1
Multi Within 18 months after treatment 1
Multi Completed adjuvant chemotherapy and scheduled 1
Uni for autologous bone marrow/peripheral blood stem cell transplant
- 1-5 years after initial breast cancer diagnosis 1
Multi 786 ± 463 (SD) days after surgery 1
Uni Off-treatment: breast cancer survivor (6-26 months) and 20 (diary)
benign breast problems (4-312 months)
Healthy women were also measured
Assessments: at four specific times each day during 5 consecutive days
- 1-5 and 5-20 years after diagnosis 2
+ Two subscales were used: the vitality and mental health subscales.
§ Health-related quality of life scale with energy/fatigue subscale.
# CT, chemotherapy; RT, radiotherapy.
$ Two subscales were used: the vitality and the bodily pain subscales.
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Stage of Age 
Author disease Treatment / group n range, y
Studies assessing fatigue during, during and after or pre and after receiving chemotherapy
Blesch et al. (1991) Unknown Chemotherapy and/or radiation therapy 44 24-69
(patients with breast cancer)
Chemotherapy and/or radiation therapy 33 38-74
(lung cancer patients)
Greene et al. (1994) I or II Cyclophosphamide, methotrexate, 37 29-75
and 5-fluorouracil (CMF)
Cyclophosphamide, doxorubicin, 29 31-75
and 5-fluorouracil (CAF)
Cyclophosphamide, mitoxantrone, 20 41-70
and 5-fluorouracil (CNF)
Longman et al. (1996) I-IV Chemotherapy 169 25-82*
Radiation therapy 117
Hormone therapy 98
Hyperthermia 3
Follow-up care rather than adjuvant therapy 14
Hoskins (1997) Diagnosed with Chemotherapy ? ?
breast cancer Radiation therapy ? ?
Chemotherapy and radiation therapy ? ?
No adjuvant treatment ? ?
Longman et al. (1997) I-IV Chemotherapy 32 26-80*
Radiation therapy 18
Hormone therapy 15
Berger (1998) I or II CMF 26 33-69*
Berger and Farr (1999) Doxorubicin and cyclophosphamide (AC) 20
CAF 26
Sitzia and Huggins (1998) Diagnosed wit0h CMF 21 30-72*
breast cancer CMF and hormone (replacement) therapy 31
*  Total group †  Treatment group ‡  Breast cancer group
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Fatigue 
prevalence, % Main results Limitation of the study
99% - No distinction made in breast cancer 
treatment
- Instruments: lack of reliability and validity 
data
Timing of measurements doubtful
Small sample size
82-68-77-73 Fatigue was one of the most frequently Sample sizes too small to compare results
reported side effects and did not differ Only the first days (days 2 and 5 after the first 
86-67-74-76 in incidence among the 3 drug regimens 2 cycles) studied
Fatigue was significant for time; however,
58-70-80-70 no distinct clinical pattern of fatigue
was apparent
83 Fatigue was the most common as well as the Instrument: lack of reliability and validity data
most problematic side effect No distinction made in breast cancer 
treatment
Timing of measurements doubtful
8-26-35-22-14-1* Fatigue and emotional distress were the Instrument: lack of reliability and validity data
most persistent issues No distinction made in breast cancer 
treatment
No distinction made between patients still 
receiving treatment and patients having 
completed treatment 
70-77-79* Fatigue was the most frequent as well as Instrument: lack of reliability and validity data
the most problematic side effect over time No distinction made in breast cancer 
treatment
No distinction made between patients still 
receiving treatment and patients having 
completed treatment 
Timing of measurements doubtful
Small sample size
Unknown Levels of fatigue 48 hours after each of the Small sample size
first 3 chemotherapy treatments were not 
significantly different over time
Fatigue scores were significantly different over 
time, with scores higher at treatments and lower 
at cycle midpoints (roller-coaster pattern)
89 (mean The most commonly reported problem was Small sample size
incidence)* alopecia followed by fatigue Retrospective design may have biased 
Patients judged fatigue and nausea to be the findings
most troublesome problems
Mean severity of fatigue remained stable 
throughout the treatment cycles
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Stage of Age 
Author disease Treatment / group n range, y
Studies assessing fatigue during, during and after or pre and after receiving chemotherapy
Wyatt and Friedman (1998) Diagnosed with Surgery and adjuvant therapy 30 57-81
breast cancer Surgery only 16 55-89
Jacobsen et al. (1999) I-III Doxorubicin 14 28-77†
AC 25
AF 11
Doxorubicin, cyclophosphamide, and 4
methotrexate
No treatment (no cancer history) 54 32-77
Jacobsen et al. (1999) ? Undergoing chemotherapy 36 28-86*
Undergoing radiotherapy 36
Completion of radiotherapy 44
Undergoing bone marrow transplantation 30
Berger and 
Higginbotham (2000) I or II AC 14 32-69
Schwartz (2000) I-IV AC  women who did    23 35-57*
CMF         (n=16) or did  not 7
Vinorelbine  (n=11) exercise 1
Berger and Walker (2001) I or II Cytoxan, methotrexate, 5-FU 23 33-69*
Cytoxan, adriamycin 15
Cytoxan, adriamycin, 5-FU 22
Haghighat et al. (2003) I-IV Surgery, chemotherapy, radiotherapy 51 22-76*
Surgery, chemotherapy 49
Surgery, radiotherapy 5
Surgery alone 3
Chemotherapy alone 4
Tchen et al. (2003) Unknown Chemotherapy or neoadjuvant 100 27-60
chemotherapy
Healthy women 100 26-62
Bennett et al. (2004) I or II Chemotherapy 109* 36-77
Radiotherapy
Chemotherapy and radiotherapy
*  Total group †  Treatment group ‡  Breast cancer group
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Fatigue 
prevalence, % Main results Limitation of the study
70-53-56 Fatigue and pain were the most No distinction made in breast cancer
44-32-38 frequently reported symptoms in both groups treatment
Women reported relatively low levels of severity Sample sizes too small to compare results
of fatigue; symptom did not improve over time Sample relatively old (age 55 or older)
No distinction made between patients still 
receiving treatment and patients having 
completed treatment
72-92-94-91† Patients with breast cancer experienced worse Samples sizes too small to compare results
fatigue than women with  no cancer history Patients flooded with questionnaires
Fatigue worsened among patients after Diversity of the study makes it hard to get a 
treatment started, but did not increase further clear overall impression
over the first 3 treatment cycles
Unknown
Unknown Catastrophizing was significantly related to No distinction made in breast cancer 
greater fatigue intensity treatment
Patients were studied during or after
treatment
Unknown Moderate fatigue identified Small sample size
Unknown After chemotherapy a sharp rise in fatigue Small sample size
Several women had a chaotic pattern
Women who did not exercise experienced
more bad days (greater fatigue) and fewer 
good days (less fatigue)
Unknown Symptom distress, chemotherapy protocol Small sample size
and interpersonal relations behaviours
influenced fatigue at treatments
Symptom distress from the previous treatment,
physical function and social function and 
interpersonal relations behaviours influenced 
fatigue at cycle midpoints
49 In comparison to treatment factors, physical No distinction made in breast
and psychological symptoms have a more cancer treatment
important role in cancer-related fatigue Patients were studied during or after 
Fatigue should be recognized and managed treatment
even before commencing breast cancer treatment 
Unknown Patients experienced significant more fatigue Patients were studied on different times
than the controls during the treatment of chemotherapy
Fatigue had a profound effect on the No distinction is made in receiving 
quality of life of the patients chemotherapy and neoadjuvant chemotherapy
37 Fatigue and psychological distress were No distinction made in breast cancer
common treatment
Those who reported fatigue were much more Patients were studied during or after 
likely to report psychological symptoms treatment
32
Chapter 2
Stage of Age 
Author disease Treatment / group n range, y
Studies assessing fatigue during, during and after or pre and after receiving chemotherapy
Boehmke (2004) I or II Lumpectomy 74 37-83*
Quadrectomy 5
Seg. Mastectomy 9
Mastectomy 29
Mastectomy with reconstruction 3
Donovan et al. (2004) 0-II Surgery, chemotherapy, radiotherapy 57 At least 18 years
Surgery, radiotherapy 77
Jacobsen et al. (2004) 0-II Surgery, chemotherapy 42 32-78*
Surgery, radiotherapy 28
Andrykowski et al. (2005) 0-II Adjuvant chemotherapy 151 21-79*
Adjuvant radiotherapy 137
Mar Fan et al. (2005) Resectable Adjuvant or neoadjuvant chemotherapy 104 ?
breast cancer (with or without radiotherapy, hormonal 
therapy and treatment for hot flashes)
Matched healthy women 102 ?
Nieboer et al. (2005) II-III Adjuvant standard chemotherapy, 202 ?
radiotherapy and tamoxifen
Adjuvant high-dose chemotherapy, 228 ?
radiotherapy and tamoxifen
*  Total group †  Treatment group ‡  Breast cancer group
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Fatigue 
prevalence, % Main results Limitation of the study
Unknown Symptom distress scores were generally low Measurements only during one cycle of 
Fatigue is causing the greatest distress chemotherapy
Factors like, functioning, body image and No distinction made in breast cancer
menopausal symptoms cited as contributors treatment
to symptom distress level, but were not measured 
which could account for low scores
Unknown Women who received chemotherapy as their Only three times during chemotherapy and 
initial type of treatment reported greater during radiotherapy were assessed
fatigue than women who received radiotherapy Fatigue severity during two cycles of
as their initial treatment chemotherapy is not measured
Women who did not have pre-treatment with 
chemotherapy experienced increased fatigue over 
the course of radiotherapy, whereas women 
pre-treated with chemotherapy did not 
The authors reported that chemotherapy is 
associated with more severe fatigue than 
radiotherapy
The authors suggest a response shift or a change 
in internal standards, in women’s perceptions of 
fatigue as a function of prior chemotherapy 
treatment
Unknown Catastrophizing demonstrated relationships Measurements are at the start and at the
with fatigue severity and disruptiveness for RT end, not during the treatment
patients but not for CT patients
10-26* met CRF is experienced before initiation of adjuvant Measurements are at the start and at the
criteria for Cancer- therapy and post-treatment end, not during the treatment
Related Fatigue CRF has a multifactorial etiology
(CRF)
? In all assessments patients receiving Timing of measurements doubtful
chemotherapy experienced significantly more
fatigue than the controls
? Chemotherapy patients experienced
improvements over the 2-year period
19-19-17-19 Fatigue was reported in 20% of 430 Measurements are at the start and
assessable patients at the end, not during the treatment
16-21-21-22 Fatigue in both groups did not change No distinction made in the different 
over time and no statistical difference were treatments
found between the treatment groups
Mental health was the strongest fatigue predictor
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Stage of Age 
Author disease Treatment / group n range, y
Studies assessing fatigue after completion of chemotherapy
Berglund et al. (1991) Unknown Chemotherapy 203 34-77
Radiation 245 33-79
Beisecker et al. (1997) Node-negative CMF 12 32 – 66*
breast cancer CAF 5
5-fluorouracil, velban, mitoxantrone 4
and cytoxan (FuVMiC)
Leddy (1997) Diagnosed with Treatment for breast cancer 53 32-83
breast cancer No treatment (healthy women) 89 24-82
Andykowski et al. (1998) 0-IIIA Chemotherapy 27 35-76‡
Radiation 24
Chemotherapy and radiation 8
Tamoxifen 43
Benign breast Benign breast problem group 88
problems
Broeckel et al. (1998) I-III AC 24 29-75†
CMF 19
CAF 11
Cyclophosphamide, doxorubicin, 5
and paclitaxel
Cyclophosphamide, doxorubicin, 2
fluorouracil and methotrexate
Adjuvant radiotherapy 37
Hormonal therapy 37
No treatment (women with no history 59 29-77
of cancer)
Lindley et al. (1998) I or II Radiation 16 29-86*
Chemotherapy 22
Tamoxifen 31
Chemotherapy plus tamoxifen 33
Mast (1998) I-III Surgery only 38 45-90
Surgery and radiation 26 43-80
Surgery and chemotherapy 21 35-78
Surgery, chemotherapy and radiation 24 29-72
*  Total group †  Treatment group ‡  Breast cancer group
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Fatigue 
prevalence, % Main results Limitation of the study
68 No support for the hypothesis that Instrument: lack of reliability and validity data
76 chemotherapy would lead to more severe late Range in periods after treatment too large
consequences than radiotherapy
Fewer than 10% reported severe symptoms
No significant difference (chemo vs radio) in 
reported fatigue
95-83* - Instrument: lack of reliability and validity data
Small sample size
Unknown No significant differences between the 2 groups No distinction made in breast cancer
in health, fatigue and symptom experience treatment
Range in periods after treatment too wide
Samples not equal in size
Unknown Breast cancer group reported more No distinction  made in breast cancer
fatigue, more weakness and less vitality treatment
relative to benign breast problem group Retrospective design may have biased 
findings
Timing of measurements doubtful
Unknown Women with no history of cancer reported No distinction made in breast cancer 
more severe fatigue (p< 0.01) and worse treatment
quality of life because of fatigue (p<0.05) 
than former adjuvant chemotherapy patients
31 Most commonly reported moderate to No distinction made in breast cancer 
(moderate severe symptom was fatigue treatment
to severe)* Less than one third of patients reported Range in periods after treatment too wide
moderate to severe symptoms
Unknown Intensity of fatigue low to moderate Instrument: lack of reliability and validity data
No distinction made in breast cancer
treatment
Range in periods after treatment too wide
in their study of 54 patients with breast cancer who were receiving adjuvant
chemotherapy. Patients had to complete the Memorial Symptom Assessment
Scale (MSAS) in the clinic immediately before the start of each of the first 4
chemotherapy cycles. The MSAS assesses symptoms commonly associated with
cancer and its treatment in terms of their prevalence, severity and distress. Fatigue
increased after the start of chemotherapy but did not increase further during the
first 3 treatment cycles. The prevalence rates of fatigue at the 4 measurement
points were 72%, 92%, 94% and 91%, respectively. Their study also compared
patients with breast cancer with women with no cancer history using the Fatigue
36
Chapter 2
Stage of Age 
Author disease Treatment / group n range, y
Studies assessing fatigue after completion of chemotherapy
Woo et al. (1998) All Hormone therapy alone 116 31-90*
Chemotherapy and radiation 57
Chemotherapy alone 44
Radiation alone 34
Radiation and hormone therapy 27
Chemotherapy and hormone therapy 22
Chemotherapy, radiation and 22
hormone therapy
Gaston-Johansson et al. (1999) II-IV Adjuvant chemotherapy 127 22-60
Bower et al. (2000) 0-II Surgery only 454 ?
Surgery and radiation 701 ?
Surgery and chemotherapy 336 ?
Surgery, chemotherapy and radiation 462 ?
Tamoxifen 935 ?
No treatment (age-matched women) 1953 ?
Okuyama et al. (2000) 0-III Chemotherapy 38 28-86*
Radiation 12
Current fluoropyrimidine compounds use 14
Current tamoxifen citrate us 55
Curran et al. (2004) 0-II, Breast cancer survivor (BC) 25 28-63
unknown Chemotherapy
Radiotherapy
Chemotherapy and radiotherapy
Benign breast problems (BBP) 24 28-63
Healthy women (HC) 25 30-65
Bower et al. (2005) Diagnosed with Surgery only 61 ?
breast cancer Surgery and radiation 74 ?
Surgery and chemotherapy 49 ?
Surgery, chemotherapy and radiation 73 ?
Tamoxifen 157 ?
*  Total group †  Treatment group ‡  Breast cancer group
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Scale from the Profile of Mood States (POMS-F) and the Fatigue Symptom
Inventory (FSI). The patients completed these questionnaires at home on 3
occasions: before the start of chemotherapy, between the second and third cycles,
and between the third and fourth cycles. The noncancer comparison subjects
who agreed to participate were mailed the POMS-F and FSI 3 times, at 3- to 6-
week intervals. Women receiving adjuvant chemotherapy for breast cancer
experienced significantly worse fatigue than the age-matched comparison group
of women with no cancer history. Jacobsen et al. [24] used 3 measuring
instruments for fatigue and assessed data at 7 measurement points. The use of a
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Fatigue 
prevalence, % Main results Limitation of the study
Unknown Fatigue varies with type of cancer therapy No distinction made in breast cancer
treatment
Factors such as depression and menopausal 
status may have contributed to fatigue, but
were not analyzed
91 Overall: low to moderate levels of fatigue Timing of measurements doubtful
Unknown Survivors not more fatigued than No distinction made in breast cancer 
an age-matched group of women treatment
56* - No distinction made in breast cancer 
treatment
Range in periods after treatment too wide
Unknown BC reported greater levels of fatigue relative The off-treatment period of the BC
to BBP and HC groups and the BBP group is not comparable
No group difference in mood, activity type No distinction is made in breast cancer
or level, sleep duration, or diurnal pattern treatment
of fatigue were evident Small sample size
35-34* Many years after cancer diagnosis No distinction made in breast cancer
fatigue continues to be a problem treatment
for breast carcinoma survivors 
Approximately 21% reported fatigue at
both measurements points
control group in this study strengthens its validity and enhances the comparison
of results. The large number of questionnaires administered to patients may,
however, have led to inaccurate and incomplete information because respondents
may have become tired of answering so many questionnaires, which is known to
adversely influence the results.
In a more recent study of Jacobsen et al. [25], the authors revealed that the
level of fatigue severity reported by the average patient with breast cancer
following the start of chemotherapy can be characterized as moderate. In the
study of Andrykowski et al. [26] 10% of 288 women reported cancer related
fatigue (CRF) before adjuvant therapy (chemotherapy or radiotherapy). At post-
treatment the CRF prevalence was 26%. Sixty patients (21%) were incident
cases of CRF, a relatively large sample. Nieboer et al. [27] reported similar
results. They found that fatigue was reported in 20% of 430 assessable patients
with at least a 3-year follow-up. Fatigue did not change over time or differ
between the treatment arms. Fatigue was assessed before and 1, 2, and 3 years
after chemotherapy (standard or high-dose). 
Studies with unclear timing of measurements relative to that of
administration of chemotherapy 
Haghighat et al. [28] studied 112 patients with breast cancer. The assessment
for patients receiving chemotherapy was scheduled after three cycles of
chemotherapy, while patients off treatment were assessed at least 2 weeks after
completion their treatment [28]. Overall 49% reported fatigue to some degree
(from quite a bit to very much). Bennett et al. [29] found a rate of 37%. The
authors included patients with breast cancer who were receiving treatment or
had completed treatment, which can be seen as a limitation [29]. 
Longman et al. [30] studied side effects in 307 women receiving treatment
for breast cancer. They found fatigue to be the most common (83%) as well as the
most problematic side effect. The Side Effects Checklist used in this study consisted
of 16 common side effects of breast cancer treatment and was developed during a
pilot study among 24 women who each cited specific side effects experienced
after 2 to 4 weeks of adjuvant therapy and again 6 weeks later. A limitation of this
checklist is the lack of reliability and validity data. The prevalence rate of fatigue
was assessed without distinguishing between the types of treatment patients
underwent, and a combination of treatments could have influenced the experience
of fatigue and therefore biased the results. Likewise, the timing of the measurements
in this cross-sectional study was doubtful, with measurements performed at a
designated point in time after the start of medical treatment to allow for the
appearance of treatment-related side effects. It is difficult, sometimes even
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impossible, to determine such a designated point. Longman et al. [31] subsequently
extended their study with a longitudinal design in which 53 of the 307 respondents
were interviewed during a 4- to 5-months period. Data were collected at 3 points:
a designated point in time after the medical treatment had started to allow for the
appearance of treatment-related side effects, then 6 to 8 weeks later, and again 3
months later. They found prevalence rates of fatigue at the points of 70%, 77% and
79%, respectively. Despite its limitations, the longitudinal design of this study
reveals more details about the prevalence rate of fatigue. It appears to indicate that
more patients experience fatigue with time. Hoskins [32] also studied side effects
in a longitudinal design. Data were collected from 93 women diagnosed with
breast cancer at 6 points in time: 7-10 days, 1 month, 2 months, 3 months, 6 months
and 1 year after surgery. In this study, fatigue was one of the most prominent side
effects. The investigators developed their own checklist, the Treatment Recovery
Inventory, whose content validity was only verified by one clinical oncology nurse,
making its value doubtful. The prevalence values of fatigue at the 6 data collection
points were 8%, 26%, 35%, 22%, 14%, and 1%, respectively. Just as in the study
by Longman [31], a limitation of this study was the lack of clarity on fatigue and
the timing of the chemotherapy. 
Wyatt and Friedman [33] investigated the patterns of functional and
psychosocial adjustment of midlife and older women after surgery for breast
cancer. They compared women who received follow-up adjuvant therapy (n =
30) with those who did not (n = 16). The presence and severity of the symptoms
were measured at 3 time points after surgery (6 weeks, 3 months, 6 months).
Fatigue and pain were the most frequently reported symptoms in both groups.
In the group with adjuvant treatment, 70% of the patients experienced fatigue
after 6 weeks, 53% after 3 months, and 56% after 6 months. In the surgery-
only group the corresponding percentages were 44%, 32%, and 38%,
respectively. Women reported relatively low levels of severity of fatigue and this
symptom did not improve over time. Differences between the two groups were
not analysed because of small sample sizes. The study by Wyatt and Friedman
[33] and the study by Hoskins [32] shared two of their measurement points: 3
months and 6 months after surgery. Nevertheless, their findings were very
different, which may have been caused by the different measuring instruments
and age ranges of the populations. 
Tchen et al. [34] studied patients with breast cancer who were receiving
adjuvant chemotherapy or neoadjuvant chemotherapy before scheduled surgery.
A control group of healthy women was also studied. Patients with breast cancer
who were receiving adjuvant chemotherapy experienced much more fatigue
than healthy controls [34]. Mar Fan et al. [35] found a similar result. Also in this
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study the patients receiving chemotherapy experienced significantly more
fatigue than healthy controls. Chemotherapy patients experienced improvements
in fatigue over the 2-year period.
Studies with measurements within two cycles of chemotherapy 
Berger [22] found that reported fatigue intensities were significantly lower at the
midpoint of each cycle than they were 48 hours after each of the first 3
treatments. Berger called this development of intensity the roller-coaster pattern.
A recent study by Schwartz [36] among 31 patients with breast cancer had a
similar result. Patients who did or did not exercise were asked to record the
fatigue they experienced in a diary during 3 cycles of chemotherapy. The most
common pattern was a rapid increase in the first 24 to 48 hours after chemotherapy,
although several women demonstrated a chaotic pattern of fatigue, with erratic
and wide swings.
In the side effects study by Greene et al. [37], 86 patients with breast
cancer recorded the incidence and severity of side effects 2 and 5 days after the
administration of the first and second cycles of chemotherapy [28]. The authors
used a self-care diary to collect patient-reported side effects for 3 chemotherapy
regimens for breast cancer (Table 2). Fatigue was the most frequently reported
side effect. The percentage of patients experiencing fatigue varied from 58% to
86% (Table 2), and the mean severity scores for those who experienced fatigue
indicated mild to moderate severity. The incidences did not differ for the 3 drug
regimens. Greene et al. [37] did not find a distinct clinical pattern of fatigue,
although fatigue was significant for time. A reason for not finding any pattern
may have been the choice of the measurement points, which may have been
too close together in time to reveal any effect. If the purpose of the study was to
describe the pattern of fatigue within 2 cycles of chemotherapy, they would
probably have had to cover a longer and/or different period of time. The study
also had several other limitations: a relatively small sample size was evaluated
and subjects were not randomized into the treatment regimens. 
Fatigue after completion of chemotherapy
Gaston-Johansson et al. [38] studied 127 patients with breast cancer who had
undergone mastectomy, had completed chemotherapy, and were scheduled for
autologous bone marrow/peripheral blood stem cell transplant. The prevalence
rate of fatigue was 91% as measured by the Fatigue Visual Analogue Scale
(VAS). Participants reported low to moderate levels of fatigue. A limitation of
this study was that no data were collected on the length of time between
chemotherapy completion and the assessment of fatigue. 
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Mast [39] studied fatigue in 109 survivors of breast cancer 1 to 6 years after
treatment and found that they experienced low to moderate fatigue. The authors
did not report figures on the incidence of fatigue. Fatigue was measured by a
single item in the revised version of the Symptom Distress Scale (SDS): a linear
analogue self-assessment scale. The reliability and validity of this item as a
measure have not been assessed. Other limitations of this study are the wide
range of periods after treatment and that the pattern, consistency, and intensity
of fatigue over time were not evaluated.
Lindley et al. [40] used the semantic version of the SDS in 86 patients with
breast cancer who had survived for 2 to 5 years after the initiation of adjuvant
cytotoxic and/or hormonal therapy. Sixteen of these patients had undergone
radiation therapy. The most commonly reported moderate to severe symptom
was fatigue (31.4%), followed by insomnia (23.3%), worsening appearance
(14.0%), and altered bowel function (11.6%). Berglund et al. [41] studied
patients over an even wider range of periods after treatment for breast cancer.
They reported prevalence rates in patients with breast cancer who were free of
recurrence 2 to10 years after treatment. Sixty-eight percent of the patients who
had received adjuvant chemotherapy perceived fatigue, compared with 76% of
the postoperative radiotherapy patients. No significant differences were found
between the two groups in the reported frequencies of fatigue. This self-made
instrument, a symptom list with 32 items, was not tested for reliability or validity,
making the results difficult to interpret. 
Okuyama et al. [42] studied 134 disease-free patients with breast cancer
786 ± 463 (SD) days after surgery, and found a prevalence rate of fatigue of
56%. Unlike Okuyama et al. [42], Leddy [43] did a comparative study, that
found no significant differences in fatigue between women who had been
treated for breast cancer within the past 10 years (n = 53) and healthy women
(n = 89). Fatigue was assessed using the Fatigue Experience Scale, which has
been sufficiently tested for validity and reliability. In this study, the women
treated for breast cancer were significantly older than the control group, and
the two sample sizes were unequal. The influence of these differences on the
fatigue data is unclear. 
Broeckel et al. [44] also compared two groups, 1 of 61 women who had
completed an average of 471 days of adjuvant chemotherapy and 1 of 59
women with no history of cancer. Results indicated that the former chemotherapy
patients reported more severe fatigue as measured by the POMS-F than the
noncancer comparison subjects. In addition, the former chemotherapy patients
reported higher levels of current fatigue as measured by the Fatigue Symptom
Inventory (FSI) and scored significantly higher on the general, physical and mental
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subscales of the Multidimensional Fatigue Symptom Inventory (MFSI). A
limitation of the study is that there was no control group of patients with other
forms of breast cancer treatment besides adjuvant chemotherapy, which may have
influenced the differences in fatigue.
Curran et al. [45] did also a comparative study examining the diurnal
pattern of off-treatment fatigue in survivors of breast cancer, women with benign
breast problems, and an age-matched group of healthy women. The participants
of the study completed a daily diary at four specific times each day during 5
consecutive days. The group with survivors of breast cancer reported greater
fatigue throughout the day than the two other groups. Data suggest that fatigue
levels can continue to be elevated long after completion of adjuvant therapy. In
the diurnal pattern of fatigue evidenced by the group with survivors of breast
cancer, relative to the two other groups no difference was observed. An identical
U-shaped pattern of fatigue ratings across the course of the day was found [45]. 
Bower et al. [46] compared 1,957 survivors of breast cancer at an average
of 3 years after initial breast cancer diagnosis with age-matched women (n =
1,953) from a general population, using the energy/fatigue scale of the RAND
Health Survey. The majority of survivors of breast cancer did not experience
increased levels of fatigue relative to women in the general population. A strong
methodological aspect of this study is the large sample size, although its value is
limited by its cross-sectional design. In another study of Bower [47], a longitudinal
study, approximately 21% of a sample of 763 breast carcinoma survivors reported
fatigue at both assessment points (1-5 years and 5-10 years after diagnosis).
Beisecker et al. [48] studied 21 patients with node-negative breast cancer who
had undergone adjuvant chemotherapy; they also made two assessments, one
shortly after the completion of adjuvant chemotherapy and one 6 months later.
The prevalence rates of fatigue at these two moments were 95% and 83%,
respectively. Although the researchers did not study the course of the severity of
fatigue, the study found that fewer patients experienced fatigue at the second
assessment moment. The research team had developed the interview protocol
themselves, and its reliability and validity had not been demonstrated. The small
sample size was justified by the researchers by their desire to limit the sample to
node-negative patients with breast cancer.
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These studies are difficult to compare because of the differences in the timing
and number of measurements, instruments, populations, sample sizes and
treatments. In summary, high prevalence rates were found during as well as
after the administration of adjuvant chemotherapy. The intensity of fatigue
seems to have been stable throughout the treatment cycles, although the first
two days after a chemotherapy treatment seem to be the worst period. 
FACTORS RELATING TO FATIGUE
The actual mechanisms that produce fatigue are unknown [6, 49]. The most
reasonable approach is to consider multiple factors. Numerous factors have
been found to influence fatigue, including demographic factors, disease/
physical factors, treatment factors and symptoms. Tables 1 and 2 present specific
details of the studies. An overview of the factors relating to fatigue is shown in
Tables 3a and 3b. Figure 1 presents a model of fatigue and its related factors
based on the literature. 
Demographic factors
Mast [39], Jacobsen et al. [24], Haghighat et al. [28], Donovan et al. [23], and
Jacobsen et al. [25] found no significant relationship between fatigue and age.
Woo et al. [51] found that younger women experienced significantly higher
fatigue levels than older women. They investigated the differences in fatigue for
different treatment methods in 322 survivors of breast cancer, who had received
their treatment within the last 18 months. Bower et al. [46] also found a
negative association between fatigue and age. The results showed that women
in the group that was fatigued were slightly younger, had a lower annual
income, and were less likely to be married or in a significant relationship than
those in the nonfatigued group. This study did not find ethnicity, educational
attainment and employment status to be associated with fatigue. In a study of
Haghighat et al. [28], marital status and educational level were no significant
predictors of fatigue. Jacobsen et al. [25] found also no significant correlation
between fatigue and marital status, but a lower educational level was
significantly associated with higher fatigue scores at the pre-treatment
assessment. At the follow-up assessment, educational level also demonstrated a
marginally significant negative correlation with fatigue [25]. Both, income and
ethnicity were not related to fatigue [25]. 
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Pre and after Pre and after Pre and during During During
chemotherapy chemotherapy chemotherapy chemotherapy chemotherapy
Author  →
Andrykowski Nieboer Jacobsen Blesch Berger
et al. et al. et al. et al. and Farr
(2005) (2005) (2004) (1991) (1999)
Demographic
Age 0
Marital status 0
Income 0
Ethnicity 0
Educational attainment - †/ 0 ‡
Employment status
Disease/physical
Stage of disease 0
Haemoglobin level 0
Duration of illness +
Biochemical factors 0
Concurrent disease
Low level of activity +
Menopausal status 0 0
Symptoms
Symptom distress
Physical symptom distress
Pain +
Muscle and joint pain +
Sleeping problems +
Nausea
Mouth sores
Muscle weakness
Change in taste
Chills
Vomiting
Menopausal symptoms
Body mass
Dyspnea
Psychological symptom distress
Depression
History of major depressive disorder +
Poor mental health +
Emotional upset
Anxiety
Adjustment or mood disorder
Positive mood
Negative mood
Illness uncertainty
+, positive relationship; -, negative relationship; 0, no significant relationship
*  CT, chemotherapy; RT, radiotherapy; †  pretreatment assessment; ‡  follow-up assessment; ¥ only at the initial assessment
§  JPSM: Journal of Pain and Symptom Management; CRTC: Cancer Research Therapy and Control
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During During During During 
chemotherapy chemotherapy chemotherapy chemotherapy
Jacobsen Jacobsen Berger and Berger and 
et al. JPSM§ et al. CRTC§ Higginbotham Walker
(1999) (1999) (2000) (2001)
0
0
+
+
+ +
+
+ +
+
+
+
+
+
+
0
+
During During During & after During & after
chemotherapy chemotherapy chemotherapy chemotherapy 
Tchen  Donovan Haghighat Mar Fan
et al. et al. et al. et al.
(2003) (2004) (2003) (2005)
0 0
0
0
0 0
- -¥
0
+
0
+ +
0
+
+
Disease / physical factors
Mast [39], Jacobsen et al. [24], Okuyama et al. [42], Haghighat et al. [28],
Donovan et al. [23], and Jacobsen et al. [25] found no relationship between
fatigue and stage of disease. Irrespective of the type of cancer treatment,
concurrent illness was found to have a strongly positive relation with fatigue
[39, 46]. Bower et al. [46] specifically reported the correlation with chronic
medical problems. The relationship between the two variables is not surprising,
because the most common symptom of illness is fatigue [1]. Blesch et al. [52]
reported a positive relationship between the duration of illness and fatigue in
patients with breast cancer. Their results with respect to concurrent illness are
corroborated by the findings by Gaston-Johansson et al. [38] and Berger and
Higginbotham [53]. Gaston-Johansson et al. [38] undertook a correlational
study of 127 women with breast cancer who had undergone mastectomy and
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Pre and after Pre and after Pre and during During During
chemotherapy chemotherapy chemotherapy chemotherapy chemotherapy
Author →
Andrykowski Nieboer Jacobsen Blesch Berger
et al. et al. et al. et al. and Farr
(2005) (2005) (2004) (1991) (1999)
Coping
Catastrophizing + 0
Treatment
Type of surgery 0
Undergoing mastectomy
Receiving treatment
Chemotherapy
Chemotherapy regimen
Number of courses of chemotherapy
Treatment type (CT or RT)* CT 0
Treatment type (CT or RT or both)*
Radiotherapy
Current tamoxifen use
Hormonal treatment
Combination of therapies
Extent of treatment
Time since treatment completion
Time since treatment
No. of years since initial diagnosis
No. of days since operation
+, positive relationship; -, negative relationship; 0, no significant relationship
*  CT, chemotherapy; RT, radiotherapy; †  pretreatment assessment; ‡  follow-up assessment; ¥ only at the initial assessment
§  JPSM: Journal of Pain and Symptom Management; CRTC: Cancer Research Therapy and Control
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had completed chemotherapy, while Berger and Higginbotham [53] undertook
a pilot study of 14 women with breast cancer to examine the relationship
between health status and fatigue. Both teams found a negative association
between fatigue and health status, with patients with a better health status
experiencing less fatigue. Jacobsen et al. [24] found the same negative association
before the start of treatment. On the other hand, they found no relationship
after the start of chemotherapy. 
None of the biochemical factors, such as hemoglobin or white blood
count, significantly influenced fatigue in the study by Blesch et al. [52]. They
mentioned that the nonsignificant findings might have been caused because
biochemical factors were abstracted from the medical record and were often
not collected concurrently with the person’s self-assessment of fatigue [52].
Tchen et al. [34] and Mar Fan et al. [35] found that the level of hemoglobin was
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During During During During 
chemotherapy chemotherapy chemotherapy chemotherapy
Jacobsen Jacobsen Berger and Berger and 
et al. JPSM§ et al. CRTC§ Higginbotham Walker
(1999) (1999) (2000) (2001)
+
0
0
During During During & after During & after
chemotherapy chemotherapy chemotherapy chemotherapy 
Tchen  Donovan Haghighat Mar Fan
et al. et al. et al. et al.
(2003) (2004) (2003) (2005)
0
+
0
0
0 0
0 0
CT 
0 0
+
0
↓
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After After After
chemotherapy chemotherapy chemotherapy
Author →
Andrykowski Broeckel Mast
et al. et al.
(1998) (1998) (1998)
Demographic
Age 0
Marital status
Income
Ethnicity
Educational attainment
Employment status
Disease/physical
Stage of disease 0
Haemoglobin level
Duration of illness
Biochemical factors
Concurrent disease +
Low level of activity
Menopausal status
Symptoms
Symptom distress
Physical symptom distress
Pain
Muscle and joint pain
Sleeping problems +
Nausea
Mouth sores
Muscle weakness
Change in taste
Chills
Vomiting
Menopausal symptoms +
Body mass +
Dyspnea
Psychological symptom distress
Depression +
History of major depressive disorder
Poor mental health
Emotional upset
Anxiety +
Adjustment or mood disorder +
Positive mood
Negative mood
Illness uncertainty +
+, positive relationship; -, negative relationship; 0, no significant relationship
* CT, chemotherapy; RT, radiotherapy
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After After After After After After 
chemotherapy chemotherapy chemotherapy chemotherapy chemotherapy chemotherapy
Woo Gaston- Bower Okuyama Curran Bower 
et al. Johansson et al. et al. et al. et al. et al.
(1998) (1999) (2000) (2000) (2004) (2006)
- -
-
-
0
0
0
0
+ +
+ + +
+ +
+
+
+ + + +
-
+
negatively associated with fatigue. On the other hand Nieboer et al. [27] did
not find any relationship. No relationship was also found between menopausal
status and fatigue [23, 25, 27]. 
The study by Berger and Farr [54] supports the idea that daytime inactivity
is associated with higher cancer-related fatigue. They studied the influence of
daytime inactivity and nighttime restlessness in 72 patients with breast cancer
during the first 3 chemotherapy cycles. Berger and Higginbotham [53] found
similar results in their pilot study: there was a positive relation between lower
activity rates and fatigue. Both studies found fatigue to be positively related to
night-time restlessness. 
Treatment factors
Jacobsen et al. [24], Donovan et al. [23], and Jacobsen et al. [25] concluded that
fatigue was not influenced by the type of surgery (lumpectomy or mastectomy). In
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After After After
chemotherapy chemotherapy chemotherapy
Author →
Andrykowski Broeckel Mast
et al. et al.
(1998) (1998) (1998)
Coping
Catastrophizing +
Treatment
Type of surgery
Undergoing mastectomy
Receiving treatment
Chemotherapy +
Chemotherapy regimen
Number of courses of chemotherapy
Treatment type (CT or RT)*
Treatment type (CT or RT or both)*
Radiotherapy
Current tamoxifen use
Hormonal treatment 0
Combination of therapies
Extent of treatment 0
Time since treatment completion 0
Time since treatment 0
No. of years since initial diagnosis
No. of days since operation
+, positive relationship; -, negative relationship; 0, no significant relationship
* CT, chemotherapy; RT, radiotherapy
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contrast, undergoing mastectomy was a significant predictor of fatigue in the
study of Haghighat et al. [28]. Jacobsen et al. [24], Tchen et al. [34] and Mar Fan
et al. [35] did not find any association between fatigue and chemotherapy
regimens. Data provided by Mast [39] suggest that chemotherapy, with or without
radiation therapy, is associated with long-term fatigue. Bower et al. [46] found
similar results. They reported that women in the fatigued group were more likely
to have been treated with a combination of chemotherapy and radiation therapy
or with chemotherapy alone than those in the nonfatigued group. The latter group
was more likely to have been treated with radiation alone or with surgery alone.
This finding is corroborated by the results obtained by Okuyama et al. [42], who
found no correlation between fatigue and radiation therapy. On the other hand,
fatigue was not correlated with past intravenous chemotherapy in this study.
Jacobsen et al. [25] and Haghighat et al. [28] have similar findings. Jacobsen et al.
[25] reported no influence of type of treatment (chemotherapy or radiotherapy) on
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After After After After After After 
chemotherapy chemotherapy chemotherapy chemotherapy chemotherapy chemotherapy
Woo Gaston- Bower Okuyama Curran Bower 
et al. Johansson et al. et al. et al. et al. et al.
(1998) (1999) (2000) (2000) (2004) (2006)
+ 0
both
0
0 0
+
0
0
↓
fatigue and Haghighat et al. [28] found that variables including, receiving
treatment, receiving chemotherapy and receiving radiotherapy were not
significant predictors. Mar Fan et al. [35] did not find an association between
fatigue and the variables ‘adjuvant radiotherapy’ and ‘adjuvant hormonal
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Figure 1. Model of fatigue and its relations based on literature
therapy’. Contrary, Donovan et al. [23] found that fatigue in women with early
stage breast cancer differs as a function of the type of treatment and sequencing
of treatment. Women who received chemotherapy during initial treatment
reported greater severity of fatigue than women receiving radiotherapy during
initial treatment [23]. Andrykowski et al. [26] found similar results. Donovan et al.
[23] also reported that women not pre-treated with chemotherapy experienced
increased fatigue over the course of radiotherapy, whereas women pre-treated
with chemotherapy did not. They believe the finding is consistent with research
suggesting a response shift, or a change in internal standards [23]. Bower et al.
[47] showed in their longitudinal off treatment study that women treated with
either radiation or chemotherapy alone experienced a small improvement in
fatigue compared with those treated with both radiation and chemotherapy. The
studies by Mast [39], Bower et al. [46], and Okuyama et al. [42] and Mar Fan et
al. [35] found no relationship between fatigue and hormonal treatment. On the
other hand, in the study of Haghighat et al. [28] fatigue was predicted by current
tamoxifen use. Recombinant human erythropoietin (rHuEPO), a red blood cell
production stimulating hormone, is nowadays frequently used in cancer patients
as a treatment of anemia and the thereby possible related symptom fatigue. In
2001 a meta-analysis of all randomised clinical trials (RCT) was executed in
cancer patients with respect to rHuEPO efficacy [55]. The authors concluded that
rHuEPO is able to heighten hemoglobin levels and to diminish the chance on
transfusions in patients with hemoglobin levels 6.2 mmol/l and lower. Moreover,
rHuEPO improved the quality of life for patients with hemoglobin levels 6.2
mmol/l and lower. For patients with hemoglobin levels 6.0 mmol/l and higher
results were not sufficiently evident [55]. Note that the studies on rHuEPO are
executed in patients with different kinds of cancer. 
A combination of treatments seems to increase the levels of fatigue, as was
found in a study by Woo et al. [51]. They concluded that women who received
combination therapy (combination of radiation, chemotherapy and hormone
therapy) experienced significantly more fatigue than those who received
radiation alone. Woo et al. [51] commented that this difference may have been
affected by the disease stage and the treatment, because combination therapy is
primarily used for women with advanced stages of breast cancer. Andrykowski
et al. [56] did not find a relationship between fatigue and the type of treatment
in the breast cancer group. 
The influence of time on fatigue has not been thoroughly examined,
although different periods of time after treatment or diagnosis have been
studied. Andrykowski et al. [56] found that time since treatment completion did
not appear to explain fatigue, and Mast [39] did not find a relationship between
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fatigue and time since treatment either. The number of years since the initial
diagnosis did not affect fatigue in the study by Bower et al. [46], and fatigue
was not influenced by the number of days since operation in the study by
Okuyama et al. [42]. Numbers of chemotherapy courses was not a significant
factor in the studies of Tchen et al. [34] and Mar Fan et al. [35].
Symptoms 
Berger and Higginbotham [53] found a correlation between greater levels of
fatigue and more symptoms of distress. Fatigue and the symptoms accompany
one another [57]. Most other studies have examined single associations
between particular symptoms and fatigue. 
Physical symptom distress
All retrieved manuscripts found a positive relationship between pain and
fatigue [24, 27, 28, 38, 45, 46, 52]. Not unexpectedly, they also found a
positive association between sleeping problems and fatigue [24, 42, 44, 46, 53,
54], except in the study of Haghighat et al. [28]. 
Okuyama et al. [42] found a positive association between fatigue and
dyspnea, which they  assumed might have been caused by the delayed effect of
cancer treatment or by fear of recurrence, because there is evidence that dyspnea
is associated with psychological status in a healthy population. On the other
hand, Haghighat et al. [28] did not find a relationship between fatigue and
dyspnea. 
Andrykowski et al. [56] found that fatigue was positively correlated with
body mass because women who were heavier experienced greater fatigue.
Weight gain caused by chemotherapy-induced hyperphagia is the most popular
theory. Other mechanisms that could explain weight gain are a reduction in
physical activity, metabolic rate or thermogenesis [58]. 
Results on the influence of menopausal symptoms have not been
unequivocal. Some researchers found that fatigue was significantly more severe
among patients with more menopausal symptoms such as hot flushes and night
sweats [34, 35, 44, 46]. Broeckel et al. [44] suggested that two mechanisms
could contribute to increased fatigue in menopausal subjects. The increase in
nighttime vasomotor symptoms and the menopausal symptoms could intensify
depressive symptoms, including fatigue. On the other hand, Jacobsen et al. [24]
found no association between fatigue and menopausal symptoms. 
Jacobsen et al. [24] mentioned positive correlations between fatigue and
some physical symptoms such as nausea, mouth sores, muscle weakness,
change in taste, chills and vomiting.
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Psychological symptom distress
Like pain and sleeping problems, depression was found to correlate with fatigue
in a number of studies [24, 28, 38, 42, 46, 47, 56]. Andrykowski et al. [26]
found that patients with CRF were more likely to have a history of major
depressive disorder. The relationship between the fatigue and depression is not
unexpected, because one of the symptoms of depression is fatigue and chronic
fatigue might be one of the causal factors of depression. Broeckel et al. [44]
reported that pain and psychological distress are likely causes of sleep disturbance.
This would imply that the variables pain, sleep problems and depression are
interrelated. 
Other positive relations between psychological symptoms and fatigue were
found in the studies by Broeckel et al. [44], Haghighat et al. [28], Mast [39],
Jacobsen et al. [24], Curran et al. [45] and Nieboer et al. [27]. Broeckel et al.
[44] reported a relationship between fatigue and the variables anxiety and mood
disorder. Haghighat et al. [28] also found a positive relationship between fatigue
and anxiety. Mast [39] reported a positive relationship with illness uncertainty,
and Jacobsen et al. [24] found a similar relationship with emotional upset. In the
study of Curran et al. [45] positive and negative mood was significantly
associated with fatigue. 
The relation between two symptoms is difficult to define, because it is
often not clear which symptom is the cause and which is the effect. Besides,
some symptoms are inextricably linked. 
Social factors 
According to social support no specific literature was found about the relationship
between this variable and fatigue in women with breast cancer. However many
authors underline the positive influence of social support on well-being of
people.
The author of an early study [59] had already reported that the uncertainties
and fears experienced by a person diagnosed with cancer are likely to result in
an enhanced need for social support. Nowadays, the importance of social
relationships and social support for an individual’s well-being has become
common knowledge [60]. Van den Akker et al. [61] reported that involvement in
more social networks seems to protect against morbidity. Social support is
expected to have buffer effects, which means that social support protects people
from the deleterious effects of stress [60]. Komproe et al. [60] reported that many
researchers have underlined the relationship between social support and
physical and psychological well-being. 
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Coping factors
McHaffie [62] reported that how well a person copes is central in determining
his or her well-being, no matter how ill he or she is. The daily lives of almost
every individual are filled with stressful experiences which require some form
of coping [62]. The impact of each varies, because people are moving among
their many roles and because these roles are changing [62]. Individuals with
cancer must deal with the treatment process and its side effects, the uncertainty
of the disease course and adapt to the changes in physical functioning and
other negative life changes that are inevitably imposed by the disease [63].
Distinct coping behaviours and thought can influence outcomes [64], such as
fatigue. Most researchers have focused on individual coping behaviours or
thoughts [64]. Like Broeckel et al. [44], Jacobsen et al. [65] and Andrykowski et
al. [26], they found a positive relation between fatigue and the use of
catastrophizing as a coping strategy, which is characterized by negative self-
statements and negative thoughts and ideas about the future. In these studies
women with breast cancer were examined. In another breast cancer study of
Jacobsen et al. [25] no relationship was reported between these two variables. 
A study [64] in women with stage II breast cancer receiving adjuvant
chemotherapy showed that confrontive subjects reported significantly fewer
side effects than avoidant-confrontive and avoidant-resigned copers. Confrontive
copers reported more optimism, information seeking, and more willingness to
be involved in treatment decisions. 
Manne et al. [63] studied 43 women receiving adjuvant chemotherapy for
breast cancer. They found that avoidant coping was associated with negative
affect. In their study, escape-avoidance was described as behavioural and
cognitive efforts to escape or avoid [63]. In the same study of Manne et al. [63],
‘distancing’ was described as cognitive strategies to create a positive outlook or
detach from situation. Manne et al. [63] reported that ‘distancing’ was positively
associated with positive affect.
DISCUSSION AND CONCLUSIONS
Fatigue is one of the most common and problematic side effects of breast cancer
treatment. High and fluctuating prevalence rates of fatigue have been found not
only during but also after the administration of adjuvant chemotherapy.  
In contrast with the common perception that more chemotherapy treatments
lead to greater fatigue, studies reported on in the literature found the intensity of
fatigue to be stable throughout the treatment cycles. Patients becoming accustomed
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to fatigue might cause this. In other words, the standard for determining the level
of fatigue might be changing, a shift in the internal norm. This process of changing
one’s internal standard is called response shift [66]. 
After the treatment with adjuvant chemotherapy has ended, patients with
breast cancer still experience fatigue, but because everyone experiences fatigue
on a daily basis, it is unknown whether this fatigue can be regarded as normal
fatigue. Further research should include this important aspect. 
There is clearly a fluctuating intensity of fatigue within two cycles of
chemotherapy treatment. The first two days after the administration of the
chemotherapy treatment seem to be the worst. Practitioners should inform
patients with cancer about this potential pattern of fatigue to help them, for
example, make appropriate plans for daily activities. 
The mechanisms of fatigue development are still poorly understood. The
present literature study tried to identify factors relating to fatigue in patients with
breast cancer, but found, for instance, that the relationship between fatigue and
age does not seem to be unequivocal. Whereas some studies found no evidence
of a relation between the two factors, some found a significant negative correlation,
with younger women appearing to be more fatigued. Woo et al. [51] commented
that this negative association might be caused by the more aggressive therapy that
may have been given to younger women compared to those aged over 60 years.
Another reason they suggested may be that more of the younger women had jobs
and had the responsibility of caring for their families and young children, giving
them fewer opportunities to save energy. 
The relationships between fatigue and poorer health status and between
fatigue and concurrent illness are unequivocally positive. These relationships are not
unexpected, because the most common symptom of illness is fatigue [1]. By
contrast, stage of disease did not appear to explain fatigue. Ongoing research
involving the hormonal treatment, such as rHuEPO, must be done. The influence of
rHuEPO on quality of life is not clear. EPO may be helpful in a subset of patients. 
It is obvious that fatigue is associated with various physical and psychological
symptoms. More specifically, research has shown that pain, sleeping problems and
depression are positively related to fatigue. It is not unlikely that these variables are
interrelated. For instance, Broeckel et al. [44] reported that pain and psychological
distress are likely causes of sleep disturbance. Contradictory results have been
found with respect to the influence of menopausal symptoms. Lower levels of
activity seem to show a positive relationship with fatigue, whereas some factors,
such as change in weight, biochemical factors, the effect of certain coping strategies,
and social support, have not been thoroughly studied, or even studied at all, so
there is a clear need for further research.
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The outcomes of the studies suggest that several of the symptoms are interrelated
in a network of symptoms. This could explain why the results often fail to prove
clearly whether it is the physical and/or psychological symptoms that cause
fatigue or vice versa. 
Studies examining the unusual character of fatigue in patients with cancer
have been virtually lacking, although the NCCN definition of cancer-related
fatigue suggests that fatigue in patients with cancer is of a specific and unusual
nature. Only the study by Schwartz [36] assessed the specific character of
fatigue in patients with cancer. 
Comparisons between the various studies are hampered by a number of
aspects, the most obvious of which is the use of many different measuring
instruments for fatigue and side effects: more than 10 different instruments were
used for fatigue and as many for side effects. This raises questions about the
validity of these comparisons. The differences in the answering options/ categories,
the use of unidimensional or multidimensional measures of fatigue and the
reliability and validity of the instruments must be considered. Three of the fatigue
studies used only unidimensional instruments, which means that the value of their
findings is very limited. Some studies used combinations of different instruments
and assessed data at different points in time. Patients were sometimes flooded
with questionnaires, which might lead to them becoming tired of filling in
questionnaires and hence affect the value of their answers. Other factors that may
impede comparisons between the studies include the lack of a uniform definition
of fatigue, the use of insufficiently valid and reliable instruments to measure
fatigue, the lack of uniformity in measurement points, and the variety of research
designs used in the studies.
Some studies collected data during chemotherapy, whereas others collected
data after the completion of chemotherapy. Few studies have so far addressed the
effect of chemotherapy on fatigue during as well as after the administration of
chemotherapy. A few studies had cross-sectional designs, whereas others had
longitudinal designs. Research with a longitudinal design can address the
development of fatigue over time, while studies with a cross-sectional design,
which involve the collection of data only at one point in time, cannot. 
It should be noted that women might already have experienced fatigue
before starting any treatment. Authors often suggest that fatigue did not occur in
their population before surgery. A study by Cimprich [67], however, provides
evidence to the contrary. She studied 74 newly diagnosed patients with breast
cancer, gathering data about 11 days before primary surgery, and found that 77%
of the patients in the sample reported fatigue (ranging from mild to moderate
levels). Longitudinal research that starts before surgery is needed. Fatigue as a
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sequela of surgery in patients with cancer has rarely been examined, perhaps
because it is difficult to separate the consequences of surgery and anaesthesia
from those of subsequent treatment [68]. Patients with cancer have often not fully
recovered from surgery when adjuvant therapy is started [7]. 
An additional problem is the small sample size used in some of the studies,
which makes it difficult to draw firm conclusions. 
Because everyone experiences fatigue on a daily basis, it is difficult to
distinguish between cancer-related fatigue and normal fatigue. A possible
solution to this problem would be to study patients with cancer as well as
healthy subjects. Most studies included in the present literature review did not
use control groups. Another difficulty in measuring fatigue is its subjectivity. A
person who objectively suffers a high level of fatigue may be less bothered by it
than someone suffering less fatigue. Everyone copes with fatigue in a different
way, and this variation in coping with fatigue has hardly been studied. Besides,
most studies fail to distinguish whether the fatigue experienced affected daily
functioning.
That breast cancer is a leading type of cancer among women, and that
fatigue is recognised as having a great impact on the quality of life means that
further research is needed. Ongoing studies are expected to tell us more about
fatigue and the related factors and to provide more information about possible
treatments of this complex problem.
Further research, involving larger and more homogeneous samples, must
be done. The use of healthy control subjects for comparison in a study with a
longitudinal design would be advisable, while the typical characteristics of
cancer-related fatigue must also be taken into account. 
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ABSTRACT
Background: The purpose of this study was to determine the prevalence of
fatigue and the course of fatigue as a function of chemotherapy in breast cancer
patients undergoing adjuvant chemotherapy. 
Patients and methods: In a prospective cohort study, a sample of 157 patients
with breast cancer were interviewed, using the Rotterdam Symptom Checklist
and the Multidimensional Fatigue Inventory, at the first, third and fifth cycle of
adjuvant chemotherapy, as well as 4 and 12 weeks after the last cycle of adjuvant
chemotherapy. Patients were treated with either a doxorubicin-containing schedule,
or cyclophosphamide, methotrexate and 5-fluorouracil (CMF). 
Results: The courses of general and physical fatigue are to a large extent similar.
After the last cycle of chemotherapy, the CMF group reports a significant increase
in fatigue, which was followed by a significant reduction. In the doxorubicin group
a significant increase in fatigue was only seen during the first cycles of
chemotherapy. The fatigue experienced at the first and the last measurements
do not differ significantly. 
Conclusions: The prevalence of fatigue increased significantly after the start of
chemotherapy. After chemotherapy treatment the prevalence rate seemed to
decline. A different impact of chemotherapy on the course of fatigue was found.
In the doxorubicin group a direct increase in fatigue was found. In the CMF
group a moderate direct increase occurred, followed by a delayed strong
increase. An increase in fatigue was associated with a decrease in daily
functioning. At all measurement occasions fatigue was affected by type of
operation, such that women with a mastectomy were more fatigued than women
that underwent a lumpectomy. Receiving radiotherapy also led to an increase in
fatigue. With this knowledge breast cancer patients can be better informed
about what they can expect. Further research should include interventions
addressing how to reduce or cope with fatigue during as well as after receiving
adjuvant chemotherapy. 
Keywords: adjuvant chemotherapy, breast cancer, fatigue
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INTRODUCTION
Fatigue is a major concern for the patient with cancer [1]. Partly as a result of
longer cancer survival, it is increasingly being realised that quality of life in
cancer patients is affected by fatigue. The National Comprehensive Cancer
Network (NCCN) stated that fatigue affects 70-100% of cancer patients [2]. 
Fatigue is a universal experience and is normally relieved by a good night’s
sleep. For cancer patients fatigue often becomes a chronic and unpleasant
sensation [3]. Fatigue can be a symptom of the disease itself and may accompany
cancer treatment [4]. Cancer patients receiving chemotherapy may experience a
variety of side-effects, such as pain, nausea, vomiting, hair loss, weight changes,
fatigue and anxiety; however, the most commonly reported side-effect is fatigue. 
Breast cancer has been the most frequent type of cancer in women since
the early 1990s, not only in the Netherlands but also elsewhere. Adjuvant
chemotherapy is part of the standard treatment in a large subset of patients. 
According to the literature, 58-94% of the breast cancer patients
experience fatigue during treatment with adjuvant chemotherapy [5-7]. In the
study of Sitzia and Huggins [6] patients with breast cancer (n = 52) who were
receiving six cycles of cyclophosphamide, methotrexate, and 5-fluorouracil
(CMF) were examined. Data were collected after each cycle. An incidence rate
of approximately 90% was found. Fatigue severity remained stable throughout
the treatment cycles. Results from Berger [8], who showed that in 72 patients
with breast cancer fatigue levels 48 hours after each of the first three chemotherapy
cycles were not significantly different over time, support this finding. Jacobsen
et al. [7] also reported similar result, though the prevalence and severity of
fatigue significantly increased after the start of chemotherapy, after which the
prevalence of fatigue showed a stable pattern. The chemotherapy regimens in
this study contain all doxorubicin. Data were collected before the start of each
of the first four chemotherapy cycles [7].
Studies on fatigue in breast cancer patients after the treatment with adjuvant
chemotherapy show prevalence rates between the 56% and 95% [9-12]. Only
Beisecker et al. [10] reported prevalence rates at several time points after the
treatment with adjuvant chemotherapy. They studied 21 patients with node-
negative breast cancer who had undergone adjuvant chemotherapy. Shortly
after completion the prevalence rate was 95% followed by 83% 6 months later. 
Berger and Higginbotham [13] studied 14 breast cancer patients during as
well as after doxorubicin-cyclophosphamide chemotherapy. In this pilot study,
fatigue was a significant problem throughout cycle three of adjuvant breast cancer
chemotherapy and continued at lower levels 2 months after the last treatment. 
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The impact of different chemotherapy regimens, such as doxorubicin-containing
regimens, on the course of fatigue is unclear and less studied. Greene et al. [5]
reported no significant differences in intensity of fatigue related to whether
doxorubicin was included. Berger and Walker [14] found recently that
chemotherapy protocols which contain intravenous doxorubicin were directly
associated with higher fatigue at the first treatment. They studied 60 women
during the first three cycles of adjuvant breast chemotherapy [14]. 
There is evidence that fatigue has a strong impact on daily functioning.
Berger and Higginbotham [13] reported that higher fatigue was associated with
lower activity; Berger and Far [15] found similar results. The latter studied 72
breast cancer patients during the first three chemotherapy cycles after surgery for
stage I/II disease [15]. The study strongly supports the position that higher fatigue
is associated with daytime inactivity. Berger [8] reported in her study not only a
negative correlation between fatigue and activity level, but also found that activity
levels were significantly lower in women receiving doxorubicin-based protocols. 
Taken together, these studies support the hypothesis that fatigue is highly
prevalent during as well as after the treatment of chemotherapy. Additionally,
these studies suggest that the intensity of fatigue stays stable throughout 
the treatment cycles and declines after completion. The impact of different
chemotherapy regimens, such as doxorubicin-containing regimens, on the course
of fatigue is unclear and will therefore be further examined in the present study.
A last hypothesis is that fatigue will have a strong impact on daily functioning. 
It should be noted that previous studies had several limitations [16], such as a
small sample size, the lack of a well-validated measure of fatigue and the absence
of a longitudinal design in which patients with breast cancer were studied during,
as well as after, receiving adjuvant chemotherapy. The purpose of the present study
was to investigate the course of fatigue during (two or three measurement points) as
well as after (two measurement points) adjuvant chemotherapy in an attempt to
circumvent the major weaknesses of previous studies.
PATIENTS AND METHODS
Population sample and procedure
All breast cancer patients with an indication for adjuvant chemotherapy treated
in six hospitals, mainly in the south of The Netherlands, were invited to participate
in this study. After checking the inclusion criteria, either the oncologist or the
oncology nurse introduced the study to the patient before the first cycle of
adjuvant chemotherapy with written information describing the purpose and
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procedure of the investigations. After the patient had given written informed
consent, either the oncologist or the oncology nurse contacted the principal
investigator of this study. The principal investigator and a properly trained
assistant conducted the interviews. The study was approved by all local medical
ethical committees of the participating centres.
Eligible breast cancer patients met the following criteria: (i) absence of
metastasis or other malignancy; (ii) no previous treatment with cytostatics; (iii)
adjuvant chemotherapy treatment was as an outpatient; (iv) absence of chronic
disease (such as hypertension, kidney disease, heart problems, diabetes mellitus,
etc.) or poor psychological state; (v) no use of morphine or narcoleptics; (vi) no
deafness; (vii) ‘18 years of age; and (viii) Dutch-speaking.
Patients were interviewed five times using the Multidimensional Fatigue
Inventory (MFI-20) [17] and the Rotterdam Symptom Checklist (RSCL) [18],
except when receiving the cyclophosphamide and doxorubicin (CA) treatment,
in which case participants were interviewed four times. The first interview was at
the start of chemotherapy, the second at the third cycle and the third at the fifth
cycle, except for the CA regimen, where the third interview was omitted. The last
two interviews were 4 weeks and 12 weeks, respectively, after the last cycle. The
first three interviews took place in the hospital and were held directly before,
during or after infusion. The last two interviews were done by phone. After the
interviews the medical data were retrieved from charts. 
Operationalisation of variables
Intensity of fatigue. The RSCL is an instrument to measure the quality of life of
cancer patients [18]. In the present study, one item of the subscale physical
symptom distress was used. At each measurement the patient was asked to
answer the following question: have you been bothered, during the last 2
weeks, by tiredness? The answers given are ‘not at all’, ‘a little’, ‘quite a bit’ and
‘very much’. This item was used to examine the prevalence of fatigue during the
study and the scores discriminated significantly between patients scoring high
and low on MFI.
MFI-20 [17] was used to assess the course of fatigue. This 20-item
questionnaire, especially designed for cancer patients, is a self-report instrument
consisting of five subscales based on different dimensions: general fatigue,
physical fatigue, reduced activity, reduced motivation and mental fatigue. Each
subscale consists of four items and the score for each subscale was calculated as
the sum of the scores of the four items. High scores indicate more subjective
fatigue. The MFI-20 was previously tested and validated in cancer patients
receiving radiotherapy, patients with ‘chronic fatigue syndrome’, psychology
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students, medical students, army recruits and junior physicians. The internal
consistency for the different scales and different patient groups, as measured by
Cronbach’s alpha averaged 0.84 (range 0.53-0.93) [19]. In the present study, we
focus on the results for the two subscales general and physical fatigue. In addition,
correlations between the subscale ‘reduced activity’ and these two subscales
were calculated to give an impression of the impact of fatigue on daily
functioning. 
In this study, patients were asked to rate, in an interview, their fatigue as
experienced during the previous 2 weeks. The items were administered in a face-
to-face interview, instead of presenting the items in a self-report questionnaire,
for the practical reason that the patients were already being interviewed. In
addition, filling in a self-report questionnaire was expected to be too time-
consuming for the patient. 
Treatment of adjuvant chemotherapy. Patients were treated with one of the
following adjuvant treatments: cyclophosphamide, 4-epi-doxorubicin and 5-
fluorouracil (CEF), every 21 days; cyclophosphamide, doxorubicin and 5-
fluorouracil (CAF), every 21 days; 4-epi-doxorubicin, every 28 days (on days 1
and 8); 4-epi-doxorubicin-taxotere with the first three cycles every 28 days (on
days 1 and 8) and the last three cycles every 21 days; cyclophosphamide and
doxorubicin (CA), every 21 days; or CMF [cyclophosphamide, methotrexate
(oral administration from days 1 to 14 or intravenous) and 5-fluorouracil] every
28 days (on days 1 and 8). Most regimens consist of six cycles, except for the
CA regimen, which consists of four. The choice for either schedule was based
on current practice in the participating hospitals. The involvement of different
adjuvant chemotherapy regimens made it possible to create a sizeable sample
in a relatively short period of time. In the analysis two groups were compared:
the doxorubicin group (CEF, CAF, 4-epi-doxorubicin, 4-epi-doxorubicin-
taxotere and CA) and the CMF group. 
Stage of breast cancer. The tumor-node-metastasis TNM clinical classification is
used to describe the anatomic extent of breast cancer [20]. 
Type of operation. Patients in the present study underwent a mastectomy or a
lumpectomy with or without lymph nodes excision. Eventually, two groups
were considered because of small sizes of the other groups: (i) mastectomy with
lymph nodes excision; and (ii) lumpectomy with lymph nodes excision. No
reconstructive surgery was done during the study period.
Statistical Analyses
First, it was statistically tested whether there were differences in patient
characteristics between the CMF group and the doxorubicin group.
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The prevalence of fatigue at each measurement point was determined by
choosing a cut-off for the scores on the single item of the RSCL. This allowed for
creating a fatigue and a non-fatigue group.  Differences in prevalence across time
were analysed through a logistic multilevel model using the MLwiN program
(version 1.10.0006) [21]. The data consist of repeated measurements nested
within hospitals and individual subjects. The data, which have a hierarchical
nature, may be characterised by dependencies between units at lower levels of
the hierarchy. In this case multilevel analysis is an appropriate technique [22]. The
course of fatigue, using two subscales of the MFI-20, and the dependency on the
type of adjuvant chemotherapy treatment, was analysed with a linear multilevel
model also using the MLwiN program. 
In the prevalence analyses, as well as the analyses concerning the effect of
chemotherapy regimen on the course of fatigue, dummy variables were included
to represent the several measurement points. When the first measurement is taken
as a reference, changes relative to the baseline measurement are analysed.  The
effect of chemotherapy on the course of fatigue was represented by interaction
terms between these dummy variables and a binary variable chemotherapy. To
correct for possibly confounding factors in this analysis, several covariates were
added: ‘age’, ‘marital status’, ‘having children’, ‘education’, ‘having a job’, ‘type
of operation’, ‘stage of breast cancer’, ‘haemoglobin level (measured in mmol/l)
before the first treatment of chemotherapy’, ‘the number of days between the
operation and the first treatment of chemotherapy’, ‘the number of treatments at
each measurement point’ and ‘radiotherapy’. For the covariate ‘radiotherapy’,
three different variables were used: a variable indicating whether a patient had
received radiotherapy at any point of measurement, the number of days of
radiotherapy the patient had had at the time of measurement and the number of
days between the last day of radiotherapy and the time of measurement. Also
these covariates were included as interaction terms with the dummy variables
representing the time points. In this way, possible differences in patient characteristics
between the chemotherapy groups are corrected for.
Stepwise deletion took place in which non-significant covariates were
removed. The effect of the variable ‘treatment of adjuvant chemotherapy’ was
examined after the final model was determined in which only significant
covariates were included. For the final model, fatigue scores, which are baseline
differences and are also adjusted for differences between the chemotherapy
groups, can be calculated. These will be denoted as adjusted baseline differences. 
Correlations were also calculated between the subscales ‘reduced activity’
and ‘general fatigue’, as well as between ‘reduced activity’ and ‘physical
fatigue’, to give an impression of their relationship. 
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RESULTS
Response Rate
A total of 175 breast cancer patients were eligible for the study. Of this sample,
18 (10%) patients were excluded for different reasons: 13 (7%) declined further
participation; three (2%) stopped adjuvant chemotherapy prematurely; and two
(1%) had a poor physical state. The remaining 157 patients were interviewed
four (n = 20) or five (n = 137) times depending on their adjuvant chemotherapy
schedule. The response rates are shown in Table 1. The non-response was
caused by a change in the schedule of the treatment of chemotherapy except
for two interviews. These two interviews were lacking because the interviewer
missed one interview and one patient refused to be interviewed. The principal
investigator of the study conducted 79% of the interviews. The other interviews
were conducted by an assistant.
Sample Characteristics
Twenty-nine percent of the patients had received the CMF treatment, the
remainder received one of the chemotherapy regimens covered by the
doxorubicin group. Information about the demographic and medical
characteristics of these two groups are listed in Table 2. There were two
characteristics on which the groups differed. Patients in the CMF group were
significantly (t = -2.133; P = 0.035) younger than patients in the doxorubicin
group. The mean age was 45.0 ± 7.9 years in the CMF group and 48.2 ± 9.0
years in the doxorubicin group. Significantly [χ2(1) = 4.768, P = 0.034] more
patients in the CMF group had a job compared with the doxorubicin group.
There were no significant differences with respect to the other characteristics in
Table 2. Details of the total number of chemotherapy treatments for each of the
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Measurement Total (n) Participants in study
n %
1 157 157 100
2 157 157 100
3* 137 135 99
4 157 152 97
5 157 152 97
* Patients receiving only four chemotherapy treatments did not have this interview.
Table 1. Response rates of patients with breast cancer specified for each measurement occasion
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Doxorubicin group CMF group Total
(n = 111) (n = 46) (n = 157)
Age (years)*
Mean (SD) 48.2 (9.0) 45.0 (7.9) 47.3 (8.8)
Range 27-70 25-62 25-70
n % n % n %
Marital status
Married/living together 91 82 40 87 131 83
Single 11 10 3 7 14 9
Divorced 7 6 3 7 10 6
Widow 2 2 - - 2 1
Children
Yes 87 78 37 80 124 79
No 24 22 9 20 33 21
Educational level
Low 43 39 13 28 56 36
Middle 43 39 24 52 67 43
High 25 23 9 20 34 22
Job*
Yes 59 53 33 72 92 59
No 52 47 13 28 65 41
Stage of breast cancer†
I 9 8 3 7 12 8
II 90 81 35 76 125 80
III 4 4 2 4 6 4
I and III (two tumours) - - 1 2 1 1
Unknown (missing at the data 
collection point) 8 7 5 11 13 8
Type of operation‡
Mastectomy without lymph nodes excision 3 3 - - 3 2
Mastectomy with lymph nodes excision 53 48 20 43 73 47
Lumpectomy without lymph nodes excision 1 1 - - 1 1
Lumpectomy with lymph nodes excision 52 47 26 57 78 50
Unknown 2 2 - - 2 1
Treatment of adjuvant 
chemotherapy
CEF 38 34 - - 38 24
CAF 27 24 - - 27 17
4 epi-doxorubicin 21 19 - - 21 13
4 epi-doxorubicin / taxotere 5 5 - - 5 3
CA 20 18 - - 20 13
CMF (no oral administration) - - 15 33 15 10
CMF (partially oral administration) - - 31 67 31 20
Radiotherapy
Yes 75 68 33 72 108 69
No 36 32 13 28 49 31
Anaemia (haemoglobin level, 
mmol/l < 7.3)§
Yes 10 9 1 2 11 7
No 99 89 43 94 142 90
Unknown 2 2 2 4 4 3
Tab
le 2.
Patient characteristics
chemotherapy regimens and the number of patients receiving radiotherapy at
the different measurement points are displayed in Tables 3 and 4, respectively. 
Prevalence of fatigue
Table 5 contains the results for the single item of the RSCL. For three different
classifications into a non-fatigue group and a fatigue group, the prevalences of
fatigue were compared across time. For each fatigue classification the prevalence
significantly increased at measurement point 2. Between following consecutive
time points no significant differences in the prevalence were found except for
classification II. For this fatigue classification the prevalence significantly
decreased at the last measurement. For the other fatigue classifications a
decrease was also seen, but these did not turn out to be significant. 
Course of fatigue
The course of fatigue was studied by analysing the results for the two subscales of
the MFI-20: general fatigue and physical fatigue. The results for these two subscales
are to a large extent similar and are therefore presented together in the next section. 
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Table 2. Patient characteristics (continued)
Length of radiotherapy treatment 
(days)
Mean (SD) 42.9 (5.7) 43.4 (5.5) 43.1 (5.6)
Range 26-51 32-57 26-57
Number of radiotherapy treatments
Mean (SD) 30.4 (3.5) 30.4 (3.4) 30.4 (3.5)
Range 25-35 25-33 25-35
Days between operation and 1st 
chemotherapy treatment
Mean (SD) 33.9 (21.6) 38.8 (26.5) 35.3 (23.2)
Range 9-215 15-125 9-215
Haemoglobin level, mmol/l§
Mean (SD) 8.1 (0.8) 8.3 (0.6) 8.2 (0.7)
Range 5.9-9.7 7.0-9.9 5.9-9.9
* Statistically significant difference (P < 0.05) in characteristic between the doxorubicin and CMF groups.
† Three groups, stage of breast cancer I, II and III, were included in the comparison between the doxorubicin 
and CMF groups.
‡ Two groups, mastectomy or lumpectomy with lymph nodes excision, were included in the comparison between 
the doxorubicin and CMF groups.
§ The haemoglobin level was determined before the first treatment of chemotherapy; the conversion factor 
from mmol/l to g/dl is 1.6.
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Table 4. Overview of numbers of patients with breast cancer receiving radiotherapy specified
for each measurement occasion
Total number of treatments → 4 5 6 8
Total (n)
Treatment of adjuvant 
chemotherapy
CEF - 6 24 8 38
CAF - 3 24 - 27
4 epi-doxorubicin - - 21 - 21
4 epi-doxorubicin-taxotere 1 1 3 - 5
CA 20 - - - 20
Total for doxorubicin group 21 10 72 8 111
CMF - - 46 - 46
Table 3. Total number of treatments specified for each chemotherapy treatment (n = 157)
GENERAL AND PHYSICAL FATIGUE
As far as the covariates are concerned, the following variables had significant
effects on general as well as physical fatigue: ‘type of operation’ [Δχ2(1) =
147.384, P < 0.01 and Δχ2(1) = 153.968, P < 0.01, respectively], ‘the duration
of radiotherapy’ [Δχ2(1) = 19.529, P < 0.01 and Δχ2(1) = 33.404, P < 0.01,
respectively]; and ‘the interval between measurement point and the last
radiotherapy’ [Δχ2(1) = 11.347, P < 0.01 and Δχ2(1) = 6.831, P < 0.01,
respectively]. Women with a mastectomy were more fatigued than women that
underwent a lumpectomy. The effects for radiotherapy were the longer the
duration of radiotherapy, the higher the fatigue, and the longer the time interval
between the last radiotherapy session and the measurement point, the less the
fatigue experienced at that measurement point.
The covariate ‘marital status’ was only significant for general fatigue [Δχ2(3)
= 10.736, P < 0.05]. Divorced women were more fatigued than women living
with a partner [Δχ2(1) = 9.515, P < 0.01], and were more fatigued than single
Measurement Receiving radiotherapy at Receiving or having finished
occasion measurement radiotherapy at measurement
n % n %
1 8 5 10 6
2 58 37 89 57
3* 3 2 94 60
4 8 5 98 62
5 2 1 103 66
* Patients receiving only four chemotherapy treatments did not have this interview.
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women [Δχ2(1) = 4.241, P < 0.05]. The course of physical fatigue is significantly
different for the number of treatments [Δχ2(4) = 10.429, P < 0.05]. The effect of
this covariate on the course of physical fatigue will be described later.
Figure 1 displays the adjusted baseline differences for general fatigue. The
course of general fatigue is significantly different for the CMF and the doxorubicin
groups [Δχ2(4) = 12.810, P < 0.05]. The intersection of the two lines in Figure
1 reflects this significant difference. In addition to the significant increase in
general fatigue between measurements one and three in the CMF group [Δχ2(1)
= 5.111, P < 0.05], the only consecutive significant increase is between
measurements three and four [Δχ2(1) = 4.310, P < 0.05] followed by a
significant decrease [Δχ2(1) = 8.555, P < 0.01]. The significant increase after
the treatment with chemotherapy, the so-called ‘late effect’, is not seen in the
Measurement point → 1st cycle* 3rd cycle 5th cycle† 4 weeks after 12 weeks after
the last cycle the last cycle 
n =157 n =157 n =135 n =152 n =152
n % n % n % n % n %
Original data RSCL:
Not at all (1) 56 36 30 19 25 19 27 18 36 24
A little (2) 61 39 59 38 50 37 62 41 69 45
Quite a bit (3) 33 21 49 31 39 29 39 26 31 20
Very much (4) 7 5 19 12 21 16 24 16 16 11
Classification of different answer categories into a non-fatigue group and a fatigue group:
Fatigue classification I:
Non-fatigue group (1) 56 36 30 19 25 19 27 18 36 24
Fatigue group 
(2, 3, and 4) 101 64 127 81 110 81 125 82 116 76
Fatigue classification II:
Non-fatigue group 
(1 and 2) 117 75 89 57 75 56 89 59 105 69
Fatigue group 
(3, and 4) 40 25 68 43 60 44 63 41 47 31
Fatigue classification III:
Non-fatigue group 
(1, 2 and 3) 150 96 138 88 114 84 128 84 136 89
Fatigue group (4) 7 4 19 12 21 16 24 16 16 11
* The first three interviews were held directly before, during or after infusion.
† Patients receiving only four chemotherapy treatments did not have this interview.
Table 5. Prevalence of fatigue
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doxorubicin group (Figure 1). For this group, the only significant difference
between consecutive measurements is found directly after the start of
chemotherapy, between measurements one and two [Δχ2(1) = 13.344, P <
0.01]. There also is an increase between measurements one and three [Δχ2(1)
= 8.393, P < 0.01], followed by a significant decrease between measurements
three and five [Δχ2(1) = 4.455, P < 0.05]. 
For the physical fatigue subscale, a similar pattern is seen in the effects of
chemotherapy (Figures 2 and 3). In both figures the two lines intersect, implying
that the course of fatigue for the two chemotherapy groups is different over
time. Here the CMF group shows also a ‘late effect’ [Δχ2(1) = 6.438, P < 0.05]
and subsequently a significant decrease [Δχ2(1) = 11.195, P < 0.01]. Physical
fatigue in doxorubicin group increases also significantly, but it does take longer.
Figure 1. The course of general fatigue as a function of the type of chemotherapy. Filled square,
CMF group (n = 46); open circles, doxorubicin group (n = 111); error bars, 95%
confidence intervals. Patients with four treatments (n = 21) did not participate in the
third measurement.
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A significant increase is seen between measurements one and three [Δχ2(1) =
7.018, P < 0.01]. Because the course of physical fatigue is not only significantly
different for the two chemotherapy groups [Δχ2(4) = 11.105, P < 0.05], but also
depends on the number of chemotherapy treatments [Δχ2(4) = 10.429, P < 0.05],
the differences in physical fatigue after measurement three were examined for
each of the chemotherapy groups stratified by the number of treatments.
Stratification was only required within the doxorubicin group, because all
patients in the CMF group had six treatments. Statistical testing was only
possible for the doxorubicin groups with four and six treatments. The remaining
groups (with five or eight treatments) were considered too small to yield reliable
results. The differences in physical fatigue in the doxorubicin groups between
consecutive measurement points after the last cycle of chemotherapy proved
Figure 2. The course of physical fatigue as a function of type of chemotherapy: CMF group and
doxorubicin group with six treatments. Filled square, CMF group (n = 46); open
circles, doxorubicin group (n = 72); error bars, 95% confidence intervals.
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not to be significant. Although there is a decrease in the mean fatigue scores for
these groups (Figures 2 and 3), the results were not significant, possibly due to
the smaller size of the groups that were examined. 
Furthermore, interestingly, for each of the groups the level of fatigue at the last
measurement was not significantly different from the fatigue at baseline. This was
the case for general fatigue [CMF group: Δχ2(1) = 0.624, P = 0.430; doxorubicin
group: Δχ2(1) = 1.02, P = 0.313], and for physical fatigue [CMF group: Δχ2(1) =
0.042, P = 0.838; doxorubicin group with 4 treatments: Δχ2(1) = 0.361, P = 0.548;
doxorubicin group with 6 treatments: Δχ2(1) = 0.459, P = 0.498]. 
An examination of the points at which the changes in general and physical
fatigue between consecutive time points are different between the two
chemotherapy groups, revealed a significant difference only for the changes
Figure 3. The course of physical fatigue as a function of type of chemotherapy: CMF group and
doxorubicin group with four treatments. Filled square, CMF group (n = 46); open
circles, doxorubicin group (n = 21); error bars, 95% confidence intervals. Patients
with four treatments (n = 21) did not participate in the third measurement.
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between measurements three and four [Δχ2(1) = 10.547, P < 0.01 and Δχ2(1) =
10.896, P < 0.01, respectively]. This again underlines that the interaction
between chemotherapy and the measurements is mainly due to the strong ‘late
effect’ in the CMF group. Besides, a significant impact of the number of
treatments [Δχ2(2) = 9.168, P < 0.01] on physical fatigue is only found at the
last measurement, indicating a delayed effect for this factor. 
Impact of fatigue on the activity of the patient
Table 6 presents the correlations between the subscales ‘reduced activity’ and
‘general fatigue’ and between ‘reduced activity’ and ‘physical fatigue’ at each
measurement point. All correlations are significant at P < 0.01. The lowest
correlation is 0.57 and the highest 0.86. Fatigue is accompanied by a strong
reduction in activity. 
DISCUSSION
This longitudinal study is the first large-scale examination of the course of
fatigue in 157 patients with breast cancer during as well as after receiving
adjuvant chemotherapy. Patients were studied directly before, during or after
infusions at the first, third and fifth cycle of chemotherapy, 4 and 12 weeks after
completion of chemotherapy.
Measurement point → 1st cycle† 3rd cycle 5th cycle‡ 4 weeks after 12 weeks after
the last cycle the last cycle 
n Correlation n Correlation n Correlation n Correlation n Correlation
General fatigue
Total group 157 0.59 157 0.65 135 0.70 152 0.69 152 0.78
CMF group 46 0.57 46 0.66 46 0.61 45 0.67 45 0.70
Doxorubicin group 111 0.60 111 0.65 89 0.72 107 0.70 107 0.81
Physical fatigue
Total group 157 0.67 157 0.72 135 0.80 152 0.80 152 0.83
CMF group 46 0.61 46 0.74 46 0.79 45 0.82 45 0.75
Doxorubicin group 111 0.70 111 0.71 89 0.80 107 0.78 107 0.86
* All correlations are significant at P < 0.01.
† The first three interviews were held directly before, during or after infusion.
‡ Patients receiving only four chemotherapy treatments did not have this interview.
Table 6. Correlations between subscales ‘reduced activity’ and ‘general fatigue’ and between
‘reduced activity’ and ‘physical fatigue’*
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Prevalence of fatigue
For three different classifications into a fatigue group and a non-fatigue group
the prevalence of fatigue was compared across time. The hypothesis that fatigue
is highly prevalent during, as well as after, chemotherapy treatment can be
supported, but, of course, it also depends on the method of classification of
patients into fatigue and non-fatigue groups. More interesting is the fact that the
changes in prevalence over time, as found in our study, are comparable, regardless
of how this classification was done. In the present study, as in the previous
study by Jacobsen et al. [7], a significant increase in the prevalence rates of all
groups is seen after the start of chemotherapy. After this increase, as in previous
studies [6, 7], a stability in the prevalence rate is found during chemotherapy
treatment. After the treatment of chemotherapy the prevalence rates seem to
decline.
Course of fatigue
The results for the subscales general and physical fatigue are to a large extent
similar. 
The type of operation turns out to influence fatigue. Women with a
mastectomy operation were significantly more fatigued during the whole
observation period than women who underwent a lumpectomy. Probably, the
extent of the surgery influences the experience of fatigue, and the loss of a
breast can have devastating psychological effects on women [23]. 
Supplementary to chemotherapy, 69% of the women in the present study
received radiotherapy. Receiving radiotherapy led to an increase in fatigue.
More specifically, the longer the duration of radiotherapy (number of days of
receiving radiotherapy), the higher the fatigue, and the longer the time interval
between the last radiotherapy session and the measurement point, the less
fatigue was experienced at that measurement point. The findings with regard to
radiotherapy are logically explicable. The accumulation of radiotherapy treatments
increased the experience of fatigue. This may be explained by the trip to the
treatment centre. Women had to go each weekday to the treatment centre during
a period of about 5 weeks. This could be rather intensive. Besides, daily routine
activities had to be adjusted to the treatments. Finally, it may be the effect of
radiotherapy itself or a combination of the therapies that makes these patients
more fatigued [24]. After radiotherapy treatment, women recover from this
intensive period, which makes the normalisation after the last treatment
comprehensible. The work of Irvine et al. [25]  partially support this reasoning. 
Only general fatigue was influenced by marital status: divorced women were
more fatigued than women living with a partner or single women. An explanation
for the significant differences between the groups might be the change in the
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domestic atmosphere in the (recent) past and emotional distress caused by the
divorce. The finding that women living with a partner reported less fatigue might
also be dependent on whether there is tangible support reducing fatigue. 
The course of fatigue during the study is different for the CMF group and
the doxorubicin group. Although the measurement points did not cover each
treatment cycle, the intensity of fatigue in the CMF group seems to be relatively
stable throughout the treatment cycles. This finding supports the hypothesis that
the intensity of fatigue stays stable throughout the treatment cycles. Sitzia and
Huggins [6] and Berger [8] found similar results. A reason for the stability could
be habituation to the experience of fatigue. The standard for determining the
level of fatigue might be changing, a shift in the internal norm. This process of
changing one’s internal standard is called response shift [26]. 
In the doxorubicin group only a significant increase in fatigue was seen
during the initial measurements. Berger and Walker [14] found similar results.
They found that chemotherapy protocols that contain intravenous doxorubicin
were directly associated with higher fatigue levels at the first treatment. Also
Jacobsen et al. [7] reported that breast cancer patients receiving chemotherapy
protocols that all contain intravenous doxorubicin experienced significantly
more fatigue after the start of chemotherapy. 
The CMF group shows a ‘late effect’ on fatigue, which was not seen in the
doxorubicin group. The CMF group reported significantly more fatigue 4 weeks
after the completion of chemotherapy than that in the fifth cycle of chemotherapy.
An explanation for this finding might be that healthcare providers become a
support system for patients. The end of chemotherapy marks the loss of this
support system and a change in routine. The support system is suddenly closed
at a time when their fears of recurrence are enhanced [10]. This may have a
negative impact on fatigue. The contact the women in the CMF group have with
healthcare providers is probably more intensive than in the doxorubicin group,
because they had to visit the hospital more frequently. After the significant
increase in the CMF group, a significant decrease in the level of fatigue is seen
12 weeks after chemotherapy, probably because the patients have become
accustomed to their daily activities again. An alternative explanation may be that
the metabolism of the orally administered drug in the CMF schedule is different
resulting in this delayed effect. 
The level of fatigue at the last measurement did not significantly differ
from the pre-treatment measurement. The hypothesis that the intensity of fatigue
declines after completion is therefore supported. A limitation of the present
study is the absence of a healthy control group to compare fatigue levels.
Everyone experiences fatigue on daily basis. It is not known whether the fatigue
at the last measurement can be regarded as normal fatigue. Probably, it cannot
be regarded as normal fatigue. First, previous studies show that the time span
after completion of chemotherapy considered in our study is most probably too
short [27-29]. Secondly, it should be noted that women might be fatigued
before starting any treatment. Cimprich [30] found a prevalence of fatigue of
77% before primary surgery. This increased fatigue in patients before the start of
chemotherapy may reflect lingering physical and psychological stress associated
with having recently undergone breast cancer surgery [7]. It should be noted
that the comparability of the results of this study to other studies may be limited
because of different measurement points that are utilized during, as well as
after, receiving adjuvant chemotherapy [16].  
Impact of fatigue on the activity of the patient
Fatigue has a strong impact on daily functioning. This finding is supported by
previous studies [8, 13, 15]. 
One limitation of the present study may be the lack of homogeneity in the
doxorubicin group, in which five different chemotherapy regimens are
represented. This may have affected the power to detect more changes in
fatigue over time for this particular group. From this study we may conclude
that CMF is likely to result in a delayed increase in fatigue. However, note that
no measurement took place at the last chemotherapy treatment. The possibility
exists that fatigue levels at the last treatment were higher than the levels one
cycle before the end of treatment. Further research, in which an assessment at
the last chemotherapy treatment is included is needed to conclude whether
there is really a late effect in the CMF group. In addition, ongoing studies
should include a comparison group of healthy subjects; fatigue tends to decline
after completion of chemotherapy, but whether the fatigue levels can be
regarded as ‘normal’ is not yet clear. 
Based on the results of this study, more specific information about fatigue
can be given to breast cancer patients receiving adjuvant chemotherapy. In
addition, ongoing research should include interventions addressing how to
reduce or to cope with fatigue during, as well as after, receiving adjuvant
chemotherapy. 
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ABSTRACT
Background: The purpose of this study is to determine the course of fatigue
referring to cognitive symptoms (scale ‘mental fatigue’) as well as the motivation
to start any activity (scale ‘reduced motivation’), as a function of chemotherapy,
in breast cancer patients undergoing adjuvant chemotherapy. 
Patients and methods: In a prospective cohort study a sample of 157 patients
with breast cancer was interviewed at the first, third and fifth cycle of adjuvant
chemotherapy as well as 4 and 12 weeks after completion of adjuvant chemotherapy.
Patients were treated with standard adjuvant chemotherapy, either a doxorubicin
containing schedule or cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
The psychological dimensions of fatigue were measured by the Multidimensional
Fatigue Inventory. A linear multilevel model was used for analysing the courses. 
Results: The course of mental fatigue and motivation were not affected by the
type of chemotherapy. The course of mental fatigue and motivation varied, but
seemed to be stable during the treatment of chemotherapy. After the completion
of chemotherapy, a weak improvement was seen. Relatively many patients
experienced depressive symptoms during the study. These symptoms were
correlated with both dimensions of fatigue. 
At all measurements mental fatigue was influenced by type of operation where
women with a mastectomy were significantly more mentally fatigued than
women that had undergone a lumpectomy, but nevertheless they were significantly
more motivated to start any activity. Age, marital status, number of treatments
and the interval between the operation and the first treatment of chemotherapy
seem to be also important determinants.
Conclusions: An unequivocal pattern of mental fatigue and reduced motivation
during as well after adjuvant chemotherapy was not found. Depressive symptoms
are definitely related to these variables.  Type of operation had a significant impact
on mental fatigue and motivation to start any activity. 
Health care providers should be aware of the high rate of patients who experience
depressive symptoms during and after the treatment of chemotherapy. 
Further research should include the trajectory preceding adjuvant chemotherapy
and a longer study period afterwards. Moreover, the exact influence of the
variables ‘age’, ‘marital status’, ‘number of treatments’ and ‘the interval between
the operation and the first treatment of chemotherapy’ on fatigue is unclear and
needs further study. 
Key words: adjuvant chemotherapy, breast cancer, mental fatigue, motivation 
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INTRODUCTION
Fatigue has been identified as the most disabling symptom experienced by
patients during treatment for cancer. The National Comprehensive Cancer
Network (NCCN) found that 70-100% of the cancer patients were affected by
fatigue [1]. Despite the high prevalence of fatigue and its profoundly negative
effect on patients’ quality of life, little is known about fatigue [2]. 
Breast cancer has been 0the most frequently occurring malignancy in
women since the early 1990s in the Netherlands [3]. A large subset of these
patients receives adjuvant chemotherapy as part of the standard treatment. The
course of fatigue in these patients has also hardly been examined. In a recent
literature review [2], high and fluctuating prevalence rates of fatigue in breast
cancer patients have been found not only during but also after adjuvant
chemotherapy. The intensity of fatigue seems to be stable throughout the treatment
cycles. After the treatment of adjuvant chemotherapy, patients still experience
fatigue, but it is unknown whether this fatigue can be regarded as normal fatigue.
The influence of different factors on the course of fatigue is unclear and less well
studied [2]. The impact of different chemotherapy regimens on the course of
fatigue is not unequivocal, but seems to be an important factor. Berger and Walker
found [4] recently that chemotherapy protocols that contain intravenous
doxorubicin were directly associated with higher fatigue at the first treatment.
They studied 60 women during the first three cycles of adjuvant breast chemotherapy
[4]. De Jong et al. [5] reported that the course of general and physical fatigue
during and after chemotherapy treatment was significantly different for the CMF
group (cyclophosphamide, methotrexate and 5-fluorouracil), compared with a
doxorubicin group. After the start of chemotherapy, a direct increase in fatigue in
the doxorubicin group is seen, whereas the increase in the CMF group does not
show until after the fifth cycle of chemotherapy.
Fatigue is associated with various symptoms [2]. There is evidence for a
relationship between fatigue and the severity of psychological symptoms [2]. The
loss of a breast can have devastating psychological effects on women [6].
Depressive symptoms are a common and disruptive problem for cancer patients
[7]. That fatigue and depression are related is beyond doubt, but the interpretation
of this relation is, however, complicated [8]. The symptoms of fatigue and
depression overlap. In addition, fatigue is one of the key symptoms of depression
and may be the result of depressed mood. On the other hand, a person who
continuously perceives his or her energy as insufficient may become depressed.
Cancer fatigue and depression may co-occur without having a causal relationship,
because they can both originate from the same pathology [8].
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The course of fatigue in breast cancer patients receiving adjuvant chemotherapy
with regard to psychological aspects, such as cognitive functioning, concentration
ability, mental effort and mood-state, is less frequently studied. Cimprich [9] has
reported a decline in the capacity for attention and concentration in women
undergoing treatment for breast cancer in the initial phases of illness. 
In a recent study by De Jong et al. [5] the course of general and physical
fatigue, as a function of chemotherapy (CMF group versus doxorubicin group),
was studied in 157 breast cancer patients undergoing adjuvant chemotherapy.
These two dimensions of fatigue were measured by the Multidimensional Fatigue
Inventory (MFI-20) [5]. This study is part of this large-scale examination and will
describe, also using the MFI-20, the psychological dimensions of fatigue: mental
fatigue and reduced motivation. Cognitive symptoms such as having difficulties
concentrating are included in the scale ‘mental fatigue’ [10]. Lack of motivation
to start any activity is covered by the scale ‘reduced motivation’ [10]. In this study,
these two subscales were examined, because only these two subscales relate to
psychological aspects of fatigue and both may be related in a unique way to
quality of life as compared with the other subscales of the MFI-20. Depression
was measured by the Center for Epidemiological Studies Depression Scale (CES-D)
[11]. This scale measures depressive feelings which may result from experiencing
a particular incident [12].
As a result of the absence of longitudinal studies on the course of dimensions
of fatigue conducted thus far, the purpose of the present study was to examine
the course of ‘mental fatigue’ and ‘reduction in motivation’ during (two or three
measurement points) as well as after (two measurement points) adjuvant
chemotherapy. 
In this manuscript, we test two hypotheses. The first is mainly based on a
literature review [2]: the intensity of mental fatigue and reduction in motivation
remains stable during the treatment of chemotherapy and changes in a positive
direction after completion. The impact of different chemotherapy regimens, like
doxorubicin containing regimens, on the course of fatigue is unclear and will
therefore be further investigated in the present study. The second hypothesis
holds that, during as well as after adjuvant chemotherapy, fatigue and depressive
symptoms are related. 
PATIENTS AND METHODS
Patient selection
Breast cancer patients treated in six hospitals, mainly in the south of the
Netherlands, were enrolled in this study if they met the following criteria: (1)
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had no metastasis or other malignancy, (2) were not treated with cytostatics
before, (3) had to be treated with outpatient adjuvant chemotherapy, (4) did not
have a chronic disease (such as hypertension, kidney disease, heart problems,
diabetes mellitus, etc.) or a poor psychological state (such as diagnosed with a
depression), (5) did not use morphine or narcoleptics, (6) were not deaf, (7) had
to be 18 years or older, and (8) could speak and understand Dutch. Patients were
recruited in the period from March 1998 till October 2000. 
Before the first cycle of adjuvant chemotherapy and after checking the
inclusion criteria, the oncologist or the oncology nurse introduced the study to
the patient with written information describing the purpose and procedure of the
investigations. The oncologist or the oncology nurse contacted the principal
investigator of this study after obtaining written informed consent. The principal
investigator and a properly trained assistant interviewed the participants. All local
medical ethical committees of the participating centres had approved the study. 
Data collection
Data were collected, using the Multidimensional Fatigue Inventory (MFI-20)
[13], five times except when receiving the CA (cyclophosphamide and doxorubicin)
treatment, in which case participants were interviewed only four times. Patients
had the first interview at the start of chemotherapy, the second at the third cycle
and the third at the fifth cycle except for the CA regimen, where the third
interview was omitted. The last two interviews were held 4 and 12 weeks after
the last cycle. The first three interviews took place directly before, during or after
infusion in the hospital. The interviews after the last cycle were done by phone.
The medical data were retrieved from charts after the interviews. 
Operationalisation of variables
The intensity of fatigue. Fatigue was assessed by a 20-item questionnaire, the
Multidimensional Fatigue Inventory (MFI-20) [13]. This self-report instrument,
especially designed for cancer patients, consists of five scales based on different
dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation
and mental fatigue. Each scale consists of four statements. The score for each scale
was calculated as the sum of the scores of the four statements, for which high
scores indicate more subjective fatigue. Statements should be answered with
respect to the last days. Data of all subscales were collected. This study will focus
on the results of two scales ‘mental fatigue’ and ‘reduced motivation’. Cognitive
symptoms such as having difficulties concentrating are included in the scale
‘mental fatigue’ [10]. Lack of motivation to start any activity is covered by the scale
‘reduced motivation’ [10]. The items of these subscales are presented in Table 1. 
The MFI-20 was previously tested and validated in studies with cancer
patients receiving radiotherapy, patients with ‘chronic fatigue syndrome’,
psychology students, medical students, army recruits and junior physicians. The
internal consistency for the two scales ‘mental fatigue’ and ‘reduced motivation’
in these studies as measured by Cronbach’s alpha averaged 0.86 (with a range of
0.77 to 0.93) and 0.72 (with a range of 0.57 to 0.82), respectively [14].
Patients in this study were asked to rate, in an interview, their fatigue as
experienced during the previous 2 weeks. A period of 2 weeks was chosen to
obtain a more stable a measure of the experienced fatigue between chemotherapy
cycles. Instead of presenting the items in a self-report questionnaire, the items were
administered in a face-to-face interview, since this took less time of the
respondents. Another reason for administering the scales in a face-to-face interview
was that there was a closer contact between the interviewer and patient. The
personal attention of the interviewer was thought to be more motivating for
respondents to continue participating in the study. 
Depressive symptoms. The Center for Epidemiological Studies Depression Scale
(CES-D) [11] was used to measure depressive symptoms. This self-report scale,
administered as a structured interview in the present study, contains 20 items
selected from the previously validated scale of depression. Patients indicated
how often within the last 2 weeks they experienced the symptoms, responding
‘rarely or none of the time’ (0); ‘some or little of the time’ (1); ‘occasionally or a
moderate amount of time’ (2); and ‘most or all of the time’ (3). The range of
scores is 0 to 60, with higher scores indicating more symptoms. The cut-off score
for a depressive syndrome is 16. 
The CES-D has been tested in healthy subjects, cancer patients, myocardium
infarct patients and students. The internal consistency was good and varied
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Items
Subscale
Mental fatigue 1. When I am doing something, I can keep my thoughts on it*
2. I can concentrate well
3. It takes a lot of effort to concentrate on things
4. My thoughts easily wander
Reduced motivation 1. I feel like doing all sorts of nice things
2. I dread having to do things
3. I have a lot of plans
4. I don’t feel like doing anything
* The response categories range from ‘yes, that’s correct’ (score 1) to ‘no, that’s incorrect’ (score 5).
Table 1. Items of the subscales ‘mental fatigue’ and ‘reduced motivation’ of the MFI-20
between 0.79 and 0.92 [12]. In another study the psychometric properties of
CES-D were assessed for both women undergoing treatment for breast cancer
and for women with no history of cancer. Here, also good internal consistencies
were found, with alpha coefficients larger than 0.85 [7].  
Treatment of adjuvant chemotherapy. Patients were receiving one of the
following adjuvant treatments: CEF (cyclophosphamide, 4-epi-doxorubicin and
5-fluorouracil) every 21 days, CAF (cyclophosphamide, doxorubicin and 5-
fluorouracil) every 21 days, 4-epi-doxorubicin every 28 days (on days 1 and 8),
4-epi-doxorubicin/taxotere with the first three cycles every 28 days (on days 1
and 8) and the last three cycles every 21 days, CA (cyclophosphamide and
doxorubicin) every 21 days and CMF [cyclophosphamide, methotrexate (oral
administration from day 1 to day 14 or intravenous) and 5-fluorouracil] every
28 days (on days 1 and 8). Most regimens consisted of six cycles except the CA
regimen which consisted of four cycles. 
In this study, two groups were compared: the doxorubicin group (CEF,
CAF, 4-epi-doxorubicin, 4-epi-doxorubicin/taxotere and CA) and the CMF
group. The participating hospitals based the choice for either schedule on their
current practice. The involvement of different adjuvant chemotherapy regimens
in the doxorubicin group made it possible to create a sizeable sample in a
relatively short period of time. 
Stage of breast cancer. The anatomic extent of breast cancer was described by
using the TNM (tumour-node-metastasis) clinical classification [15].
Type of operation. In this study, patients underwent a mastectomy or a lumpectomy
with or without lymph nodes excision. In the analyses two groups were
compared because of small sizes of the other groups: (1) mastectomy with
lymph nodes excision, and (2) lumpectomy with lymph nodes excision. During
the study period no reconstructive surgery was done. 
Statistical Analyses
It was statistically tested whether there were differences in patient characteristics
between the CMF group and the doxorubicin group.
The reliability of the MFI-20 and the CES-D was examined by calculating
Cronbach’s α. This coefficient of internal consistency was calculated for each
measurement point.
The course of mental fatigue, as well as motivation and the dependency
on the type of treatment of adjuvant chemotherapy, were analysed with a linear
multilevel model using the MLwiN program (version 1.10.0006) [16]. The data
consist of a series of repeated measurements nested within hospitals and
individual subjects. The data, which have a hierarchical nature, may be
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characterised by dependencies between units at lower levels of the hierarchy. In
this case, multilevel analysis is an appropriate technique [17]. Before the main
analyses were executed, a PP-plot of the residuals at the individual level was
made  to check the normality assumption of multilevel analysis. 
In the analyses concerning the effect of chemotherapy regimen on the course of
fatigue, dummy variables were included to represent the several measurement points.
When the first measurement is taken as a reference, changes relative to the baseline
measurement are analysed. The effect of chemotherapy on the course of fatigue was
represented by interaction terms between these dummy variables and a binary
variable chemotherapy. To correct for possibly confounding factors in this analysis
several covariates were added: ‘age’, ‘marital status’, ‘having children’, ‘education’,
‘having a job’, ‘type of operation’, ‘stage of breast cancer’, ‘haemoglobin level
(measured in mmol/l) before the first treatment of chemotherapy’, ‘the number of
days between the operation and the first treatment of chemotherapy’, ‘the number
of treatments at each measurement point’ and ‘radiotherapy’. For the covariate
‘radiotherapy’ three different variables were used: a variable indicating whether a
patient had received radiotherapy at any point of measurement, the number of days of
radiotherapy the patient had had at the time of measurement and the number of days
between the last day of radiotherapy and the time of measurement. Also these
covariates were included as interaction terms with the dummy variables representing
the time points. In this way, possible differences in patient characteristics between the
chemotherapy groups are corrected for. 
A multi-collinearity analysis was done to determine whether independent
variables were strongly associated with each other. 
Stepwise deletion took place in which non-significant covariates were
deleted. A significance level of 0.05 was used. The least significant covariate, with
significance level above 0.05 was deleted first. A new analysis was done, without
this particular covariate, after which the least significant covariate was again
deleted, provided that its significance level was above 0.05. This process
continued until all covariates with significance level above 0.05 were deleted. For
this model, the effect of the variable ‘treatment of adjuvant chemotherapy’ was
examined. For the final model fatigue scores, which are differences relative to
baseline and are also adjusted for differences between the chemotherapy groups,
can be calculated. These will be denoted as adjusted baseline differences. 
Finally, correlations were also calculated between depressive symptoms
and the subscale ‘mental fatigue’ as well as depressive symptoms and the
subscale ‘reduced motivation’ to examine their relationship.
RESULTS
Response rate
A sample of 175 breast cancer patients were eligible for the study. Eighteen
patients (10%) were excluded for different reasons: 13 (7%) declined further
participation, three (2%) stopped the adjuvant chemotherapy prematurely
because of physical problems and two (1%) had a poor physical state.
Depending on their adjuvant chemotherapy schedules the remaining 157
patients could be interviewed four (n = 20) or five (n = 137) times. The response
rate for the first two interviews was 100%. Two respondents were not interviewed
at the third measurement (response rate 99%). At the last two measurements,
the response rate was 97%. A change in the treatment schedule was the cause
of the non-response except for two interviews. Most interviews (79%) were
conducted by the principal investigator. 
Sample Characteristics
The characteristics of the patients who were excluded from the study (n = 18)
were not available. Demographic and medical characteristics of the included
patients are shown in Table 2. Forty-six patients (29%) had received the CMF
treatment, the remainder had received one of the chemotherapies covered by
the doxorubicin group. There were two characteristics on which the groups
differed: ‘age’ and ‘having a job’. Patients in the doxorubicin group were
significantly (t = -2.133; P = 0.035) older than patients in the CMF group. The
mean age was 48.2 years (SD = 9.0) in the doxorubicin group and 45.0 years
(SD = 7.9) in the CMF group. Significantly (χ2(1) = 4.768, P = 0.034) fewer
patients in the doxorubicin group had a job compared to the CMF group.
Details on the total number of chemotherapy treatments are shown in Table 3. 
Internal consistency of the MFI-20 and the CES-D
For all five measurement occasions, Cronbach’s α for the subscale ‘mental
fatigue’ was greater than 0.90 (Table 4). The mean Cronbach’s α of this subscale
averaged across all measurement occasions was 0.93. The mean Cronbach’s α
of the subscale ‘reduced motivation’ was lower, 0.82. At measurement occasion
1 and 2 the Cronbach’s α values for this scale were below 0.80, but above 0.75. 
The Cronbach’s α values of the CES-D were 0.90 or higher, with a mean of 0.91. 
Normality and multcollinearity
A PP-plot of the residuals at the individual level was made to check the normality
assumption. The PP-plot shows that residuals at this level are normally distributed.
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Doxorubicin group CMF group Total
(n = 111) (n = 46) (n = 157)
Age (years)*
Mean (SD) 48.2 (9.0) 45.0 (7.9) 47.3 (8.8)
Range 27-70 25-62 25-70
n % n % n %
Marital status
Married/living together 91 82 40 87 131 83
Single 11 10 3 7 14 9
Divorced 7 6 3 7 10 6
Widow 2 2 - - 2 1
Children
Yes 87 78 37 80 124 79
No 24 22 9 20 33 21
Educational level†
Low 43 39 13 28 56 36
Middle 43 39 24 52 67 43
High 25 23 9 20 34 22
Job*
Yes 59 53 33 72 92 59
No 52 47 13 28 65 41
Stage of breast cancer‡
I 9 8 3 7 12 8
II 90 81 35 76 125 80
III 4 4 2 4 6 4
I and III (two tumours) - - 1 2 1 1
Unknown (missing at the data 
collection point) 8 7 5 11 13 8
Type of operation§
Mastectomy without lymph nodes excision 3 3 - - 3 2
Mastectomy with lymph nodes excision 53 48 20 43 73 47
Lumpectomy without lymph nodes excision 1 1 - - 1 1
Lumpectomy with lymph nodes excision 52 47 26 57 78 50
Unknown 2 2 - - 2 1
Treatment of adjuvant 
chemotherapy
CEF 38 34 - - 38 24
CAF 27 24 - - 27 17
4 epi-doxorubicin 21 19 - - 21 13
4 epi-doxorubicin / taxotere 5 5 - - 5 3
CA 20 18 - - 20 13
CMF (no oral administration) - - 15 33 15 10
CMF (partially oral administration) - - 31 67 31 20
Radiotherapy
Yes 75 68 33 72 108 69
No 36 32 13 28 49 31
Anaemia (haemoglobin level, 
mmol/l < 7.3)¥
Yes 10 9 1 2 11 7
No 99 89 43 94 142 90
Unknown 2 2 2 4 4 3
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Length of radiotherapy treatment 
(days)
Mean (SD) 42.9 (5.7) 43.4 (5.5) 43.1 (5.6)
Range 26-51 32-57 26-57
Number of radiotherapy treatments
Mean (SD) 30.4 (3.5) 30.4 (3.4) 30.4 (3.5)
Range 25-35 25-33 25-35
Days between operation and 1st
chemotherapy treatment
Mean (SD) 33.9 (21.6) 38.8 (26.5) 35.3 (23.2)
Range 9-215 15-125 9-215
Haemoglobin level, mmol/l¥
Mean (SD) 8.1 (0.8) 8.3 (0.6) 8.2 (0.7)
Range 5.9-9.7 7.0-9.9 5.9-9.9
* Statistically significant difference (P < 0.05) in characteristic between the doxorubicin group and CMF group.
† Low is primary school/lower vocational education; middle is lower general secondary education/intermediate 
vocational education; and high is higher general secondary education/higher vocational education/university.
‡ Three groups, stage of breast cancer I, II and III, were included in the comparison between the doxorubicin
group and CMF group.
§ Two groups, mastectomy or lumpectomy with lymph nodes excision, were included in the comparison
between the doxorubicin group and CMF group.
¥ The haemoglobin level was determined before the first treatment of chemotherapy; the conversion factor 
from mmol/l to g/dl is 1.6.
Table 2. Patient characteristics (continued)
Total number of treatments → 4 5 6 8
Total (n)
Treatment of adjuvant 
chemotherapy
Doxorubicin group 21 10 72 8 111
CMF - - 46 - 46
Table 3. Total number of treatments specified for the two chemotherapy groups (n = 157)
Measurement point → 1st cycle* 3rd cycle 5th cycle† 4 weeks after 12 weeks after
the last cycle the last cycle 
n =157 n =157 n =135 n =152 n =152
n IC n IC n IC n IC n IC
Mental fatigue 157 0.92 157 0.93 135 0.94 152 0.91 152 0.93
Reduced motivation 157 0.75 157 0.77 135 0.85 152 0.85 152 0.87
CES-D 155 0.90 156 0.90 135 0.92 151 0.92 152 0.94
* The first three interviews were held directly before, during or after infusion.
† Patients receiving only four chemotherapy treatments did not have this interview.
Table 4. Internal consistencies (IC) of the MFI-20 and CES-D
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None of the independent variables was very strongly associated with another
independent variable (correlations always lower than 0.2) indicating that
multicollinearity was not problem for the analysis.  
Course of two psychological dimensions of fatigue
The course of fatigue is studied by analysing separately the results of two scales
of the MFI-20 corresponding to the different dimensions that can be
distinguished: mental fatigue and reduced motivation. In Figure 1, raw mean scores
of both subscales are presented to give a first impression of the course of the
two dimensions of fatigue. Both courses seemed to be relatively stable during
the study period. A specific description of both courses is given next. 
Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’
(range 4-20, the higher the score the more mental fatigue or reduction in motivation
is experienced) (n=157).
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Course of mental fatigue
Mental fatigue is not affected by the type of chemotherapy. The course of
mental fatigue during the study is significantly different for groups depending
on the variables ‘interval between operation and first treatment of chemotherapy’
(Δχ2(4) = 11.754, P < 0.05), ‘number of treatments’ (Δχ2(4) = 14.362, P < 0.01),
and ‘marital status’ (Δχ2(12) = 21.868, P < 0.05). 
The variable ‘interval between operation and first treatment of chemotherapy’ was
categorised into the groups: 1 to 25 days (n = 46), 26 days to 50 days (n = 97) and
51 days or more (n = 14). When combining all variables, the subgroups were too
small to perform separate analyses for each resulting stratum. Consequently,
stratification only took place for each variable separately that interacted with the
variable ‘measurement points’. By investigating the time effects in this way for
each stratum, the averaged effects are examined, where the other two variables
that interact with measurement points were averaged across. 
Figure 2. The course of mental fatigue as a function of the days between the operation and the
start of chemotherapy.
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The course of mental fatigue for the different groups that were distinguished
with respect to the variable ‘interval between operation and first treatment of
chemotherapy’, is displayed in Figure 2. The level of mental fatigue seems to be
higher in those with a larger interval between operation and first treatment of
chemotherapy. The subgroup whose interval is 51 days or more was too small
to warrant a reliable analysis. For the group ‘1 to 25 days’ there was a decrease
in the mental fatigue from the first measurement occasion onwards. The
difference in mental fatigue between consecutive measurement points turns 
out not to be significant. There is, however, a significant decrease between
measurements 1 and 4 (Δχ2(1) = 4.678, P < 0.05) and measurements 1 and 5
(Δχ2(1) = 6.349, P < 0.05). After the last chemotherapy treatment patients
experience significantly less mental fatigue than at the start. 
For the group ‘26 to 50 days’ an initial increase was followed by a
decrease from measurement occasion 2 onwards. None of the pairwise
Figure 3. The course of mental fatigue as a function of the number of chemotherapy treatments.
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comparisons between measurement occasions, however, were significant. 
For the variable ‘number of treatments of chemotherapy’, only the groups
with four (n = 21) and six (n = 118) treatments were large enough for reliable
analyses. Figure 3 shows the development of mental fatigue for both groups. Note
that the group with four treatments did not have any observations at measurement
point 3. For this group, none of the pairwise comparisons between measurements
occasions are significant. There is mainly a decrease in mental fatigue for the group
with six treatments. However, only the consecutive measurement occasion 4 and
measurement occasion 5 differed significantly (Δχ2(1) = 5.661, P < 0.05). Furthermore,
it was noticeable that there was the significant decrease between measurements 1
and 5 (Δχ2(1) = 3.975, P < 0.05). In this subgroup too, mental fatigue was also
significantly diminished after the last chemotherapy treatment. 
Concerning the variable marital status, only the group of married women 
(n = 131) was large enough to warrant a reliable analysis. Their scores on mental
Figure 4. The course of mental fatigue and reduction in motivation for married women (n=131).
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fatigue are displayed in Figure 4. In this subgroup mental fatigue also declined
after the last treatment of chemotherapy, but nevertheless no pairwise comparison
differed significantly.
Considering the other covariates, there were significant effects of type of
operation (Δχ2(1) = 150.057, P < 0.01) and age (Δχ2(1) = 9.397, P < 0.01). The final
model of mental fatigue indicated that patients who underwent a lumpectomy
experience significantly less mental fatigue than patients who underwent a mastectomy.
The effect of age on mental fatigue was negative, meaning that older patients
reported significantly less mental fatigue than younger patients. 
Course of reduced motivation
The course of reduction of motivation during the study was not significantly
different for the CMF and the doxorubicin group, which means an equality in the
changes of the motivation in both chemotherapy groups during the whole study.  
The final model contains a significant interaction between the measurement
occasions and marital status (Δχ2(12) = 24.236, P < 0.05). This indicates that
the course of reduced motivation during the study is different for married
women, single women, divorced women and widows. It is impossible to examine
all courses statistically because of the small sample sizes. Only the sample with
married women was large enough to examine further. Figure 4 displays the
course of reduced motivation for married women. This is conspicuously similar
to the curve of mental fatigue for married women. As in the course of mental
fatigue for married women, results show no significant differences between
consecutive measurement points. Considering consecutive measurement points,
the degree of motivation of the married women remains stable. Nevertheless, a
significant difference was found between measurement occasion 3 and
measurement occasion 5 (Δχ2(1) = 3.961, P < 0.05). Married women were
significantly more motivated at measurement 5 than at measurement 3. The
mental experienced fatigue, on the other hand, was not significantly different
between these two measurements points. 
Of the other covariates considered, there were significant effects of type of
operation (Δχ2(1) = 136.640, P < 0.01) and the number of treatments of
chemotherapy (Δχ2(2) = 8.876, P < 0.05). Patients who underwent a lumpectomy
reported significantly more reduced motivation than those who underwent a
mastectomy. Furthermore, the total number of chemotherapy treatments had a
significantly negative effect on the reduced motivation (Δχ2(1) = 3.881, P < 0.05).
The motivation of women who received in total more treatments is significantly
higher.
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Results with respect to depressive symptoms
Table 5 contains the results for the CES-D. At each measurement point, about 20%
of the sample has a score higher than the cut-off point 16 and was depressed. 
Table 6 presents the correlations between depressive symptoms and subscale
‘mental fatigue’ and between depressive symptoms and subscale ‘reduced
motivation’ at each measurement point. All correlations are significant at P < 0.01.
The lowest correlation is 0.52 and the highest 0.71. Depressive symptoms were
strongly associated with the psychological dimensions of fatigue. 
Measurement point → 1st cycle† 3rd cycle 5th cycle‡ 4 weeks after 12 weeks after
the last cycle the last cycle 
n Correlation n Correlation n Correlation n Correlation n Correlation
Depression and 
mental fatigue 155 0.61 156 0.60 135 0.70 151 0.63 152 0.71
Depression and  
reduced motivation 155 0.57 156 0.52 135 0.59 151 0.56 152 0.68
* All correlations are significant at p < 0.01.
† The first three interviews were held directly before, during or after infusion.
‡ Patients receiving only four chemotherapy treatments did not have this interview.
Table 6. Correlations between ‘depressive symptoms’ and the subscale ‘mental fatigue’ and
between ‘depressive symptoms’ and ‘reduced motivation’*
Measurement point → 1st cycle* 3rd cycle 5th cycle† 4 weeks after 12 weeks after
the last cycle the last cycle 
n =157 n =157 n =135 n =152 n =152
n % n % n % n % n %
Total CES-D score 
(range 0-60) 155 100 156 100 135 100 151 100 152 100
Not depressed (score 0-15) 123 79 125 80 105 78 119 79 115 76
Depressed (score 16-60) 32 21 31 20 30 23 32 21 37 24
* The first three interviews were held directly before, during or after infusion.
† Patients receiving only four chemotherapy treatments did not have this interview.
Table 5. Depressive symptoms (CES-D scores)
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DISCUSSION
This longitudinal study represents the first large-scale examination of the course
of two psychological dimensions of fatigue, ‘mental fatigue’ and ‘reduced
motivation’, of the Multidimensional Fatigue Inventory (MFI-20), in 157 patients
with breast cancer during (at the first, third and fifth treatment of chemotherapy)
as well as after (4 and 12 weeks after the last treatment of chemotherapy)
receiving adjuvant chemotherapy. The subscale ‘mental fatigue’ refers to cognitive
symptoms, such as having difficulties concentrating, and lack of motivation to
start any activity is covered by the subscale ‘reduced motivation’.
In this study, the following two hypotheses are examined. (1) The intensity
of mental fatigue and reduction in motivation remains stable during the treatment
of chemotherapy and changes in a positive direction after completion. The
impact of different chemotherapy regimens, like doxorubicin-containing regimens,
on the course of fatigue is unclear and is investigated in the present study. (2)
Fatigue and depressive symptoms during as well as after receiving adjuvant
chemotherapy are related. Below, the conclusions with respect to the
hypotheses are discussed. 
Course of the two psychological dimensions of fatigue
Neither the course of mental fatigue nor the course of motivation was affected
by type of chemotherapy. In other words, the extent of mental fatigue as well as
the motivation in the CMF group and the doxorubicin group were the same. De
Jong et al. [5] reported in another study that the course of general and physical
fatigue was significantly different for these chemotherapy groups. Apparently,
the difference in the chemical composition of the chemotherapies only has
effect on the physical part of fatigue. 
The course of mental fatigue, on the other hand, was affected by the
interval between operation and first treatment of chemotherapy, number of
treatments as well as marital status. The subgroups created for each of these
variables were too small to carry out separate analyses for each resulting
stratum. Analyses were done examining the course of fatigue by averaging
across the strata defined by other interacting covariates. This, however, did not
give insight into the exact courses of fatigue for each of the different groups that
should be distinguished. In most of the analyses we see a stability of mental
fatigue during the treatment of adjuvant chemotherapy, with a significant
improvement in the last phase of the study. The hypothesis that the intensity of
the dimensions is stable during the treatment of adjuvant chemotherapy and
changes positively after completion is therefore supported. Although the course
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of motivation was affected by marital status and could only be described for
married women, a similar tendency was seen. It should be noted that mental
fatigue and reduction in motivation show a similar pattern across time which
may be explained by both aspects reflecting the psychological side of fatigue.
This finding additionally motivates presenting the results of these two dimensions
of fatigue in one study.  
An explanation for the stability during the treatment of chemotherapy could
be that there is an increase in mental fatigue directly after hearing the diagnosis.
Mental fatigue increases immediately, because of worries or anxiety about the
recovery process or the treatment route and the motivation to start any activity
might reduce. A recent study [18] in breast cancer patients partly supports this
argument. The authors of this study found that cognitive fatigue was predicted by
anxiety and pain [18]. In another study, a high prevalence of fatigue (77%) was
found before primary surgery [19]. Cimprich [9] has demonstrated a decline in
the capacity for attention and concentration in women undergoing treatment for
breast cancer in the initial phases of illness. Another reason for the increased
fatigue in patients before the start of chemotherapy is the lingering physical and
psychological stress associated with having recently undergone breast cancer
surgery [20]. Patients with a short interval between the operation and the first
treatment of chemotherapy could experience a heightened level of fatigue before
the start of chemotherapy, which can actually only decrease. A final reason might
be a shift in the internal norm of the experience of these dimensions of fatigue of
the patient. This process of changing one’s internal standard is called response
shift [21]. Further research, in which the period preceding chemotherapy is also
examined, must be done. 
After the treatment of chemotherapy, mental fatigue diminished and
motivation increased, but not all changes turn out to be significant. In fact, in
some cases the extent of the two dimensions of fatigue at the last measurement
was equal to the fatigue experienced during the treatment of chemotherapy. 
The time after the last treatment might be too short to find a change in
fatigue that is large enough to result in a significant effect in the statistical
analysis. It might be that patients needed longer to recover from the treatments or
had to cope with the treatment process they had undergone. Budin [22] reported
that the course of psychosocial adjustment confronting the woman with breast
cancer can be described as a series of phases associated with the clinical course
of the treatment. A particularly stressful period for some breast cancer patients
could be the period after completion of chemotherapy, when the woman continues
recuperation from initial treatment and begins extensive reorganization and
resumption of previous activities and roles. Beisecker et al. [23] reported that
many patients experience ambivalence at the end of chemotherapy. They are
pleased to be finished, but they are afraid they should keep doing something to
prevent a recurrence. A limitation of the present study is the absence of a
healthy control group with which to compare. In the study it is therefore unclear
whether the findings at the last measurement can be regarded as normal or
not. 
Determinants of the course of fatigue
The course of mental fatigue is influenced by type of operation. Women
undergoing a mastectomy were significantly more mentally fatigued than women
that had undergone a lumpectomy. Cimprich [24] found a similar result. She
concluded that older age and more extensive surgery increase the likelihood of
loss of attention due, in part, to greater risk of attentional fatigue. Attentional
fatigue manifests itself as a decreased capacity to concentrate or direct attention
in daily life activities. The meaning of attentional fatigue is similar to both
dimensions of fatigue investigated in the present study. Cimprich [24] studied
74 women newly diagnosed with stage I or II breast cancer. Data were obtained
at about 12 days before and 15 days after breast-conserving surgery or
mastectomy. The reason for an association here is probably not only the extent
of the surgery, but also the psychological impact of it. The loss of a breast can
have devastating psychological effects on women [6]. Research shows that
women undergoing breast conservation or post-mastectomy procedures have
better outcomes on selected psychosocial and quality-of-life measures than
those who underwent a mastectomy [25]. Surgery of the breast is still seen as a
negative aspect of the body image [25, 26]. In this context, the influence of the
type of operation on the course of motivation is therefore not expected and
hard to explain. In this study women who underwent a mastectomy reported
significantly less reduction in motivation than women undergoing a
lumpectomy. 
There is also an influence of age on the course of mental fatigue, meaning
that older patients reported significantly less mental fatigue than younger
patients. Results of other studies show that younger women with breast cancer
have more severe emotional distress than older women. Loss of a breast or poor
breast appearance would be more distressing to women whose youth gives them
high expectations for physical beauty [27]. Another reason may be that younger
women had the responsibility of caring for their families and young children
[28]. Besides, older women had normally experienced more setbacks and
therefore probably can cope better with it. Ongoing research, involving coping
strategies, must be done.  
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Furthermore, the total number of chemotherapy treatments has a significant
effect on the course of motivation. The motivation of women who received in total
more treatments is significantly less reduced. An explanation for this finding
might be that these patients got an extra boost to go for it.   
The following covariates did not influence the course of the psychological
dimensions of fatigue: ‘having children’, ‘education’, ‘having a job’, ‘stage of
breast cancer’, ‘haemoglobin level before the first treatment of chemotherapy’
and the variables with respect to radiotherapy. Bower et al. [29] found no
relation between educational attainment and fatigue nor between employment
status and fatigue. Other studies [20, 30, 31] support the absence of finding any
relationship between stage of disease and fatigue. Okuyama et al. [31] reported
that radiotherapy was not correlated with fatigue. None of these studies however
examined the course of psychological aspects of fatigue, and the covariates
used are defined differently.
Depressive symptoms and fatigue
It should be noted that the mean scores for the CES-D, given the range of
possible scores, are rather low. However, at each measurement point, a relatively
large group, that is about 20% of the sample, can be classified as suffering from
a depressive syndrome. 
A limitation of the CES-D is the validity of the cut-off point (depressed or
not depressed) [12]. In a study involving 50 patients with depression and 150
healthy men and women, the cut-off score seems to be adequate for diagnosis
of depression [32]. Results of another study showed that the standard cut-off
score appears valid, but inefficient for depression screening in low-income
women attending primary care clinics [33]. Best cut-off scores above 20 were
found in studies with different populations [34, 35]. Apparently, different
populations have different cut-off scores. In a study in cancer patients and in
healthy individuals from the general population, findings support the use of a
sumscore based on the 16 negatively formulated CES-D items as a more valid
measure of depressive symptomatology [36]. The use of the cut-off score of 16
in cancer patients therefore seems to be legitimate. Further research, involving
examination of the sensitivity and specificity, is needed to determine the most
accurate cut-off score in breast cancer patients. 
Fatigue and depressive symptoms are positively related during the whole
study period, which supports the second hypothesis. In their studies, Visser and
Smets [8] found a moderate relation. Other studies [29, 31, 37, 38] in breast
cancer patients receiving chemotherapy showed also a positive relationship
between depression and fatigue. 
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The findings of the present study clarify the psychological dimensions of
fatigue. A limitation of this study might be selection bias. The sample of patients
who declined further participation is very small, but it is not known how many
patients refused to participate in the study at the stage in which the oncologist
or the oncology nurse introduced the study to the patients. 
Note that patients were interviewed five times in relatively a short period
of time. At each interview, they had to answer the same questions, which might
cause a certain habituation. Moreover, different interview styles, i.e. face to
face interviews and interviews by phone, were carried out. The internal
consistency of both ways of administering the questionnaire are good. What is
unknown is the way these methods may bias the results obtained on respondents’
fatigue. A final remark concerning the period of study is the absence of a clear
positive effect at the end of the study. The duration of the study might be too
short to see any effect. The same can be said concerning the trajectory preceding
adjuvant chemotherapy. Measurements somewhat longer before the start of
chemotherapy may highlight increases in both mental fatigue and reduced
motivation due to chemotherapy. 
In summary, from this study we may conclude that no unequivocal pattern
of mental fatigue and motivation is found, though there is a tendency of stability
during the study with a potential decline in mental fatigue and an increase in
motivation after completion of chemotherapy. In general, relatively many patients
experienced depressive symptoms during the study. Health care providers should
pay attention to the possibility of the patients experiencing depressive symptoms.
Recognition and treatment of these symptoms can influence the course of the
chemotherapy treatment, as well as the quality of life during and after the
treatment of chemotherapy. Based on the results of this study, more specific
information about the psychological part of fatigue can be given to breast cancer
patients receiving adjuvant chemotherapy. Behaviour related to this psychological
part, like having difficulties concentrating and lack of motivation to start any
activity should be recognised by health care providers. Recognition and talking
about these disturbances can be of value for the patient. 
The depressive symptoms are definitively related to the psychological
dimensions of fatigue. The psychological dimensions of fatigue are affected by
type of operation. Age, marital status, number of treatments and the interval
between the operation and the first treatment of chemotherapy also seem to be
important determinants. Further research, involving these determinants must be
carried out. 
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ABSTRACT
The purpose of this study was to determine the course of the activity level, seen
as a dimension of fatigue, as a function of chemotherapy within a breast cancer
population receiving adjuvant chemotherapy. The second purpose of this study
was to determine the course of the interference of fatigue, in general, with daily
activities within a breast cancer population receiving adjuvant chemotherapy. 
In a prospective cohort study, a sample of 157 patients with breast cancer
was interviewed, at the first, third, and fifth cycle of adjuvant chemotherapy as
well as 4 and 12 weeks after the last cycle of adjuvant chemotherapy. The
chemotherapy was administered with either a doxorubicin-containing schedule
or cyclophosphamide, methotrexate and 5-fluorouracil (CMF). These 2 groups
were compared. The activity level was measured by the Multidimensional
Fatigue Inventory. A linear multilevel model was used to analyse the course. The
revised Piper Fatigue Scale was used to examine the behavioural changes in the
interference of fatigue with activities of daily living. A logistic multilevel model
was used to analyse the course of this interference over time. 
The activity level seems to be rather stable during the treatment with
chemotherapy. After completion of chemotherapy, an improvement is observed.
The activity level reported at the first and the last measurement do not significantly
differ. The course of the activity level is not affected by type of chemotherapy
regimen. Age, having children, and the stage of breast cancer turn out to be
important determinants of the course of activity level. At all measurement occasions,
women with a mastectomy were significantly more hampered in their activity level
than women that had undergone a lumpectomy. The longer the duration of
radiotherapy, the less active, and the longer the time interval between the last
radiotherapy session and the measurement point, the more active patients were at
that measurement point. A phenomenon not easy to explain is that the activity
level in women who had received, in total, more chemotherapy treatments was
significantly less diminished than those who had received fewer treatments.
During the study period, in approximately 15% to 35% of the sample,
fatigue interferes considerably with their daily living activities. Furthermore, the
interference of fatigue with activities in daily life first increases after the start of
chemotherapy and decreases after completion of chemotherapy.
Fatigue definitely affects the daily living activities of patients with breast
cancer receiving adjuvant chemotherapy. With this knowledge health care
providers can inform patients on what they can expect. Further research should
include the trajectory preceding chemotherapy and a healthy control group. 
Key words: activity level, adjuvant chemotherapy, breast cancer 
INTRODUCTION
Breast cancer has been the leading form of cancer in women since the early 1990s,
not only in the Netherlands but also elsewhere. Optimal symptom management
becomes increasingly important, as breast cancer treatment improves and survival
rates increase [1]. 
Fatigue is a common symptom among patients with cancer. It has been
recognized that fatigue is the most frequently reported symptom of cancer and
cancer therapy [2], notably chemotherapy [3]. The National Comprehensive
Cancer Network (NCCN) reported that 70% to 100% of the patients with cancer
experience fatigue [4]. 
Fatigue is the most distressing side effect reported by patients receiving
chemotherapy [5, 6]. It is deleterious to the activities and quality of life of
patients with cancer [7, 8]. For healthy individuals, fatigue seems to maintain a
healthy balance between rest and activity. It might be a protective, sometimes
even pleasant, regulatory response to physical or psychological stress [9]. For
patients with cancer, fatigue becomes a chronic and unpleasant sensation [10],
which can be a major obstacle to maintaining normal daily activities and
quality of life. The interference with daily functioning is highly important and
has been recognized. A recent definition of cancer-related fatigue formulated
by a panel of fatigue experts, who were convened by the NCCN, describes the
interference explicitly as “a persistent, subjective sense of tiredness related to
cancer or cancer treatment that interferes with usual functioning” [4](p. MS-2).
In this study the activity level is seen as a dimension of fatigue. It describes
the patients’ perception of her physical activities. Smets et al. [11] named this
dimension ‘reduced activity’. Despite associations reported between fatigue
and activity levels, little is known about the course of activity level, seen as a
dimension of fatigue, during and after receiving adjuvant chemotherapy treatment.
The impact of different chemotherapy regimens on the course of this dimension
of fatigue is not clear. Moreover, it is unclear which other factors are influencing
the course of the activity level. 
Early work [12-14] in patients with breast cancer had established that
higher fatigue was associated with lower activity. It is not known to what degree
the activities of daily living are disrupted as a result of fatigue. Greene et al. [15]
reported moderate levels of disruption in activities of daily living in patients
with breast cancer receiving chemotherapy. It is not clear if this disruption was
only caused by fatigue. Berger [16] reported that the behavioural subscale
scores of the revised Piper Fatigue Scale (PFS), relating to the severity, distress,
and degree of disruption in activities of daily living, were significantly different
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over time, with scores higher at chemotherapy treatments and lower at cycle
midpoints. The interference of fatigue with daily activities within a breast
cancer population has been rarely studied. 
Many previous studies are characterised by methodological shortcomings,
like a small sample size, the lack of a well-validated measure of reduced activity
and the absence of a longitudinal design, which limits the conclusions that can
be drawn [17]. The present study is part of a large-scale fatigue project in
patients with breast cancer receiving adjuvant chemotherapy trying to circumvent
the major weaknesses of previous studies. The purpose of this study was to
determine the course of the activity level, seen as a dimension of fatigue, as a
function of chemotherapy within a breast cancer population receiving adjuvant
chemotherapy. The second purpose of this study was to determine the course of
the interference of fatigue, in general, with daily activities within a breast
cancer population receiving adjuvant chemotherapy.
The present article addresses the following research questions:
1. How does the activity level, seen as a dimension of fatigue, within a breast 
cancer population receiving adjuvant chemotherapy, change in the course
of time?
2 Does the course of activity level depend on the regimen of chemotherapy 
(cyclophosphamide, methotrexate and 5-fluorouracil [CMF] or doxorubicin
group) and what other determinants are influencing this course?
3. To what degree is fatigue interfering with daily living activities and does 
the degree of interference change over time?
PATIENTS AND METHODS
Population Sample and Procedure
Patients with breast cancer treated in 6 hospitals, mainly in the south of the
Netherlands, were included in this study if they (1) had no metastasis or other
malignancy, (2) were treated with cytostatics for the first time, (3) were treated with
outpatient adjuvant chemotherapy (4) had no chronic disease (like hypertension,
kidney disease, heart problems, diabetes mellitus etc.) or a poor psychological
state (such as diagnosed with a depression), (5) did not use morphine or
narcoleptics, (6) were not deaf, (7) were 18 years or older, and (8) could speak
and understand Dutch.
The local medical ethical committees of all participating centers had
approved the study. The oncologist or the oncology nurse verified eligibility
before they introduced the study to the patients. When the patient was eligible,
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written information describing the purpose and procedure of the study was
given. The patient had given written informed consent before the interview. The
interviews were conducted by the principal investigator and a properly trained
assistant. 
Patients were interviewed, using the Multidimensional Fatigue Inventory
(MFI-20) [11] and the revised Piper Fatigue Scale (revised PFS) [18], 5 times
except when receiving the cyclophosphamide and doxorubicin (CA) treatment,
in which case participants were interviewed only 4 times. The first 3 interviews
took place in the hospital and were held directly before, during or after the first,
the third, and the fifth cycle of chemotherapy, except for the CA regimen, where
the third interview was omitted. An interview at each cycle of chemotherapy was
expected to be too much for the patients and not feasible for the investigator.
Therefore, an interval of 6 to 8 weeks between the interviews was chosen. For the
same reason the last 2 interviews were held 4 and 12 weeks after the last cycle.
These 2 interviews were done by phone because the patients were not present at
the outpatients’ department. Medical data were retrieved from charts and were
gathered after the interviews. 
Operationalisation of variables
Activity level. The Multidimensional Fatigue Inventory (MFI-20) [11] was used
to assess the course of the activity level. This 20-item self-report questionnaire
consists of 5 subscales based on different dimensions: general fatigue, physical
fatigue, reduced activity, reduced motivation and mental fatigue. Each item of
each subscale was answered on a 5-point Likert scale. The score of each subscale
was obtained as the sum of the scores on 4 items. Higher scores indicate more
subjective fatigue. In the present study, we will focus on the results of the
subscale ‘reduced activity’. High scores on this subscale indicate a low activity
level. The items of this subscale are presented in Table 1. The MFI-20 was previously
tested and validated in the following patient groups: cancer patients receiving
radiotherapy, patients with ‘chronic fatigue syndrome’, psychology students,
Subscale Items*
Reduced activity 1. I feel very active 
2. I think I do a lot in a day
3. I think I do very little in a day
4. I get little done
* For each item, there are 5 response categories ranging from ‘yes, that’s correct’ (score 1) to ‘no, that’s incorrect’ (score 5).
Table 1. Items of the subscale ‘reduced activity’ of the MFI-20 (range of scale score: 4-20)
medical students, army recruits and junior physicians. The mean internal
consistency for the subscale ‘reduced activity’ in different patient groups was
0.76 with a range of 0.53 to 0.86 [19]. The mean of Cronbach’s α’s across all
measurement points in this study is 0.87, with a range of 0.84 to 0.91. For the
practical reason that the patients were already being interviewed, patients were
asked to rate their fatigue as experienced during the previous 2 weeks in a face-
to-face interview. In addition, a self-report questionnaire was expected to be
too time-consuming for the patient.
Interference of fatigue with activities in daily living. The revised Piper Fatigue
Scale (revised PFS) is an instrument to measure subjective fatigue [18]. This 22-
item questionnaire consists of 4 subscales. In the present study, 1 subscale was
used: the behavioural/severity subscale. This subscale reflects the degree to
which fatigue interferes with activities of daily living [18]. The subscale
contains 6 items, and the score has to be calculated as the sum of the scores on
these 6 items. The questions of this subscale are displayed in Table 2. In the
present study, the subscale included 5 items instead of 6 because an older
version of the PFS was used. The scores in the present study were calculated as
the sum of the scores of the 5 items. High scores indicate that fatigue is
interfering more with activities of daily living. The behavioural/ severity scale of
the revised PFS was previously tested and validated in women with breast
cancer [18]. The internal consistency of the subscale in this study was 0.92
[18]. A pilot study [12] in breast cancer patients receiving adjuvant
chemotherapy showed internal consistencies for the total and all subscale
scores ranging from 0.91 to 0.98. For the behavioural/severity subscale, the
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Subscale Items*
Behavioural/severity 1. To what degree is the fatigue you are feeling now causing you distress?†
2. To what degree is the fatigue you are feeling now interfering with your ability to complete 
your  work or school activities?
3. To what degree is the fatigue you are feeling now interfering with your ability to visit or 
socialize with your friends?
4. To what degree is the fatigue you are feeling now interfering with your ability to engage in 
sexual activity?
5. Overall how much is the fatigue, which you are experiencing now, interfering with your 
ability to engage in the kind of activities you enjoy doing?
6. How would you describe the degree of intensity or severity of the fatigue which you are 
experiencing now?
* Each answer could be given on a scale ranging from 0 to 10; higher scores indicate that fatigue is interfering more 
with activities of daily living.
† This question was not included in the questionnaire.
Table 2. Items of the subscale ‘behavioural/severity’ of the revised PFS (range of scale scores: 0 – 60)
mean of Cronbach’s α’s across all measurement points in this study is 0.89, with
a range of 0.78 to 0.98. 
In the present study, a distinction was made between little or no interference
with daily living activities (score ≤ 5)  and great interference with daily living
activities (score > 5). This distinction was made to examine the number of
patients for whom fatigue strongly interferes with their daily living activities. 
Treatment of adjuvant chemotherapy. Patients were receiving 1 of the following
adjuvant chemotherapies: CEF (cyclophosphamide, 4-epi-doxorubicin and 5-
fluorouracil) every 21 days; CAF (cyclophosphamide, doxorubicin and 5-
fluorouracil) every 21 days; 4-epi-doxorubicin every 28 days (on days 1 and 8);
4-epi-doxorubicin/taxotere with the first three cycles every 28 days (on days 1
and 8) and the last three cycles every 21 days, CA (cyclophosphamide and
doxorubicin) every 21 days; and CMF (cyclophosphamide, methotrexate [oral
administration from day 1 to day 14 or intravenous] and 5-fluorouracil) every 28
days (on days 1 and 8). Most regimens consist of 6 cycles except the CA regimen
which consists of 4 cycles. The choice of regimen was based on current practice
in the participating hospitals. The involvement of different adjuvant chemotherapy
regimens made it possible to create a sizeable sample in a relatively short period
of time. In the present study, 2 groups were compared: the doxorubicin group (CEF,
CAF, 4-epi-doxorubicin, 4-epi-doxorubicin/taxotere and CA) and the CMF group.
Stage of breast cancer. The anatomic extent of breast cancer was reported by
using the TNM clinical classification [20].
Type of surgery. In this study, patients underwent a mastectomy or a lumpectomy
with or without lymph nodes excision. Two groups were compared because of
small sizes of the other groups: (1) mastectomy with lymph nodes excision, and
(2) lumpectomy with lymph nodes excision. During the study period, no
reconstructive surgery was done.  
Statistical Analyses
First, it was statistically tested whether there were differences in patient
characteristics between the CMF group and the doxorubicin group. 
Furthermore, an overview of raw mean scores of the subscale ‘reduced
activity’ of the MFI-20 was described to obtain a general impression of the
course of the activity level. The course of the activity level was analysed with a
linear multilevel model using the MLwiN program (version 1.10.0006) [21].
The data consist of a series of repeated measurements nested within hospitals
and individual subjects. The data, which have a hierarchical nature, may be
characterised by dependencies between units at lower levels of the hierarchy. In
this case multilevel analysis is an appropriate technique [22].  
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In the analyses concerning the effect of chemotherapy regimen on the course of
fatigue, dummy variables were included to represent the several measurement
points. When the first measurement is taken as a reference, changes relative to the
baseline measurement are analysed. The effect of chemotherapy on the course of
fatigue was represented by interaction terms between these dummy variables and
a binary variable chemotherapy. To correct for possibly confounding factors in this
analysis, several covariates were added: ‘age’, ‘marital status’, ‘having children’,
‘education’, ‘having a job’, ‘type of surgery’, ‘stage of breast cancer’, ‘haemoglobin
level (measured in mmol/L) before the first treatment of chemotherapy’, ‘the
number of days between the operation and the first treatment of chemotherapy’,
‘the number of treatments at each measurement point’ and ‘radiotherapy’. For the
covariate ‘radiotherapy’ 3 different variables were used: a variable indicating
whether a patient had received radiotherapy at any point of measurement, the
number of days of radiotherapy the patient had had at the time of measurement
and the number of days between the last day of radiotherapy and the time of
measurement. Also these covariates were included as interaction terms with the
dummy variables representing the time points. In this way, possible differences in
patient characteristics between the chemotherapy groups are corrected for.
Stepwise deletion took place in which nonsignificant covariates were
deleted. The effect of the variable ‘treatment of adjuvant chemotherapy’ was
examined after the final model was determined in which only significant
covariates were included. For the final model fatigue scores, which are baseline
differences and are also adjusted for differences between the chemotherapy
groups, can be calculated. These will be denoted as adjusted baseline differences. 
For the subscale ‘behavioural/severity’ of the revised PFS an overview of
the mean subscale score as well as the mean item scores was displayed. The
interference with daily living activities at each measurement point was
examined by choosing a cutoff for the scores on the subscale of the PFS. A ‘little
or no interference’ and a ‘strong interference’ group was created. Differences in
the incidence of strong interference across time were analysed through a
logistic multilevel model using the MLwiN program (version 1.10.0006) [21]. In
this model, only dummy variables were included to represent the several
measurement occasions. 
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RESULTS
Response Rate
A total of 175 breast cancer patients were recruited for the study. For different
reasons, 18 (10%) patients were excluded. To be precise: 13 (7%) declined further
participation, 3 (2%) stopped the adjuvant chemotherapy prematurely, and 2 (1%)
had a poor physical state. The remaining 157 patients were interviewed four (n =
20) or five (n = 137) times depending on their adjuvant chemotherapy schedule.
The response rates are displayed in Table 3. The cause of the nonresponse was
mainly a change in the treatment schedule. The principal investigator conducted
79% of the interviews; the other interviews were conducted by an assistant. 
Sample Characteristics
Information on the demographic and medical characteristics is shown in Table 4.
Seventy-one percent of the patients had received one of the chemotherapy
regimens covered by the doxorubicin group; the remainder had received the
CMF treatment. There were 2 characteristics on which the doxorubicin group
and CMF group differed: ‘age’ and ‘having a job’. The CMF group was
significantly (t = -2.133; P = 0.035) younger than the doxorubicin group. The
average age in the CMF group was 45.0 years (SD = 7.9) compared with 48.2
years (SD = 9.0) in the doxorubicin group. In the CMF group significantly (χ2(1)
= 4.768, P = 0.034) more patients had a job compared to the doxorubicin group.
No other characteristics were significantly different between the 2 groups. Table
5 describes the total number of chemotherapy treatments for each of the
chemotherapy regimens, and Table 6 describes the numbers of patients receiving
radiotherapy at the different measurement points. Most patients received 
Measurement Total (n) Participants in study
n %
1 157 157 100
2 157 157 100
3* 137 135 99
4 157 152 97
5 157 152 97
* Patients receiving only 4 chemotherapy treatments did not have this interview.
Table 3. Response rates of patients with breast cancer specified for each measurement occasion
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Doxorubicin group CMF group Total
(n = 111) (n = 46) (n = 157)
Age (years)*
Mean (SD) 48.2 (9.0) 45.0 (7.9) 47.3 (8.8)
Range 27-70 25-62 25-70
n % n % n %
Marital status
Married/living together 91 82 40 87 131 83
Single 11 10 3 7 14 9
Divorced 7 6 3 7 10 6
Widow 2 2 - - 2 1
Children
Yes 87 78 37 80 124 79
No 24 22 9 20 33 21
Educational level†
Low 43 39 13 28 56 36
Middle 43 39 24 52 67 43
High 25 23 9 20 34 22
Job*
Yes 59 53 33 72 92 59
No 52 47 13 28 65 41
Stage of breast cancer‡
I 9 8 3 7 12 8
II 90 81 35 76 125 80
III 4 4 2 4 6 4
I and III (two tumours) - - 1 2 1 1
Unknown (missing at the data 
collection point)
8 7 5 11 13 8
Type of operation§
Mastectomy without lymph nodes excision 3 3 - - 3 2
Mastectomy with lymph nodes excision 53 48 20 43 73 47
Lumpectomy without lymph nodes excision 1 1 - - 1 1
Lumpectomy with lymph nodes excision 52 47 26 57 78 50
Unknown 2 2 - - 2 1
Treatment of adjuvant 
chemotherapy
CEF 38 34 - - 38 24
CAF 27 24 - - 27 17
4 epi-doxorubicin 21 19 - - 21 13
4 epi-doxorubicin / taxotere 5 5 - - 5 3
CA 20 18 - - 20 13
CMF (no oral administration) - - 15 33 15 10
CMF (partially oral administration) - - 31 67 31 20
Radiotherapy
Yes 75 68 33 72 108 69
No 36 32 13 28 49 31
Anaemia (haemoglobin level, 
mmol/l < 7.3 or g/dl < 11.7)¥
Yes 10 9 1 2 11 7
No 99 89 43 94 142 90
Unknown 2 2 2 4 4 3
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6 treatments of chemotherapy. Most patients who received radiotherapy were
receiving radiotherapy at the second measurement (corresponding to the third
treatment of chemotherapy). 
Activity level
The course of the activity level was studied by analysing the results for the
subscale ‘reduced activity’ of the MFI-20. The raw mean scores and accom-
panying confidence intervals of this subscale are displayed in Figure 1. It seems
that the activity level is stable during the study period with an improvement at
the end. However, notice the large confidence intervals of these mean scores
indicating that there are large variances in the scale scores at each time point.
In the next section, a more detailed description of the course of the activity level
and its determinants is given. 
Course of the activity level and its determinants
Type of chemotherapy does not affect the activity level of the patients, which
Length of radiotherapy treatment 
(days)
Mean (SD) 42.9 (5.7) 43.4 (5.5) 43.1 (5.6)
Range 26-51 32-57 26-57
Number of radiotherapy treatments
Mean (SD) 30.4 (3.5) 30.4 (3.4) 30.4 (3.5)
Range 25-35 25-33 25-35
Days between operation and 1st
chemotherapy treatment
Mean (SD) 33.9 (21.6) 38.8 (26.5) 35.3 (23.2)
Range 9-215 15-125 9-215
Haemoglobin level, mmol/l or g/dl¥
Mean mmol/l or g/dl (SD mmol/l or g/dl) 8.1 or 13.0 (0.8 or 1.3) 8.3 or 13.3 (0.6 or 1.0) 8.2 or 13.1 (0.7 or 1.1)
Range mmol/l or g/dl 5.9-9.7 or 9.4-15.5 7.0-9.9 or 11.2-15.8 5.9-9.9 or 9.4-15.8
* Statistically significant difference (P < 0.05) in characteristic between the doxorubicin group and CMF group.
† Low is primary school/lower vocational education; middle is lower general secondary education/intermediate 
vocational education; and high is higher general secondary education/higher vocational education/university.
‡ Three groups, stage of breast cancer I, II and III, were included in the comparison between the doxorubicin
group and CMF group.
§ Two groups, mastectomy or lumpectomy with lymph nodes excision, were included in the comparison 
between the doxorubicin group and CMF group.
¥ The haemoglobin level was determined before the first treatment of chemotherapy; the conversion factor 
from mmol/l to g/dl is 1.6.
Table 4. Patient characteristics (continued)
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means that the course in the activity level in the 2 chemotherapy groups (CMF
versus doxorubicin) was equal during the whole study period. However, the
course of the activity level was significantly different for groups defined by the
variables ‘age’ (Δχ2(4) = 10.606, P < 0.05), ‘having children’ (Δχ2(4) = 10.303,
P < 0.05) and ‘stage of breast cancer’ (Δχ2(8) = 16.020, P < 0.05). 
Subgroups were formed based on these variables. The variable ‘age’ was
categorised into two groups: 25 to 45 years (n = 71) and 46 to 70 years (n = 86).
Separate analyses for each stratum that could be defined based on these 3
interacting variables were not performed because these strata were too small.
Therefore, for each variable separately, stratification was conducted. By inves-
tigating the time effects in this way for each stratum the averaged effects were
examined, where the other 2 variables that interact with measurement points
were averaged across. 
Figure 2 shows the course of reduced activity for the different groups 
that were distinguished with respect to the variable ‘age’. Adjusted baseline
Total number of treatments → 4 5 6 8
Total (n)
Treatment of adjuvant 
chemotherapy
Doxorubicin group 21 10 72 8 111
CMF - - 46 - 46
Table 5. Frequency of the total number of treatments specified for each chemotherapy
treatment  (n = 157)
Measurement Receiving Receiving or having Not having 
Totaloccasion radiotherapy finished radiotherapy received 
at measurement at measurement radiotherapy
n % n % n % n
1 8 5 11 7 146 93 157
2 58 37 89 57 68 43 157
3* 3 2 94 70 41 30 135
4 8 5 98 64 54 36 152
5 2 1 103 68 49 32 152
* Patients receiving only 4 chemotherapy treatments did not have this interview.
Table 6. Overview of numbers of patients with breast cancer receiving radiotherapy specified
for each measurement occasion
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differences are displayed. The level of activity for the group ‘46-70 years old’ is
quite stable during the whole study period, except for the significant difference
between measurements 4 and 5 (Δχ2(1) = 5.216, P < 0.05). Patients were
significantly more active at measurement 5 than at measurement 4. The difference
in activity level between measurements 3 and 5 is also significant (Δχ2(1) = 6.418,
P < 0.05). For the group of 45 years and younger, none of the pairwise comparisons
between measurement occasions were significant. Here, the activity level is
constant during the whole study period. Examining Figure 2, one would expect
a difference between measurement occasion 1 and 5 for this age group, but
probably because of the large variance of the scores within this group, no
significant difference was found. 
An examination of the time points at which the changes in the activity level
are different between the 2 ‘age’ groups revealed significant differences for the
changes between measurements 1 and 3 and between measurements 2 and 3
(Δχ2(1) = 9.246, P < 0.01 and Δχ2(1) = 4.466, P < 0.05, respectively). The older
Figure 1. Raw mean scores of the subscale ‘reduced activity’ of the MFI-20 (range 4-20) and
the subscale ‘behavioural/severity’ of the revised PFS (range 0-10) (n=157).
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group was more restricted in activity than the younger group at these time points.
The course of the level of activity for the different groups of the variable
‘having children’ is presented in Figure 3. As can be seen, the 2 lines intersect
at measurement 5, which turns out to correspond with a significant difference
in the course of the activity level  between the groups with and without children,
when comparing measurements 4 and 5 (Δχ2(1) = 6.799, P < 0.01). The group
‘having children’ shows an increase in activity level, whereas the group “no
children” shows a slight decrease. When other differences over time between
the 2 groups are examined, a significant difference is only found between
measurements 1 and 4 (Δχ2(1) = 4.705, P < 0.05).
Furthermore, for the group ‘having children’ a significant difference is
seen between measurements 4 and 5 (Δχ2(1) = 6.03, P < 0.05). Patients with
children are significantly more active at measurement 5 than at measurement 4.
Figure 2. The course of the subscale ‘reduced activity’ as a function of age.
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The changes between measurements 2 and 5 as well as between measurements
3 and 5 are also significant (Δχ2(1) = 4.905, P < 0.05 and Δχ2(1) = 4.387, P <
0.05, respectively): patients are more active at measurement 5 when compared
to measurement 2 and 3. The group ‘no children’ on the other hand, showed no
significant changes in the activity level, probably because of large score variances
within this group. 
For the different groups of the variable ‘stage of breast cancer’, statistical
testing was only possible for the group ‘stage II’. The remaining groups (stages I
and III) were considered too small to yield reliable results. Also the group ‘stage
II’ showed stability in activity levels during the treatment of chemotherapy and
4 weeks after the last treatment of chemotherapy (see Figure 4). At the last
measurement, compared to the measurements 2, 3 and 4, a significant (Δχ2(1)
= 4.041, P < 0.05, Δχ2(1) = 4.178, P < 0.05 and Δχ2(1) = 4.884, P < 0.05,
Figure 3. The course of the subscale ‘reduced activity’ as a function of having children.
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respectively) increase in activity is seen in these patients. All significant comparisons
for the group ‘stage II’ are such that the activity level at the last measurement is
significantly higher than at the other measurements. 
With respect to the other covariates, there were significant main effects for
type of surgery (Δχ2(1) = 145.924, P < 0.01), the duration of radiotherapy (Δχ2(1)
= 7.429, P < 0.01), the interval between measurement point and time of the last
radiotherapy (Δχ2(1) = 11.296, P < 0.01) and the number of treatments of
chemotherapy (Δχ2(2) = 10.104, P < 0.01). Patients who had undergone a
lumpectomy had a higher level of activity than those who had had a mastectomy.
The effects for radiotherapy were the following: the longer the duration of
radiotherapy, the less active, and the longer the time interval between the last
radiotherapy session and the measurement point, the more active patients were
at that measurement point. Moreover, women who received in total more
chemotherapy treatments were significantly more active than those who received
fewer. In other words, the activity level was less restricted. 
Figure 4. The course of the subscale ‘reduced activity’ for the patients in stage II of breast cancer.
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The impact of fatigue on daily living activities
The subscale ‘behavioural/severity’ of the revised PFS reflects the impact of
fatigue on activities of daily living. Figure 1 shows that the mean subscale scores
are relatively low and are stable over time. Mean subscale scores as well as
mean item scores are presented in Table 7. In general during the study period,
the mean item scores were also relatively low, but the high standard deviations
indicate a lot of individual differences between women. The sample sizes for
item 1 are very small. This indicates that not many women were working or had
school activities. It is noticeable that after completion of chemotherapy, more
and more patients were getting back to work or to school activities. The sample
sizes for this item were too small to identify a reliable pattern or to report
meaningful results. Not all women answered item 3, the question about the
interference with the ability to engage in sexual activity. The reason was that
some women did not wish to comment or that the interviewer assessed it was
not appropriate to ask this question given the patient’s situation. For the items ‘to
visit or socialize with your friends’ (item 2), ‘to engage in sexual activity’ (item 3)
and ‘to engage in the kind of activities you enjoy doing’ (item 4), a slight mean
increase is seen in the intensity of interference after the start of the first treatment
of chemotherapy. The mean scores on item 5, which describes the degree of
intensity or severity of fatigue, are at almost all measurement points the highest
scores. For this item too, a slight mean increase can be seen after the first
measurement. However, these observations are not statistically significant. 
Examining the prevalences of strong interference as based on the total
subscale score in Table 7, it can be noted that at each measurement these
prevalences are between 15% and 35%. Statistical testing shows that the
prevalence of strong interference, first increases significantly after the start of
chemotherapy (t = 2.597, P < 0.01). The increase continues, in that between the
third and the fifth cycle of chemotherapy also a significant increase was
observed (t = 2.519, P < 0.02). After completion of chemotherapy, however, the
number of patients in the ‘strong interference’ group decreases. Between
measurements 3 and 4 no significant difference (t = -1.712, P > 0.08) was
observed in the prevalence, but between measurements 4 and 5, a significant
decline (t = -2.271, p < 0.03) was seen. Twelve weeks after completion of
chemotherapy, the prevalence of strong interference was not larger when
compared to the prevalence at the start of chemotherapy (t = 1.120, P > 0.25).  
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Measurement point → 1st cycle† 3rd cycle
n(%) mean(SD) n(%) mean(SD)
Total score subscale 157(100) 2.2(2.3) 157(100) 3.2(2.5)
Little or no interference* 133(85) 1.5(1.6) 118(75) 2.1(1.7)
Strong interference 24(15) 6.4(1.1) 39(25) 6.7(1.1)
Item 1§ (total score) 11(100) 3.4(2.8) 13(100) 3.1(3.0)
Little or no interference* 8(73) 2.1(2.2) 10(77) 1.8(2.1)
Strong interference 3(27) 6.7(0.6) 3(23) 7.3(0.6)
Item 2 (total score) 157(100) 1.5(2.4) 156(100) 2.2(2.5)
Little or no interference* 142(90) 0.9(1.6) 136(87) 1.5(1.8)
Strong interference 15(10) 7.2(1.1) 20(13) 6.9(1.0)
Item 3 (total score) 132(100) 1.9(3.1) 122(100) 3.3(3.3)
Little or no interference* 114(86) 0.9(1.6) 91(75) 1.6(2.0)
Strong interference 18(14) 8.6(1.5) 31(25) 8.0(1.5)
Item 4 (total score) 157(100) 2.0(2.8) 156(100) 2.9(3.1)
Little or no interference* 139(89) 1.3(1.9) 122(78) 1.6(2.0)
Strong interference 18(11) 7.8(1.3) 34(22) 7.5(1.3)
Item 5 (total score) 157(100) 3.2(2.9) 157(100) 4.5(3.0)
Little or no interference* 127(81) 2.2(1.9) 98(62) 2.7(2.0)
Strong interference 30(19) 7.8(1.4) 59(38) 7.6(1.3)
* Little or no interference involves a score ≤ 5 and strong interference a score > 5.
§ The items are as follows:
item 1: To what degree is the fatigue you are feeling now interfering with your ability to complete your  work or 
school activities?
item 2: To what degree is the fatigue you are feeling now interfering with your ability to visit or socialize with 
your friends?
item 3: To what degree is the fatigue you are feeling now interfering with your ability to engage in sexual activity?
item 4: Overall how much is the fatigue, which you are experiencing now, interfering with your ability to engage in 
the kind of activities you enjoy doing?
item 5: How would you describe the degree of intensity or severity of the fatigue which you are experiencing now?
† The first three interviews were held directly before, during or after infusion.
‡ Patients receiving only four chemotherapy treatments did not have this interview.
Table 7. Raw mean scores of the subscale ‘behavioural/severity’ of the revised PFS (range 0-10)
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5th cycle‡ 4 weeks after 12 weeks after 
the last cycle the last cycle 
n(%) mean(SD) n(%) mean(SD) n(%) mean(SD)
135(100) 3.5(2.8) 152(100) 3.5(2.6) 152(100) 2.6(2.5)
89(66) 1.8(1.5) 111(73) 2.2(1.6) 122(80) 1.6(1.5)
46(34) 6.9(1.1) 41(27) 6.9(1.3) 30(20) 6.7(1.2)
14(100) 3.1(3.3) 19(100) 2.8(2.6) 36(100) 2.1(2.6)
11(79) 1.7(2.0) 15(79) 1.8(1.7) 31(86) 1.3(1.6)
3(21) 8.0(1.7) 4(21) 6.8(1.5) 5(14) 7.2(0.8)
135(100) 2.6(2.9) 152(100) 2.4(2.8) 152(100) 1.8(2.5)
105(78) 1.3(1.8) 127(84) 1.4(1.7) 137(90) 1.2(1.7)
30(23) 7.0(1.1) 25(16) 7.5(1.0) 15(10) 7.4(1.1)
97(100) 3.9(3.7) 114(100) 3.7(3.2) 116(100) 2.7(3.0)
62(64) 1.5(2.0) 84(74) 2.1(1.9) 95(82) 1.5(1.8)
35(36) 8.1(1.4) 30(26) 8.1(1.3) 21(18) 7.8(1.4)
134(100) 3.1(3.3) 152(100) 3.2(3.1) 152(100) 2.3(2.8)
95(71) 1.3(1.7) 115(76) 1.7(1.8) 126(83) 1.3(1.8)
39(29) 7.7(1.3) 37(24) 7.8(1.1) 26(17) 7.4(1.2)
135(100) 4.5(3.0) 152(100) 4.6(3.1) 152(100) 3.7(3.0)
81(60) 2.4(1.7) 96(63) 2.7(1.9) 109(72) 2.1(1.6)
54(40) 7.7(1.2) 56(37) 8.0(1.3) 43(28) 7.9(1.2)
DISCUSSION
This longitudinal study represents the first large-scale examination of the course
of the activity level, seen as a dimension of fatigue, as well as the extent of
interference of fatigue in general with daily activities within 157 patients with
breast cancer during as well as after receiving adjuvant chemotherapy. Measure-
ment occasions were before, during or after infusion at the first, third and fifth
cycle of chemotherapy, as well as four and twelve weeks after completion of
chemotherapy. 
In this study the following research questions were addressed: 
1. How does the activity level, seen as a dimension of fatigue, within a breast 
cancer population receiving adjuvant chemotherapy, change in the course
of time?
2. Does the course of activity level depend on the regimen of chemotherapy 
(CMF or doxorubicin group) and what other determinants are influencing
this course?
3. To what degree is fatigue interfering with daily living activities and does the 
degree of interference change over time?
Course of the activity level and its determinants (questions 1 and 2)
During the study, the course of the activity level, measured by a subscale of the
MFI-20, was the same for the CMF group and for the doxorubicin group. It is
remarkable that in another study of De Jong et al. [23], the courses of general
fatigue and physical fatigue (2 other subscales of the MFI-20), were significantly
different for the 2 chemotherapy groups. Comparing these courses to the course
of the activity level, no similarity was seen in the pattern across time. We [23] also
reported that the doxorubicin group showed a significant increase in general and
physical fatigue during the first cycles of chemotherapy and the CMF group after
the last cycle of chemotherapy. The activity level as examined in this study, on the
other hand was stable until the fourth measurement occasion, 4 weeks after
completion of chemotherapy, after which patients became more active. A so-
called mirror-image pattern of fatigue as found by Berger [16], where an increase
in fatigue is accompanied by a reduction in the activity level, was therefore not
found in our study. Note that in Berger’s study other measurement points and
measurement instruments were used as compared in the present study. 
The course of mental fatigue and motivation in the study of De Jong et al.
[24], on the other hand, tended to be stable during the study, but with a decline
in mental fatigue and an increase in motivation after the completion of chemo-
therapy. This would be in line with the course of the activity level found in the
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present study. A limitation of the present study is that, in the scale no distinction
is made between physical and mental activities. This would enable a more
precise analysis of the relations between activity level, on the one hand, and
mental and physical fatigue on the other hand.
The course of the activity level was affected by age and having children as
well as the stage of breast cancer. The subgroups created for these variables
simultaneously were too small to perform separate analyses for each resulting
subgroup. Overall, a significant improvement of the activity level is seen in the
last phase of the study. Like the present study, Berger [16] found a kind of
stability in the activity level during the treatment of chemotherapy. Berger and
Higginbotham [12] found an improvement in the activity level after completion
of chemotherapy. 
In a literature review [17] on breast cancer patients receiving chemotherapy,
the findings on stability in the intensity of fatigue throughout the treatment cycles
were also reported. The stability can be explained by an enhanced need for social
support before initiation of chemotherapy. The uncertainties and fears experienced
by the cancer patients are likely to result in this need [25]. Activities of the patients
can be taken over, not only because of psychological reasons but also because of
the physical condition after surgery. Even before primary surgery, a high prevalence
of fatigue is found [26]. The activity level can therefore be influenced at an early
stage. Further research involving the period preceding chemotherapy is needed. 
Another reason for the stability in activity during treatment might be a shift
in the internal norm of the patient [27]. For example, the same degree of fatigue
experienced can be later described as a no-fatigue experience. Moreover, there
is a risk that patients, because of the relatively short period of time between the
measurements, may recognize the questions, which can thus influence the way
they respond. 
Apparently, the measurement time selected in this study (12 weeks after
chemo) after completion of chemotherapy is long enough to show any
improvement in the activity level. It is notable that the activity level at 12 weeks
post chemo is comparable to the activity level at the start of the study. In the
present study, it is clear that patients are becoming more active after the
chemotherapy treatment, but whether the activity level can be regarded as
‘normal’ is not yet clear. A limitation of the present study is the absence of a
control group with which to compare the findings. Future research should
involve a healthy control group. 
Type of surgery was found to influence the level of activity over time.
Women treated with a mastectomy were significantly more hampered in activity
than women that had undergone a lumpectomy. Undergoing mastectomy was a
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significant predictor of fatigue in a recent study [28]. Another study [29] shows
that women undergoing breast conservation or postmastectomy procedures have
better outcomes on selected psychosocial and quality-of-life measures than
those who had only undergone a mastectomy. The extent of the surgery might
influence the activity level, but so might the possible destructive psychological
impact on a woman who lost a breast. 
In the present study, supplementary to chemotherapy, 69% of the women
received radiotherapy. The activity level was also influenced by radiotherapy
variables. The longer the duration of radiotherapy, the less active patients were.
In addition, the longer the time interval between the last radiotherapy session
and the measurement point, the more active patients became. These findings
can be explained by the fact that the trips to the treatment centre can be very
exhausting [23]. Woo et al. [30] concluded in their study that the effect of
radiotherapy itself or a combination of therapies makes the patients more
fatigued. This finding might be explaining the result found in this study. The
normalisation after the last treatment of radiotherapy is comprehensible knowing
that women recover from the intensive period of receiving radiotherapy [23].
This reasoning is partially supported by Irvine et al. [31].  
A phenomenon which is difficult to explain is the influence of the number
of chemotherapy treatments on the level of activity. The activity level in women,
who had received in total more treatments of chemotherapy, was significantly
higher than those who completed fewer treatments. In another study of De Jong
[24], related to our project, the motivation level of women who received, in
total, more treatments was also significantly higher. This could be an explanation
for this finding. That is, the treatments provide the patients with a kind of extra
boost ‘to go for it’.   
None of the following variables influenced the activity level: ‘marital
status’, ‘education’, ‘having a job’, ‘haemoglobin level before the first treatment
of chemotherapy’, ‘the number of days between the operation and the first
treatment of chemotherapy’ and ‘type of chemotherapy’. Similar results were
found in studies related to our project [23, 24]. Other existing studies did not
examine the course of different dimensions of fatigue, which makes it almost
impossible to compare results. Bower et al. [32] and Haghigat et al. [28] found
no relation between educational attainment and fatigue. Employment status
was also not associated with fatigue [32]. Okuyama et al. [33] reported that the
number of days since operation was not correlated with fatigue. 
Impact on daily life activities (question 2)
Although the mean score of the subscale of the PFS was low (indicating little or
no interference) and seemed stable during the study period, at each measure-
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ment, a relatively large group, approximately 15% to 35% of the sample, reported
that fatigue interfered to a strong extent with their daily living activities. 
It is also clear that for significantly more patients fatigue interferes to a strong
extent with their daily living activities after the first infusion of chemotherapy.
During chemotherapy, this group grows significantly. After completion of
chemotherapy this group shrinks. At the end of the study, the group with strong
interference is similar in size to the group at the start of chemotherapy. The
present results cannot be compared to previous work, because no comparable
division was made. 
The results presented must be considered within the limitations of this study.
The present study used an earlier version of the revised PFS to examine changes
in the interference of fatigue with activities of daily living. One item is missing
compared to the new version of this scale, which may have influenced the results. 
Another limitation is that it is not clear whether fatigue causes a reduction in
activity or vice versa. A reduction in acitivity might refer to a consequence of
fatigue, but an adjustment or a decline in physical activities can also be the start
of fatigue. Studies [34-36] support this assumption. 
Before the start of chemotherapy, the activity level might already have
changed. The experienced activity level at the end of the study compared to the
measurement at the start of the chemotherapy treatment was not different. In
that case, the measurement time after completion was too short to show any
improvement in the activity level. Further research, involving the trajectory
preceding adjuvant chemotherapy and a longer study period afterwards, needs
to be done. 
Improved understanding of the activity level and the impact of fatigue on
daily life activities of breast cancer patients receiving chemotherapy will better
equip healthcare providers to understand and address the needs of these
patients. Finally, future research should include interventions addressing how
patients can maintain or improve the activity level during as well as after
receiving adjuvant chemotherapy.
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ABSTRACT
The purpose of this study was to determine the course of fatigue in patients with
breast cancer between 2 cycles of adjuvant chemotherapy, from the day of admini-
stration until the day of the next infusion. In a prospective cohort study, a sample
of 151 patients with breast cancer receiving adjuvant chemotherapy was recruited
from 6 hospitals in mainly the south of the Netherlands. Patients reported their
experience of fatigue in a diary, the Shortened Fatigue Questionnaire, on a daily
basis between the third and fourth treatment with adjuvant chemotherapy. 
Patients were treated with either a doxorubicin containing schedule or with
cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 28 days). In the 28-day
regimens, infusions were given on day 1 and day 8. The days after completion of
the third and the start of the fourth treatment with chemotherapy were statistically
analyzed. We tested the hypothesis that the maximum fatigue score occurs in the
first 4 days after treatment. 
The mean age of the sample was 47.2 years (SD = 8.8). Most women (84%)
were married or lived together with a partner. The majority (80%) of all patients
had been diagnosed with stage II breast cancer. The division between
mastectomies (47%) and lumpectomies (52%) was approximately equal. Sixty
percent of the patients received radiotherapy before the third treatment with
chemotherapy and/or in the period they kept the diary. A chaotic pattern of
fatigue between the 2 cycles of chemotherapy emerged. Smooth (splines) curves
showed an average highest level of fatigue on day 3 from the start. For the 28 day
regimens another distinct peak was seen around day 11. A relatively larger
number of patients experienced peak fatigue levels before day 5. The course of
fatigue in the CMF group was significantly different compared to the doxorubicin
regimens. The fatigue peak in the CMF group was lower. Women taking
cyclophosphamide orally experienced the peak level of fatigue significantly later.
Influences of other variables were not observed in any chemotherapy group. 
Cancer-related fatigue has a chaotic nature. The first days after treatment
with chemotherapy are the worst. The type of chemotherapy has a significant
impact on the course of fatigue. Improved understanding of the nature and
course of fatigue could equip health care providers better for informing patients
about what they may expect. Future research should include interventions
aimed at reducing or coping with fatigue. 
Key words: adjuvant chemotherapy, breast cancer, fatigue
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INTRODUCTION
Fatigue is one of the most common complaints of patients undergoing cancer
treatment [1]. The National Comprehensive Cancer Network (NCCN) has
reported that 70% to 100% of the patients with cancer report fatigue [2]. Most
patients report fatigue while undergoing cancer-related therapies. The exact cause
of fatigue is unknown [1]. Factors associated with fatigue include the cancer itself,
cancer treatment, depression or anxiety, some medications, pain, nausea, vomiting,
diarrhoea, poor nutrition, anaemia, infections and insomnia [1]. Fatigue is a complex,
multicausal and multidimensional subjective experience, and therefore, no single
definition is widely accepted [3-5]. However, a panel of experts in the field of
fatigue, convened by the NCCN, defined cancer-related fatigue as “a persistent,
subjective sense of tiredness related to cancer or cancer treatment that interferes
with usual functioning” [2](p. MS-2). In a study by Holley [6], cancer-related fatigue,
when compared with ‘typical’ fatigue, was found to be more rapid in onset, more
energy draining, more intense, longer lasting, more severe and more unrelenting.
The unusual character of cancer-related fatigue described in Holly’s study [6] is in
line with the definition of the NCCN. Fatigue is the most frequently reported side
effect in cancer patients who receive chemotherapy. Hilfinger Messias et al. [7]
state results on how overwhelming and debilitating fatigue can be for patients
undergoing chemotherapy.
The leading form of cancer in women since the early 1990s has been
breast cancer, not only in the Netherlands but also elsewhere. 
Schwartz [8] reported that breast cancer patients receiving adjuvant
chemotherapy demonstrated a chaotic pattern with erratic and wide swings in
their fatigue. De Jong et al. [9] reported in their literature review on breast cancer
patients who received chemotherapy that the first 2 days after chemotherapy
treatment seemed to be the worst period. Other symptoms in women
undergoing chemotherapy for breast cancer show a similar pattern. The worst
nausea and the worst vomiting occurred on the third day after having
chemotherapy [10, 11].
According to recent breast cancer studies [12, 13], the type of surgery does
influence the course of fatigue, whereas the influence of other characteristics,
such as radiotherapy, marital status, and age, is unclear.
The intensity of fatigue in patients with breast cancer between 2 cycles of
chemotherapy treatments has rarely been investigated. Previous studies, mentioned
in a literature review [9], are marked by several limitations, including a small
sample size. In addition, information about fatigue on each day between 2
cycles of chemotherapy treatments is often missing, which means that the
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understanding of the course of fatigue remains incomplete. Moreover, the
influence of other characteristics on the course of fatigue is unknown. 
The present study is part of a fatigue project in breast cancer patients receiving
adjuvant chemotherapy. The purpose of the present study was to investigate the
course of fatigue in patients with breast cancer between 2 cycles of chemotherapy
treatment, from the day of administration until the day on which the next cycle
starts. The research questions are: How does the experience of fatigue change in
the course of time and are there any factors which are influencing the course of
fatigue? More specific, in the present study, we tested one hypothesis. Previous studies
support the hypothesis that the intensity of fatigue increases directly after
administering chemotherapy. Therefore, the hypothesis that the maximum fatigue
score occurs in the first 4 days after treatment with chemotherapy was tested. The
impact of different chemotherapy regimens on the course of fatigue was unclear
and was therefore further examined in this study. Finally, the influence of other
characteristics on the course of fatigue was studied. 
PATIENTS AND METHODS
Population sample and procedure
Patients with breast cancer attending for adjuvant chemotherapy were accrued
from 6 hospitals in mainly the south of the Netherlands. 
After checking the inclusion criteria, the study was introduced by an
oncologist or the oncology nurse before the first treatment with adjuvant
chemotherapy. Written information was given in which the purpose and
procedure of the investigation were explained. The principal investigator of the
present study was contacted by the oncologist or the oncology nurse if the patient
agreed to participate. All patients gave their informed consent in writing. The
procedures were approved by all local medical ethical committees of the
participating health centres.
To be eligible for participation, patients with breast cancer: (1) had to have
no metastasis or other malignancy, (2) had to be treated with cytostatics for the
first time, (3) had to be treated with outpatient adjuvant chemotherapy, (4)
should not suffer from a chronic disease (including hypertension, kidney disease,
heart problems, diabetes mellitus etc) or be in a poor psychological state, (5)
should not use morphine or narcoleptics, (6) should not be deaf, (7) had to be 18
years or older, and (8) had to be able to speak and understand Dutch.
Patients were seen 3 times during chemotherapy for this fatigue project: at
the beginning of the first, third, and fifth cycles of chemotherapy. After intake at
142
Chapter 6
the first visit, a diary, the Shortened Fatigue Questionnaire (SFQ) [14], was given
at the time of the third treatment with chemotherapy and had to be filled in
daily, starting on the day of the third chemotherapy treatment until the day of
the fourth chemotherapy treatment. The interviewer explained the importance
of filling in the diary and emphasised the need of completeness. The start of the
third cycle was chosen because the patient should be more familiar with
receiving a chemotherapy treatment than at the start of the first cycle of
chemotherapy. Besides, the opportunity to bring the diary back existed, which
might raise the response. Patients were asked to bring the diary at the third
measurement point, the fifth treatment of chemotherapy. Medical data were
collected from the charts afterwards. 
Operationalisation of variables
Intensity of fatigue. The SFQ [14] is an instrument to determine the intensity of
the patient’s bodily fatigue. The SFQ, a 7-point scale, was developed based on 2
Dutch fatigue questionnaires: the Checklist Individual Strength (CIS)[15] and the
Multidimensional Fatigue Inventory (MFI-20)[16]. The SFQ, in the present study
used as a diary, was developed for daily medical practice and clinical scientific
studies. The questionnaire is reliable, easy to use and can be completed quickly.
Its internal consistency is good (Cronbach’s alpha: 0.88) and it can discriminate
between patient groups and healthy control groups [14]. The questionnaire
consists of 4 questions: ‘I feel tired’, ‘I tire easily’, ‘I feel fit’ and ‘I feel physically
exhausted’, each with a 7-point answer scale. The properly-signed sum score
varies from a minimum of 4 to a maximum of 28. High scores indicate more
subjective fatigue. 
Patients were asked to rate their fatigue as experienced during 1 day for a
period of 21 or 28 days, depending on their chemotherapy regimen. The diary
had to be filled in all days between the third and fourth treatment with adjuvant
chemotherapy. 
Treatment with adjuvant chemotherapy. The treatment regimens used were:
CEF (cyclophosphamide, 4-epi-doxorubicin and 5-fluorouracil), CAF
(cyclophosphamide, doxorubicin and 5-fluorouracil), 4-epi-doxorubicin, 4-epi-
doxorubicin/taxotere, CA (cyclophosphamide and doxorubicin) and CMF
(cyclophosphamide, methotrexate (oral administration from day 1 to day 14 or
intravenous) and 5-fluorouracil) (see Table 1). Most regimens consisted of 6
cycles except the CA regimen, which consisted of 4 cycles.
For some chemotherapy schedules, the third treatment existed of 2
infusions given on day 1 and day 8 (see Table 1). These patients filled in 28 days
of the diary, whereas others filled in 21 days. 
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Several groups were compared for the analysis: the ‘21 days-doxorubicin
group’ or ‘dox21’ (CEF, CAF and CA), the ‘28 days-doxorubicin group’ or ‘dox28’
(4-epi-doxorubicin and 4-epi-doxorubicin/taxotere) and the CMF group (28 days).
The choice of schedule was based on current practice in the participating
hospitals. The involvement of various adjuvant chemotherapy regimens made it
possible to generate a sizeable sample in a relatively short period of time. The
days that followed on completion of the full third treatment were compared. This
means that only the last 3 weeks, 21 days, were compared. We chose for a time
schedule in which no infusion took place because of its possible influence on the
course of fatigue. 
Stage of breast cancer. The TNM (T, tumor; N, regional lymph node; M, distant
metastases) clinical classification for describing the anatomic extent of breast
cancer was used [17]. Indications for adjuvant chemotherapy were standard. 
Type of surgery. In the present study, 2 types of surgery were compared: (1)
mastectomy with lymph nodes excision; and (2) lumpectomy with lymph nodes
excision. The other types, mastectomy or lumpectomy without lymph nodes
excision, were excluded because of their small sample size. No reconstructive
surgery was done during the study period.
Statistical analyses
It was statistically tested whether there were differences in patient characteristics
between the different chemotherapy groups. We used chi-square tests for categorical
Infusion 3rd treatment given on Total number of days of the diary
Treatment with adjuvant 
chemotherapy (n)
doxorubicin-group (n = 107)
dox21 group (n = 82):
CEF (n = 37) day 1 21
CAF (n = 25) day 1 21
CA (n = 20) day 1 21
dox28 group (n = 25):
4 epi-doxorubicin (n = 20) day 1 and day 8 28
4 epi-doxorubicin / taxotere (n = 5) day 1 and day 8 28
CMF group
CMF (n = 44) day 1 and day 8 28
Table 1. Characteristics of the diary specified by chemotherapy treatment (n = 151)
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characteristics and t tests for continuous data. The Mann-Whitney U test was used
to compare the level of education. 
The reliability of the SFQ was examined by calculating Cronbach’s α. The
Cronbach’s α of the SFQ is the mean of the Cronbach’s α of each day of the diary. 
First, an overview of raw mean scores of the SFQ of the different chemotherapy
groups was presented to give an impression of the course of fatigue between 2
cycles of adjuvant chemotherapy. 
To obtain a clearer picture of the course of fatigue, we calculated cubic
spline fits of the mean fatigue score per chemotherapy group. Cubic splines
provide a smoothly curved estimate of the mean fatigue, calculated per group
or for individual patients, using third-order polynomials between the so-called
knots. The polynomials are restricted to ensure a smooth transition at the knots.
For these splines, the knots were chosen at 5, 10 and 15 days based on the
assumption that changes in fatigue would be larger in the first weeks after
chemotherapy. We tested for overall differences between chemotherapy groups
using a longitudinal model assuming a random intercept per patient and robust
estimation of the error variance (Stata version 8) [18]. Likewise, the different
groups of the following variables were tested separately for the different
chemotherapy groups: ‘age’, ‘marital status’, ‘having children’, ‘education’,
‘having a job’, ‘season in which the diary was kept (spring and/or summer vs.
autumn and/or winter)’, ‘type of surgery’, ‘stage of breast cancer’, ‘having
cyclophosphamide oral’, ‘haemoglobin level (measured in mmol/l) before the
third cycle of chemotherapy’, ‘number of days between the operation and the
first treatment with chemotherapy’ and ‘radiotherapy’. Two different variables
were used for the covariate ‘radiotherapy’: the number of days of radiotherapy
the patient had had at the time of measuring and the number of days between
the last day of radiotherapy and the time of measuring. 
Subsequent analysis of the mean fatigue score, the maximum fatigue score
and the day of the maximum fatigue score was done on values from individually
fitted spline curves (see above), with estimated imputation of missing values
and truncation at values 4 and 28 to avoid excessive estimates. These curves
were calculated only when the number of diary entries was at least 9, again to
avoid large spurious oscillations. To compare the 21-day doxorubicin-therapy to
the two 28-days therapy groups, we chose to compare the last 3 weeks only. For
these comparisons, Kruskal-Wallis and Mann-Whitney U tests were used because
of non-normality of the tested variables. Pairwise tests between three groups were
corrected for multiple comparisons using Bonferroni correction.
For the main hypothesis, we applied binomial tests to establish whether the
maximum was reached relatively more frequently in days 1 to 4. 
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RESULTS
Response rate
A sample of 175 patients with breast cancer met the eligibility criteria for the
present study. A sample of 18 (10%) of the original participants were excluded
for various reasons: 13 (7%) declined further participation, 3 (2%) stopped the
adjuvant chemotherapy prematurely and 2 (1%) were in a poor physical state. 
Because of a start-up delay, the dairy was given to 155 instead of the
remaining 157 patients. Of the 155 patients, 151 returned the diary. The non-
response was caused by one refusal to fill-in the diary and three patients who
did not return the diary for unclear reasons. In total, 151 diaries were part of the
analyses and were kept for 21 (n = 82) or 28 (n = 69) days, depending on their
chemotherapy regimen (see Table 1). Table 2 displays the number of days on
which patients filled in the diary. 
As to the analyses of the last 3 weeks, 4 of the 151 patients were excluded
because they had filled in less than 9 days of the diary. These patients were
excluded in the calculation of individually smoothed curves since fitting the
Doxorubicin group Doxorubicin group CMF
21 days 28 days
(n = 82) (n = 25) (n = 44)
Number of days n % n % n %
28 days - - 20 80 38 86
27 days - - 2 8 1 2
26 days - - - - 1 2
25 days - - - - 1 2
22 days - - - - 1 2
21 days 67 82 - - - -
20 days 10 12 - - - -
19 days 0 0 1 4 - -
18 days 1 1 - - - -
17 days 1 1 - - - -
16 days 1 1 - - - -
14 days 1 1 2 8 1 2
10 days 1 1 - - - -
9 days - - - - 1 2
Table 2. Response rates of patients with breast cancer specified by the number of days they
filled in the diary
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curve on less than 9 data points would lead to large spurious variations. We
compared the fatigue scores of these four patients with the mean of their therapy
group and found that it was on average 4.8 points higher (SD = 2.1). However,
because of the relatively very small number of these patients their omission
could hardly influence the results of the further analyses. 
Sample characteristics
Table 3 presents information about the demographic and medical characteristics
of the sample. 
The ages of the 151 patients with breast cancer ranged from 25 to 70 years,
with a mean age of 47.2 years (SD = 8.8). As Table 3 shows, twenty-nine percent
of the patients received CMF treatment; the remainder received one of the
chemotherapies covered by the doxorubicin group. The doxorubicin 28 days
group was significantly older than the other two chemotherapy groups. The
majority (80%) had been diagnosed with stage II breast cancer. The division
between mastectomies (47%) and lumpectomies (52%) was approximately equal.
In addition to chemotherapy, 60% of the patients received radiotherapy before the
third treatment with chemotherapy and/or in the period they kept the diary. 
Internal consistency
The Cronbach’s α of the SFQ is the mean of the Cronbach’s α of all 28 days
and is 0.92. Only 2 of the 28 Cronbach’s α’s were below 0.90. The lowest
Cronbach’s α was 0.89 and the highest was 0.94. 
Course of fatigue between two cycles of adjuvant chemotherapy
The course of fatigue was studied by analysing the results of the SFQ. In Figure
1, the mean scores of the SFQ for the different chemotherapy groups are
displayed, which indicate a chaotic pattern of fatigue of patients. The line of the
mean scores in each figure indicates an increase of fatigue after the first day of
the diary. The chemotherapy groups with 28 days between the 2 cycles also
show an increase after day 8, the time of administering the second part of the
third cycle of chemotherapy. The fatigue experienced by the CMF group on the
first days is lower than the fatigue experienced by the other groups. 
Smoothed (spline) curves, displayed in Figure 2, show a similar pattern as
described for the mean scores. The highest average level of fatigue was
experienced on day 3 after the start of the cycle. For the regimens with 28 days
between two cycles of chemotherapy, a direct increase can be observed after
day 8, with another peak around day 11.
The three curves were significantly different with F14,150 = 4.57, P < 0.0001.
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Doxorubicin group 21 days Doxorubicin group 28 days
(n = 82) (n = 25)
Age (years)1,3
Mean 44.5 60.0
Range 27-70 50-69
SD 6.2 5.3
n % n %
Marital status4
living together 70 85 18 72
Living alone 12 14 7 28
Children
Yes 65 79 20 80
No 17 21 5 20
Level of education1,3
Low 27 33 15 60
Middle 33 40 7 28
High 22 27 3 12
Job1,3
Yes 54 66 2 8
No 28 34 23 92
Stage of breast cancer*
I 9 11 - -
II 64 78 23 92
III 4 5 - -
Unknown (missing at the data collection point) 5 6 2 8
Type of operation†
Mastectomy without lymph nodes excision 3 4 - -
Mastectomy with lymph nodes excision 41 50 9 36
Lumpectomy without lymph nodes excision 1 1 - -
Lumpectomy with lymph nodes excision 35 43 16 64
Unknown 2 2 - -
Radiotherapy1,‡
Yes 41 50 20 80
No 41 50 5 20
Cyclophosphamide (oral)
Yes - - - -
No 82 100 25 100
Anaemia (haemoglobin level,
mmol/l < 7.3 or g/dl < 11.7)2,3,§
Yes 14 17 6 24
No 63 77 18 72
Unknown 5 6 1 4
Moment of filling in the diary
Spring and/or summer 40 49 16 36
Autumn and/or winter 42 51 9 64
Table 3. Patient characteristics 
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Doxorubicin group total CMF group Total
(n = 107) (n = 44) (n = 151)
48.1 44.9 47.2
27-70 25-62 25-70
8.9 8.1 8.8
n % n % n %
88 82 39 89 127 84
19 18 5 12 24 16
85 79 35 80 120 80
22 21 9 21 31 21
42 39 12 27 54 36
40 37 23 52 63 42
25 23 9 21 34 23
56 52 32 73 88 58
51 48 12 27 63 42
9 8 3 7 12 8
87 81 34 77 121 80
4 4 2 5 6 4
7 7 5 11 12 8
3 3 - - 3 2
50 47 18 41 68 45
1 1 - - 1 1
51 48 26 59 77 51
2 2 - - 2 1
61 57 30 68 91 60
46 43 14 32 60 40
- - 31 71 31 21
107 100 13 30 120 80
20 19 5 11 25 17
81 76 38 86 119 79
6 6 1 2 7 5
56 52 21 48 77 51
51 48 23 52 74 49
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It should be noted that the last three weeks were compared (see Figure 3). Pairwise
comparison of the curves showed a difference between the CMF and each of the
doxorubicin regimens (CMF group vs. dox28 group, P = 0.0018; CMF group vs.
dox21 group, P < 0.0001, but not between the two doxorubicin regimens, P = 0.14
(Bonferroni correction). This means that the pattern of fatigue between 2 cycles of
chemotherapies of the CMF group is different from each of the doxorubicin
regimens. The pattern of the 2 doxorubicin regimens, on the other hand, is similar. 
MEAN FIT, MAXIMUM FIT AND DAY OF MAXIMUM FIT BETWEEN CHEMOTHERAPY GROUPS
For a more specific comparison of the chemotherapy groups, we also calculated
the mean fit, the maximum fit, and the day of maximum fit from the individually
fitted curves over the last 3 week (Table 4).
The mean fit this yielded significant differences between the treatment
groups, but pairwise tests did not yield significant results. 
Considering the maximum fit, only 1 significant effect is found between the
dox21 group and the CMF group. The top of the fatigue level is significantly
higher in the dox21 group than in the CMF group. 
There were no significant differences between the different chemotherapy
groups as to the day of maximum fit. In short, the top of the fatigue level between two
cycles of chemotherapy fell around day 3 for all regimens (median = 3, mean = 5.9). 
Doxorubicin group 21 days Doxorubicin group 28 days
(n = 82) (n = 25)
Days between operation and 
1st chemotherapy treatment1,2
Mean (SD) 31.8 (13.6) 42.0 (37.6)
Range 9-77 14-215
Haemoglobin level, mmol/l§
Mean mmol/l or g/dl (sd mmol/l or g/dl) 7.8 or 12.5 (0.7 or 1.1) 7.6 or 12.2 (0.4 or 0.6)
Range mmol/l or g/dl 6.0-9.4 or 9.6-15.0 6.5-8.3 or 10.4-13.3
1 Statistically significant difference (P < 0.05) in characteristics between the doxorubicin group 21 days and the doxorubicin 
group 28 days.
2 Statistically significant difference (P < 0.05) in characteristics between the doxorubicin group 21 days and the CMF group.
3 Statistically significant difference (P < 0.05) in characteristics between the doxorubicin group 28 days and the CMF group.
4 Two groups, living together or living alone, were compared between the different groups.
* Three groups, stage of breast cancer I, II and III, were included in the comparison.
† Two groups, mastectomy or lumpectomy with lymph nodes excision, were included in the comparison.
‡ If the answer is ‘yes’ patients were receiving radiotherapy and/or had finished radiotherapy during or before the study period.
§ The haemoglobin level was determined before the third treatment with chemotherapy; the conversion factor from mmol/l 
to g/dl is 1.6.
Table 3. Patient characteristics 
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TEST OF THE MAIN HYPOTHESIS
For this test, 8 of the 147 patients were excluded because the day of the highest
fatigue level experienced by them in the last 3 weeks of the study period could
not be calculated: 5 patients did not report any fatigue at all, 1 patient scored
the maximum score (28) and 2 patients scored ‘16’ each day. Of the remaining
Doxorubicin Doxorubicin CMF group
group 21 days group 28 days
n Median n Median n Median
(quartiles) (quartiles) (quartiles)
Mean fit 82 15.50 23 16.38 42 12.11
(10.14; 19.95) (11.43; 19.81) (8.11; 16.48)
Maximum fit1 82 23.99 23 22.94 42 19.67
(19.60; 27.95) (17.54; 27.18) (13.03; 22.89)
Day of maximum fit 80 3 21 5 38 3
(2; 6.25) (1; 13.25) (1; 6)
1 Statistically significant difference (p < 0.05) between the doxorubicin group 21 days and the CMF group.
Table 4. Mean fit, maximum fit and day of maximum fit between chemotherapy groups 
Doxorubicin group total CMF group Total
(n = 107) (n = 44) (n = 151
34.2 (21.9) 39.2 (27.1) 35.6 (23.6)
9-215 15-125 9-215
7.7 or 12.3 (0.6 or 1.0) 8.2 or 13.1 (0.7 or 1.1) 7.9 or 12.6 (0.7 or 1.1)
6.0-9.4 or 9.6-15.0 6.6-9.4 or 10.6-15.0 6.6-9.4 or 10.6-15.0
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139 patients for whom the day of maximum fit (the day of the top fatigue level)
could be determined, 84 had the maximum fit before day 5. When the
maximum occurs randomly, the expected number is 26.5, the p-value for the
binomial test was < 0.0001. This test was also highly significant within each
chemotherapy therapy group. This means that in each regimen a significant
majority of patients experienced their maximum fatigue level before day 5. 
Influence of factors on the course of fatigue for the different chemotherapy
groups
The influence of several separate factors (demographic, disease, treatment and
other, see section Statistical Analyses) for the various chemotherapy groups was
analyzed. We report on the significant associations only.
Marital status (living together, yes or no). In the dox21 group the curves were
significantly different (P = 0.0005). The test for the day of maximum fit was
significant at P = 0.040. Women with a partner have the day of maximum
fatigue later. 
Education. Only for the group dox21 was a significant difference in the 3 curves
Figure 2. Smoothed (spline) curves of the different chemotherapy groups (range 4-28).
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was found (P = 0.038).  Pairwise tests were not significant, however. 
Type of surgery. In the dox28 group, the curves (mastectomy and lumpectomy)
were significantly different (P = 0.028). Subsequent tests showed that the mean
fit was significantly higher in the group of women who had undergone a
mastectomy (P = 0.007). These patients experienced significantly more fatigue
than women who had undergone a lumpectomy.
Cyclophosphamide (oral). Cyclophosphamide was given to CMF patients only.
The curves appeared different (P = 0.0002), which was confirmed by a
difference in day of maximum fit (P = 0.0001); if cyclophosphamide (oral) was
used, the maximum was reached later. In addition, fatigue gradually declined
in the cyclophosphamide group. 
DISCUSSION
This longitudinal study is the first large-scale examination of the course of fatigue
between 2 cycles of adjuvant chemotherapy. A sample of 151 patients with breast
Figure 3. Smoothed (spline) curves of the last three weeks of the different chemotherapy
groups (range 4-8).
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cancer reported daily, between the third treatment and the fourth treatment with
adjuvant chemotherapy, their experience of fatigue in a diary, the SFQ. 
In the present study 1 hypothesis was examined, namely, that the maximum
fatigue score occurs in the first 4 days after treatment with chemotherapy. 
Course of fatigue between two cycles of adjuvant chemotherapy
In general, the pattern of fatigue in different women with breast cancer who
receive adjuvant chemotherapy, irrespective of which regimen, appeared chaotic,
a crisscross of lines. Fatigue fluctuated. Schwartz [8] supports this finding. She
found that breast cancer patients receiving adjuvant chemotherapy demonstrated
a chaotic pattern with erratic and wide swings in their fatigue. The authors of a
phenomenological study [19] confirm this result by mentioning that cancer-
related fatigue has an unpredictable nature. The fatigue experienced by patients
in connection with the disease of cancer appeared totally different from the
fatigue experienced as healthy individuals [5]. Everyone experiences fatigue on a
daily basis and this is generally relieved by a good night’s sleep. For patients with
cancer it often becomes a chronic and unpleasant sensation [20]. In sum, cancer-
related fatigue is of an unusual and chaotic nature, much like the movements of
an uncontrolled large marble. This knowledge must be included in the education
for oncology nurses, which can contribute to a better transfer of information with
respect to the nature of fatigue from oncology nurses to patients. Patients, who
know what can be expected, will be less overwhelmed. Understanding from
family members and others can ease the experience of fatigue. 
However, the experience of fatigue is subjective: in the present study overall
patterns of fatigue between 2 cycles of adjuvant chemotherapy were reported for
the 3 chemotherapy groups. Women were treated with either a doxorubicin
containing schedule (dox21 or dox28 group) or with CMF. Considering all days (21
or 28 days) directly after the start of the third treatment until the fourth treatment
with adjuvant chemotherapy, the average highest level of fatigue was experienced
on day 3. Molassiotis and Chan [21] found in a heterogeneous cancer population
a peak level of fatigue on day 3 post chemotherapy as well, which was more
evident in the evenings. In the present study, fatigue experienced during different
times in the day was not examined, which might result in an incomplete view on
the reality. The variability of fatigue should be noted. Several other studies [21-
23] of a heterogeneous cancer population support the present study’s result as
well. Days 2 to 5 post-chemotherapy seem to be the most troublesome days.
However, the pattern is not always the same [21]. De Jong et al. [9] reported in
their literature review of breast cancer patients receiving chemotherapy that the
first two days after chemotherapy treatment seem to be the worst period. A
similar finding was noted by Berger and Higginbotham [24], who observed that
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breast cancer patients receiving CA regimen (n = 14) experienced the highest
levels of fatigue and symptom distress during the first four days after treatment 3.
In this pilot study, measurements were divided into four phases during cycle 3: 2
days prior to treatment, days 1-4, days 5-10 and days 11-21. Note, that not only
the symptom fatigue in breast cancer patients is the worst occurred directly after
having chemotherapy, but also nausea and vomiting In the present study, the
regimens (dox28 and CMF) with 28 days between the two cycles also showed a
direct increase after day 8, with another top fatigue level around day 11, 3 days
after the second infusion, the last part of the third treatment. As in the study of
Richardson et al. [22], the pattern of fatigue appeared to reflect the drug
administration. In that study, breast cancer patients receiving CMF protocol also
experienced a superimposed increase of fatigue shortly after day 8 [10, 11].
Information delivery to patients of a probable peak of fatigue in the first days after
an infusion with chemotherapy must be standard performed by oncology nurses.
With this knowledge patients can prepare themselves, for example they can take
their activities of daily life into consideration. 
In the present study, the course of fatigue immediately after completion of
the full third treatment with adjuvant chemotherapy until the fourth treatment
with adjuvant chemotherapy was compared between the chemotherapy groups.
It should be noted that this means that 3 weeks were compared. The pattern of
fatigue of the CMF group was significantly different from both doxorubicin
groups. On the other hand, the pattern of fatigue of both doxorubicin groups
was similar. Although pairwise comparisons between the chemotherapy groups
showed no significant differences in the mean fit of fatigue, the average fatigue
level experienced by the CMF group was the lowest during the study period.
Recent research [12] into patients with breast cancer established a difference in
the experience of fatigue between the 2 groups as well. A difference in the
chemical composition of the chemotherapies affected only the physical part of
fatigue [12, 13]. Further research in fatigue regarding different chemotherapy
groups should be done to be able to inform patients more specifically. 
Fatigue is a multidimensional concept [9]. The use of a unidimensional
measurement therefore consitutes a limitation of the present study. For that
reason, the description of the course of fatigue remains incomplete. The advantage
of the unidimensional measurement used is the form and the length, which
makes keeping the diary a quick and easy process. A similar concept should be
developed for a multidimensional measurement. 
With regard to the maximum fit, the top of the fatigue level appeared
significant higher in the dox21 group than in the CMF group. Although Greene
et al. [25] reported no significant differences in intensity of fatigue related 
to whether doxorubicin was included, Berger and Walker [26] found that
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chemotherapy protocols that contain intravenous doxorubicin were directly
associated with higher fatigue, which supports the finding of the present study.
Jacobsen et al. [27] had similar findings after the start of chemotherapy. It should
be noted that in the present study the CMF group had already received the first
part of the third infusion one week before, which may smooth the increase. This
might be also the reason why no significant difference was found in the maximum
fit between the dox28 group and CMF group. Both chemotherapy groups had
the same drug administration. 
Considering all chemotherapy groups, the mean day of maximum fit was
around day 6. No significant differences were found in the day of maximum fit
between the different chemotherapy groups. Nevertheless, in each regimen a
significantly larger number of patients had their maximum fit before day 5. The
hypothesis that the maximum fatigue score occurs in the first four days after
treatment with chemotherapy was therefore supported. Previous studies have
shown that the highest mean score of fatigue in cancer patients receiving
chemotherapy is found directly after an infusion of chemotherapy. However, there
was no indication that these patients had their top fatigue level during that time. In
the present study it appeared that most patients reached their top fatigue level on
day 3. In general, as research by Cowley et al. [28] has shown, it can be said that
the first week after chemotherapy is the worst. Cowley et al. [28] reported that
patients still felt tired and exhausted in the second week, but were able to perform
daily tasks then, albeit with difficulty. They were approaching normality by week 3
and just as they were beginning to feel normal again they had to repeat the cycle.
Cowley et al. [28] found this in 12 women with breast cancer, which consitutes a
relatively small sample. The rapid alterations in physical and mental state during
chemotherapy resulted in a ‘roller coaster’ experience [28]. This pattern of a roller
coaster had already been mentioned in a previous breast cancer study conducted
by Berger [29] on 72 patients. In this study fatigue was found to be significantly
lower at the midpoint of chemotherapy than 48 hours after chemotherapy. In the
present study, this roller coaster pattern was also found. In week 2 and 3 after the
infusion of chemotherapy patients reported less fatigue. However, it is not clear
how patients experienced these weeks. It is, for instance, unknown whether the
fatigue experienced in week 3 may be regarded as normal fatigue. It will therefore
be necessary to conduct further research not only into these experiences, but also
into the course of fatigue between different cycles of chemotherapy. 
Summing up, it is helpful for oncology nurses to know what is happening
regarding fatigue between 2 cycles of adjuvant chemotherapy in breast cancer
patients. The existed information about fatigue for patients can be adjusted and
specified. 
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Influence of factors on the course of fatigue for the different chemotherapy
groups
The influence of various factors on the course of fatigue for the different
chemotherapy groups was examined separately. No single factor significantly
influenced the course of fatigue of all 3 chemotherapy groups.
Previous studies [12, 13, 30] into breast cancer patients during and after
adjuvant chemotherapy, part of our project, type of surgery influenced all
dimensions of fatigue. Women who had had a mastectomy were significantly
more fatigued, less motivated and more hampered in their daily activities than
women that had undergone a lumpectomy. The extent of the surgery and the
psychological impact might be the cause [30]. An unexpected outcome of the
present study was that the course of fatigue was only significantly different for
this factor in the dox28 group. It is probable that the difference in findings is
caused by the use of a unidimensional measurement instrument as well as
different measurement points. 
The course of fatigue of the dox21 group was only influenced by the variable
‘marital status’. Patients with a partner, the majority (85%) of the sample,
experienced their maximum fatigue 1 day later. This finding can not be explained. 
It is clear that the variable ‘taking cyclophosphamide orally’ influenced
the course of fatigue in the CMF group. Patients who took cyclophosphamide
orally experienced their peak level of fatigue significantly later. As in the study
of Richardson et al. [22], fatigue in patients with different types of cancer who
are administered a combination of bolus and continuous chemotherapy
declines gradually before the next cycle of treatment. Richardson et al. reported
that this combination type of administration causes fatigue that is both more
intense and unrelenting than fatigue induced by other modes of administration. 
No significant differences (pairwise tests) in the course of fatigue for the
different chemotherapy groups were found for the following variables: ‘age’,
‘having children’, ‘education’, ‘having a job’, ‘season in which the diary is kept’,
‘haemoglobin level (measured in mmol/l) before the third cycle of chemo-
therapy’, ‘the number of days between the operation and the first treatment with
chemotherapy’ and ‘radiotherapy’. Although the measurement points were
totally different, previous studies [12, 13, 30] into breast cancer patients
receiving adjuvant chemotherapy also found no significant associations between
fatigue and the variables mentioned. 
It is difficult to conclude to what extent the findings of the present study are
in line with findings of other studies. The results of the present study are quite
unique. An explanation for not finding more significant results might be found in
the relatively small sample of the (sub)groups. Not all intended tests were
feasible. Further research should be done in this way to make firm conclusions. 
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The results presented must be considered within the limitations of this study. A
comparison with other studies is difficult, as different measurements were used.
In addition, fatigue was studied as a onedimensional concept. To enhance the
understanding of fatigue, a complex and subjective phenomenon, further research
should include dimensions of fatigue. Moreover, filling in a questionnaire each
day can cause a certain routine and stress, which might influence the results.
Another limitation of the present study is that it compares the days of the
different chemotherapy groups after completion of the full third treatment with
chemotherapy. The 7 days before the second part of the third treatment with
women who were included in the dox28 or CMF group were not fully analysed,
which may distort the results. Further research that includes this part of the
course of treatment is needed to obtain a complete overview. 
In the present study only the course between the third and fourth
treatment with chemotherapy was studied. Ongoing research should include
measurement points between more cycles to investigate possible differences. 
The influence of single factors on the course of fatigue was examined
separately and is therefore limited. A combination of factors could also influence
the course. In addition, the fact that the compared samples were relatively
small makes it difficult to generalise results to a larger population. 
Further research
The pattern of fatigue is unusual and chaotic. It might be interesting to deepen
the fatigue research by studying the days more in detail, for example different
times during a day. One could combine that study with qualitative research to
try to clarify the chaotic pattern. 
Apparently, aside from the peak of fatigue, other symptoms such as nausea
and vomiting occurred during the first days after having an infusion of
chemotherapy. A research on a combination of symptoms and/or different single
symptoms next to each other would be needed to complete the understanding.  
Knowledge about fatigue should be developed more specifically, for
example including cultural aspects, so that interventions for reducing or coping
with fatigue can be built up and be detailed in measure work. 
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ABSTRACT
Background: The purpose of this prospective cohort study was to test a model
of variables that influence fatigue and vice versa in breast cancer patients both
during and after adjuvant chemotherapy.
Patients and methods: A model of variables that influence fatigue in breast
cancer patients was developed based on a literature review and previous work of
the authors. In a prospective cohort study the model was tested in a sample of 157
breast cancer patients. One model (for general fatigue) for all five time points was
developed using EQS, a computer program for linear structural equation modeling. 
Results: A reasonable fit between model and data exist. In the identifiable and
testable model two latent variables, (1) physical distress (measured by two
observed indicators: general fatigue and physical symptom distress), and (2)
psychological distress (measured by two observed indicators: depression and
psychological symptom distress), were included. Physical distress is predicted by
the variables: everyday social support, an active coping strategy, age, marital
status, job, stage of breast cancer, chemotherapy regimen, Hb level and number
of chemotherapy treatments. Psychological distress is predicted by age and
everyday social support. A significant difference between patients with or without
a job is seen during the treatment of chemotherapy with patients with a job being
less fatigued. After completion of chemotherapy, patients living alone endure
significantly more general fatigue than patients living not alone, higher social
support leads to significantly less general fatigue and high scores on an active
coping strategy leads to significantly more general fatigue. The analysis of the
reciprocal effects between the two latent variables, physical and psychological
distress, shows that during the first four measurements the effect of physical on
psychological distress is stronger, whereas at the last measurement, the opposite
holds. Now, three months after completion of chemotherapy the effect of the
psychological distress on the physical distress has become larger. 
Conclusions: Physical and psychological distress are important predictors of
general fatigue. The social aspect seems to play a valuable role too. This is
expressed by the influence of several variables of a demographic or social nature
on general fatigue. 
Improved understanding of the relation between different variables and fatigue in
breast cancer patients receiving adjuvant chemotherapy as well as after
completion of chemotherapy could better equip health care providers to
understand and address the needs of these patients. 
Key words: adjuvant chemotherapy, breast cancer, fatigue, model
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INTRODUCTION
Fatigue is a common symptom in cancer patients [1]. The National Comprehensive
Cancer Network (NCCN) reported that fatigue affects 70% to 100% of cancer
patients [2]. Little is known about fatigue, despite the high prevalence and its
profoundly negative effect on patients’ quality of life. According to the literature,
fatigue is a multicausal, multidimensional and complex concept, which is
difficult to define or describe [3]. Cancer-related fatigue is different from typical
fatigue of everyday life. It is more rapid in onset, more energy draining, more
intense, more severe, more unrelenting and it lasts longer [4]. The NCCN
convened a panel of experts in the field of fatigue, which defined cancer-related
fatigue as ‘a distressing, persistent, subjective sense of tiredness or exhaustion
related to cancer or cancer treatment that is not proportional to recent activity
and interferes with usual functioning’ [2](p. MS-2). Now, it is recognised that
cancer patients frequently become fatigued when undergoing treatment, notably
chemotherapy [5]. 
Since the early 1990s breast cancer has been the most frequently occurring
malignancy in women in the Netherlands [6]. Adjuvant chemotherapy is part of
the standard treatment in a large subset of these patients. However, the influence
of different variables on fatigue in breast cancer patients both during and after
chemotherapy is unclear and less well studied than the prevalence [3]. 
The purpose of this prospective cohort study was to test a model of variables
that influence fatigue and vice versa in breast cancer patients both during and
after adjuvant chemotherapy. Figure 1 presents a model of variables and their
expected effect on fatigue, based on literature and previous work of the authors. 
Demographic factors
The influences of age, marital status and income on fatigue are not consistent and
therefore unclear [1, 7-13]. Several studies [1, 7-9] found no association between
educational attainment and fatigue. ‘Having children’ seems to have no impact
on fatigue [1]. No influence of ethnicity [7, 9] and employment status [1, 7] on
fatigue was found in the literature. 
Disease / physical factors
No interference is seen in recent studies [1, 3, 8, 9, 13] between fatigue and stage
of breast cancer, but irrespective of the type of cancer treatment, concurrent
illness was found to have a strongly positive relation with fatigue [3].
In the literature anaemia has been characterized as a major contributor to
fatigue [14, 15]. Studies [16, 17] in breast cancer patients show that low haemoglobin
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Figure 1.  Model of fatigue and its relations based on literature and previous work of the authors
levels are associated with greater fatigue. Other studies  [1, 18-20] report that
haemoglobin was not significantly related to fatigue. 
Physical symptom distress
The literature [3, 8, 16-18, 21, 22] about the relationship between physical
distress and fatigue in women with breast cancer is unequivocally positive. The
influence of factors such as pain and impaired quality of sleep are highly
consistent across several studies [3].  
Psychological symptom distress
The relationship between fatigue and psychological symptoms, like anxiety, is
evident [3]. Recent studies [8, 18, 21, 23, 24] found similar results. Other
authors [25] reported in a study in breast cancer patients that the emphasis on
recording fatigue during and following treatments for cancer needs to be
accompanied by concurrent measurement of psychological symptoms. The loss
of a breast and the surgery can have distressing psychological effects on women
[26]. Depressive symptoms are a common problem in cancer patients and they
are definitely related to fatigue [27, 28]. It is often not clear, however, whether
it is the symptoms that cause the fatigue or vice versa. Evidently, here the
relation to fatigue can be displayed in two arrows, with either fatigue as starting
point or depression/psychological symptom distress (see Figure 1). Researchers
[3] have surmised that it is not unlikely that various variables, physical and
psychological, are interrelated (see Figure 1). 
Social factors 
Nowadays, the importance of social relationships and social support for an
individual’s well-being is generally accepted [29]. In a non-cancer study, authors
[30] reported that involvement in more social networks seems to protect against
morbidity. Many authors have underlined the relationship between social
support and physical and psychological well-being [29]. Social support is
expected to have buffer effects, which means that social support protects people
from the deleterious effects of stress [29].  
Coping factors
Coping behaviours and thought can influence fatigue [31]. The relation between
coping style ‘catastrophising’, which is characterised by negative self-statements
and negative thoughts and ideas about the future, and health has revealed
ambiguous results [9, 24, 32, 33]. It is difficult to compare studies, because the
coping concept has been operationalised in different ways [30]. 
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Treatment factors
In recent studies [1, 8] differences have been observed in the experience of
fatigue between types of operation (mastectomy versus lumpectomy), where
women who underwent a mastectomy were more fatigued. On the other hand,
other authors [9, 10, 13] concluded that fatigue was not influenced by type of
surgery (mastectomy or lumpectomy). 
The relationship between chemotherapy regimen and fatigue is not clear.
Several authors [10, 16, 17] found no association and some [1, 10, 22] did. A
literature review in breast cancer patients shows that a combination of treatments
resulted in more fatigue [3].  
It is not clear how radiotherapy and fatigue are related. Some authors [1]
found an association, others [8, 16, 34] did not. The same result, no consistency,
is seen for the influence of hormonal treatment on fatigue [3, 8, 16]. 
Recent studies [1, 16, 17] did not find a relation between the number of
chemotherapy treatments and fatigue. Time aspects seems to have no effect on
fatigue either [1, 3, 16, 17]. 
In this longitudinal study the data of 157 breast cancer patients, measured
both during and after adjuvant chemotherapy, were used. The next section
provides details regarding the sample. Moreover, the model of variables that
influence fatigue and vice versa, presented in Figure 1, was adapted to a model
that was tested in this study. More details can be found in the following sections. 
PATIENTS AND METHODS
Patient selection
Breast cancer patients with an indication for adjuvant chemotherapy treated in
six hospitals, mainly in the south of the Netherlands, were included in this
study if they met the following criteria: (1) had no metastasis or other malignancy,
(2) had not been treated with cytostatics before, (3) had to be treated with
outpatient adjuvant chemotherapy, (4) did not have a chronic disease (like
hypertension, kidney disease, heart problems, Diabetes Mellitus, etc.) or a poor
psychological state (such as diagnosed with a depression), (5) did not use
morphine or narcoleptics, (6) were not deaf, (7) were 18 years or older, and (8)
could speak and understand Dutch. In the period from March 1998 to October
2000 175 patients were recruited. In total, 18 (10%) patients were excluded for
different reasons: 13 (7%) declined further participation, 3 (2%) stopped the
adjuvant chemotherapy prematurely because of physical problems and 2 (1%)
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Measurement instruments What does the instrument measure?
Multidimensional Fatigue Inventory (MFI-20) Intensity of fatigue: general fatigue
Rotterdam Symptom Checklist (RSCL) Psychological and physical symptom distress
Utrecht Coping List (UCL)* Coping styles: ‘active’, ‘social support seeking’, ‘avoiding’ and 
palliative’
Social Support List (SSL12-I) Everyday social support, social support in problem situations and 
esteem support
The Center for Epidemiological Studies 
Depression Scale (CES-D)
Depressive symptoms
* The UCL was only inserted in the first interview.
had a poor physical state. The remaining 157 patients, depending on their adjuvant
chemotherapy schedules, were interviewed four (n = 20) or five (n = 137) times.
The response rate for the first two interviews was 100%, the third interview
99% and the last two interviews 97%. A change in the treatment schedule was
the main cause of the non-response. The majority of the interviews (79%) were
conducted by the principal investigator; a properly trained assistant conducted
the other interviews. 
Before the first cycle of adjuvant chemotherapy the patient had given written
informed consent. All interviews were conducted by either the principal
investigator or a properly trained assistant. All local medical ethical committees
of the participating health centres had approved the study. 
Data collection
Patients were interviewed five times except for those receiving the CA
(cyclophosphamide and doxorubicin) treatment, who were interviewed only
four times. Table 1 presents the measurement instruments that were used in the
present study. The first three interviews took place in the hospital. These
interviews were held directly before, during or after the first, the third and the
fifth cycle of chemotherapy, except for the CA regimen, where the third
interview was omitted. The last two interviews were held at 4 and 12 weeks,
respectively, after the last cycle and were done by phone. Medical data were
collected from charts and were gathered after the interviews. 
Sample Characteristics
The details of 18 patients were not available and were excluded from the study.
Demographic and medical characteristics of the included patients are listed in
Tables 2 and 3. The mean age was 47.3 years (SD = 8.8). The majority of the
patients (83%) lived together with a partner, had children (79%) and had been
Table 1. Measurement instruments which were used in the present study and what they measure
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Total
(n = 157)
Age (years)
Mean (SD) 47.3 (8.8)
Range 25-70
n %
Marital status
Together
Married/living together 131 83
Alone
Single 14 9
Divorced 10 6
Widow 2 1
Children
Yes 124 79
No 33 21
Educational level†
Low 56 36
Middle 67 43
High 34 22
Job
Yes 92 59
No 65 41
Stage of breast cancer‡
I 12 8
II 125 80
III 6 4
I and III (two tumours) 1 1
Unknown (missing at the data collection point) 13 8
Type of operation§
Mastectomy without lymph nodes excision 3 2
Mastectomy with lymph nodes excision 73 47
Lumpectomy without lymph nodes excision 1 1
Lumpectomy with lymph nodes excision 78 50
Unknown 2 1
Treatment of adjuvant chemotherapy¥
Doxorubicin group
CEF 38 24
CAF 27 17
4 epi-doxorubicin 21 13
4 epi-doxorubicin / taxotere 5 3
CA 20 13
CMF group 46 29
Days between operation and 
1st chemotherapy treatment
Mean (SD) 35.3 (23.2)
Range 9-215
† Low is primary school/lower vocational education; middle is lower general secondary education/intermediate 
vocational education; and high is higher general secondary education/higher vocational education/university.
‡ Three groups, stage of breast cancer I, II and III, were included in the analyses.
§ Two groups, mastectomy or lumpectomy (with or without lymph nodes excision), were included in the 
analyses.
¥ Two groups, doxorubicin group (CEF (cyclophosphamide, 4-epi-doxorubicin and 5-fluorouracil), CAF 
(cyclophosphamide, doxorubicin and 5-fluorouracil), 4-epi-doxorubicin, 4-epi-doxorubicin/taxotere, CA
(cyclophosphamide and doxorubicin)) and CMF group (cyclophosphamide, methotrexate and 5-
fluorouracil), were included in the analyses.
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diagnosed with stage II breast cancer (80%). A minority was highly educated
(higher general secondary education/higher vocational education/university)
(22%). More than half of the population (59%) had a job. The division of
mastectomies and lumpectomies was approximately equal. Twenty-nine percent
of the patients (n = 46) had received the CMF (cyclophosphamide, methotrexate and
5-fluorouracil) treatment, the remainder had received one of the chemotherapies
covered by the doxorubicin group. Information about the division of chemotherapy
regimens can be found in paragraph ‘operationalisation of variables’. The mean
day between operation and 1st chemotherapy treatment was 35.3 days (SD =
23.2). At the fifth cycle of chemotherapy 60 percent of the patients did not have
anaemia (haemoglobin level is lower than 7.3 mmol/l) (see Table 3). Most patients
received six treatments of chemotherapy (77%). Table 3 displays details of the
numbers of patients receiving radiotherapy at the different measurement points.
Most of the patients (56%) who received radiotherapy were receiving
radiotherapy at the second measurement (corresponding to the third treatment of
chemotherapy).
Model with its variables which is tested
The final model, which is tested, is presented in Figure 2. The following variables
were deleted from the model in Figure 1: income, ethnicity, concurrent disease,
combination of treatment and hormonal treatment. The variable ‘income’ was
not included because of the expectation that the variable would not add
important information on top of the other demographic factors. Ethnicity did not
play any role in this study, because all participants were white Dutch females.
One of the exclusion criteria for participation in the study was that patients did
not have any chronic disease. The variable ‘concurrent disease’ was therefore
removed. In this study all patients received adjuvant chemotherapy, some of
them received radiotherapy as well. The influence of radiotherapy was also
tested. Hence, the variable ‘combination of treatment’ was eliminated from the
model. The influence of hormonal treatment on fatigue was not possible to
measure because most patients started hormone treatment after completion of
adjuvant chemotherapy. 
In this study the variable ‘days between operation and chemotherapy’ was
the specific variable of time aspects. 
Below, a description of the variables is given which were used in this
study. For the variables regarding ‘coping’ (‘avoiding’, ‘active’, ‘social support’
and ‘palliative’ instead of the variable ‘catastrophising’) and ‘social factors’
(‘esteem support’, ‘everyday social support’ and ‘social support in problem
situations’ instead of the variable ‘social support’), Dutch validated instruments
were used. No suitable other instruments were available at the moment of
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starting. For that reason these variables were included in the model. A short
analysis of the expected direction for these variables is given in the next section. 
Operationalisation of variables
Fatigue
The Multidimensional Fatigue Inventory (MFI-20) was used to assess the intensity
of fatigue [35]. This 20-item self-report questionnaire, especially designed for
cancer patients, consists of five scales based on different dimensions: general
fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue.
Measurement point → 1st cycle‡ 3rd cycle 5th cycle¥ 4 weeks after 12 weeks after
the last cycle the last cycle 
(n =157) (n =157) (n =135) (n =152) (n =152)
Haemoglobin level, 
mmol/l*
Mean (SD) 8.2(08) 7.9(0.7) 7.5(0.7) - -
Range 5.9-9.9 6.0-9.4 5.6-9.2 - -
n % n % n % n % n %
Anaemia§
Yes 11 7 26 17 47 35 - - - -
No 142 91 124 79 81 60 - - - -
Unknown 4 3 7 5 7 5 - - - -
Number of 
treatments†
4 - - - - - - 20 13 20 13
5 - - - - - - 7 5 7 5
6 - - - - - - 117 77 117 77
8 - - - - - - 8 5 8 5
Treatment of
radiotherapy
No radiotherapy 146 93 68 43 41 30 54 36 49 32
Radiotherapy at 
measurement 8 5 58 37 3 2 8 5 3 2
Have had 
radiotherapy 
at measurement
3 2 31 20 91 67 90 59 100 66
* The haemoglobin level was determined before the treatment of chemotherapy; the conversion factor from 
mmol/l to g/dl is 1.6.
§ Anaemia haemoglobin level, mmol/l < 7.3.
† Number of treatments of adjuvant chemotherapy.
‡ The first three interviews were held directly before, during or after infusion.
¥ Patients receiving only four chemotherapy treatments did not have this interview.
Table 3. Patient characteristics (2)
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Each subscale consists of four items. The score for each subscale was calculated
as the sum of the scores of the four items, for which high scores indicate more
subjective fatigue. This study focuses on the results of one subscale ‘general
fatigue’. This subscale consists of the following four items: ‘I feel fit’, ‘I feel tired’,
‘I am rested’ and ‘I tire easily’. The MFI-20 has previously been tested and
validated in different groups: cancer patients receiving radiotherapy, patients
with ‘chronic fatigue syndrome’, psychology students, medical students, army
recruits and junior physicians. The internal consistency for the subscale ‘general
fatigue’ in these studies as measured by Cronbach’s alpha averaged 0.85 (with a
range of 0.83 to 0.90) [36]. 
Patients in this study were asked to rate their fatigue as experienced during
the previous two weeks. 
Responses were collected in a face-to face interview 
Demographic factors
Age was measured in years. The following demographic factors were binary:
marital status (together vs. alone), children (yes vs. no) and job (yes vs. no). The
variable education consists of three levels: low (primary school/lower vocational
education), middle (lower general secondary education/intermediate vocational
education) and high (higher general secondary education/higher vocational
education/university). 
Disease / physical factors
Stage of breast cancer. The TNM (tumour-node-metastasis) clinical classification
is used to report the anatomic extent of breast cancer [37].
Haemoglobin level (Hb level). Hb level was measured in mmol/l. The level of
Hb was only obtained for the first three measurement occasions. The variable is
binary: (1) mmol/l < 7.3 or (2) mmol/l ≥ 7.3. 
Physical and psychological symptom distress
Physical and psychological symptom distress. The Rotterdam Symptom Checklist
(RSCL) is an instrument to determine the quality of life of cancer patients [38].
In the present study, two subscales were used: physical and psychological
symptom distress. Patients were asked to indicate the degree to which they had
been bothered by physical (23 items) and psychological (7 items) symptoms
during the last two weeks, on a four-point Likert-scale (categories: not at all, a
little, quite a bit, and very much). The RSCL has previously been shown to 
be reliable and a valid instrument in the evaluation of patients treated with
chemotherapy [39, 40].
Depressive symptoms. Depressive symptoms were assessed by using the Center
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for Epidemiological Studies Depression Scale (CES-D) [41]. This self-report scale,
containing, 20 items from the previously validated scale of depression, was
administered as a structured interview in the present study. Patients indicated their
experience of the symptoms within the last two weeks, responding “rarely or
none of the time” (0); “some or little of the time” (1); “occasionally or a moderate
amount of time” (2); and “most or all of the time” (3). High scores indicate more
symptoms. The range of scores is 0 to 60, with a cut-off of 16 for a depressive
syndrome. The CES-D has been tested in different groups: healthy subjects, cancer
patients, myocardium infarct patients and students. The internal consistency was
good, varying between 0.79 and 0.92 [42].
Social factors
Social support was assessed with a shortened version of the Social Support List-
Interactions (SSL-I), the SSL12-I [43]. The SSL12-I consists of three subscales
with each four items: ‘everyday social support’, ‘social support in problem
situations’ and ‘esteem support’ (higher score indicates a higher level of
support) [44]. Cronbach’s alphas in a study in the elderly (older than 60 years)
were 0.72, 0.71 and 0.66 respectively [44]. The construct validity of the SSL12-I
is satisfactory [44]. The instrument is meant to be used with elderly people. The
expectation is that the instrument can also be used in younger respondents
[43]. In a study with a younger population (mean age of 25.3 years) the internal
consistency reliability of the three subscales ranges from 0.72 to 0.89 [45]. 
The three variables were expected to have a negative influence on fatigue
as hypothesised in the introduction. 
Coping
The short coping list (15 items) with a 4-point Likert scale ranging from
‘seldom/never’ to ‘very often’, based on the original 47-item ‘Utrecht Coping
List’ (UCL), was used to assess coping [46, 47]. Four coping styles can be
distinguished from the short coping list: ‘active coping’ (5 items), ‘social support
seeking’ (5 items), ‘avoiding’ (3 items), and ‘palliative coping’ (2 items) [29].
The internal consistencies were 0.84, 0.82, 0.64 and 0.44 respectively in a study
with subjects with or without (multi) new morbidity [30]. The relationships
between the coping strategies and fatigue are not clear. 
Treatment factors
Treatment of adjuvant chemotherapy. Patients were treated with one of the
following adjuvant treatments: CEF (cyclophosphamide, 4-epi-doxorubicin and
5-fluorouracil) every 21 days, CAF (cyclophosphamide, doxorubicin and 5-
fluorouracil) every 21 days, 4-epi-doxorubicin every 28 days (on days 1 and 8),
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4-epi-doxorubicin/taxotere with the first three cycles every 28 days (on days 1
and 8) and the last three cycles every 21 days, CA (cyclophosphamide and
doxorubicin) every 21 days and CMF (cyclophosphamide, methotrexate (oral
administration from day 1 to day 14 or intravenous) and 5-fluorouracil) every 28
days (on days 1 and 8). Most of these regimens consist of six cycles except the
CA regimen, which consists of four cycles. The choice for either schedule was
based on current practices in the health centres. In the analysis chemotherapy is
a binary variable: the doxorubicin group (CEF, CAF, 4-epi-doxorubicin, 4-epi-
doxorubicin/taxotere and CA) and the CMF group. The involvement of different
adjuvant chemotherapy regimens in the doxorubicin group made it possible to
form a sizeable sample in a relatively short period of time. 
Note that the first measurement moment coincided with patients starting
their chemotherapy treatment. 
Type of operation. In the present study, patients underwent a mastectomy or a
lumpectomy with or without lymph nodes excision. In the analyses two groups
were compared because of small sizes of the other groups: (1) mastectomy, and
(2) lumpectomy. None of the patients underwent a reconstructive surgery during
the study period. 
Radiotherapy. In this study the variable radiotherapy was assessed at each
measurement: (1) no radiotherapy, (2) receiving radiotherapy at measurement or
(3) having finished radiotherapy at measurement. 
Number of chemotherapy treatments. At the first three measurement moments
the number of treatments is equal. Therefore, this variable is only measured
after completion of the treatment of chemotherapy. 
Days between operation and chemotherapy. The days between the operation
and the first treatment of chemotherapy were counted. 
The model presented in Figure 2 is extensive and therefore not testable. In the
next sections an explanation is given of how and to what extent the model is
tested, based on theoretical and statistical foundations.
Statistical Analyses
The reliability of the MFI-20, RSCL, UCL, SSL12-I and CES-D was examined by
calculating Cronbach’s α. The coefficient of internal consistency was calculated
for each measurement point, except for the measurement UCL. The internal
consistency for the UCL subscales was only measured at the first measurement
occasion. 
A model for general fatigue is developed. Only observed variables that
correlate significantly with general fatigue are included in the model. Most of the
variables are either measured at an interval measurement level or, in the case of
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binary variables, can be considered to have been measured at an interval level.
Therefore the associations between these variables are measured using Pearson
correlation coefficients. The correlations between the included observed variables
are analysed using EQS [48], a computer program for linear structural equation
modeling [49]. 
In EQS a distinction is made between measured variables and latent
variables, such as physical distress or psychological distress. These latent variables
are measured using one or more of the observed variables also called indicators.
Reciprocal relations between physical distress and psychological distress are
investigated. Total effect (sum of direct and indirect effect) of one variable
(measured or latent) on general fatigue can be calculated using the estimated
regression coefficients. Using these effects an ordering can be obtained of the
importance of the variables included in the model on general fatigue.
Despite the fact that not all variables were measured at all measurement
points, one model for all five time points was developed. An index of the fit of
the model was obtained by means of its chi-squared value and the Benter-
Bonnet normed fit index (BB-NFI). Model parameters are estimated by means of
the maximum likelihood method.
Measurement point → 1st cycle* 3rd cycle 5th cycle? 4 weeks after 12 weeks after
the last cycle the last cycle 
n =157 n =157 n =137 n =152 n =152
n IC n IC n IC n IC n IC
MFI-20 (general fatigue) 157 0.89 157 0.89 135 0.93 152 0.93 152 0.93
RSCL
Psychological symptom 
distress 157 0.90 157 0.89 135 0.91 152 0.87 152 0.91
Physical symptom distress 157 0.80 157 0.81 135 0.86 152 0.86 152 0.87
UCL
Active 138 0.83 - - - - - - - -
Social support seeking 156 0.80 - - - - - - - -
Avoiding 140 0.17 - - - - - - - -
Palliative 156 0.33 - - - - - - - -
SSL12-I
Everyday social support 157 0.66 157 0.66 135 0.67 152 0.77 152 0.74
Social support in problem 
situation 156 0.82 152 0.80 130 0.82 142 0.83 138 0.84
Esteem support 157 0.68 157 0.69 134 0.64 151 0.78 152 0.76
CES-D 155 0.90 156 0.90 135 0.92 151 0.92 152 0.94
* The first three interviews were held directly before, during or after infusion.
† Patients receiving only four chemotherapy treatments did not have this interview.
Table 4. Internal consistencies (IC) of the MFI-20, RSCL, UCL, SSL12-I and CES-D
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Internal consistency of the MFI-20, RSCL, UCL, SSL12-I and CES-D
For all five measurements occasions, the Cronbach’s α for the subscale ‘general
fatigue’ of the MFI-20 was 0.89 or higher (see Table 4). Good internal consistency
rates can also be reported for the subscales of the RSCL (0.87 and higher for the
psychological symptom distress scale; and 0.80 and higher for the physical
symptom distress scale). 
The internal consistency of the different UCL subscales was only measured
at the first measurement occasion. The subscale ‘active coping’ and ‘social
support seeking’ showed high internal consistencies, 0.83 and 0.80 respectively.
The internal consistency of the subscale ‘avoiding’ and ‘palliative coping’ were
very low, 0.17 and 0.33 respectively. These subscales will no longer be used in
the analysis. In this study, the internal consistencies of the SSL12-I subscales
were not below the 0.64 and the rates of the CES-D were not below the
0.90.
RESULTS
Reduction of variables of the model
Table 5 gives an overview of the correlations of the observed variables from
Figure 2 with general fatigue. The table shows that a number of correlations are
significantly different from zero (p < 0.10). These variables will be entered into
the model. 
Development of an identifiable and testable model
The model of Figure 2 is convenient from the point of view of summarising the
literature, but is too complicated for testing. The model that is empirically tested
is represented in Figure 3a (inside cover, left side) (Maastricht Fatigue Model (MF
Model)). In Figure 2 there are seven clusters of factors that have some relation
with fatigue. In Figure 3a there are two latent variables: physical distress (F1) and
psychological distress (F2). Concerning the relations with fatigue, three variables
deserve particular attention: psychological and physical symptom distress and
depression. According to Figure 2, four out of the six possible relations between
these four variables are modelled either through a reciprocal relation or a
unidirectional effect. In Figure 3a this part of the model is reformulated using
two latent variables, physical distress (F1) and psychological distress (F2) that are
hypothesised to have a reciprocal relation. Each latent variable is measured using
two of the four indicators described above: physical distress (F1) by general
fatigue and physical symptom distress and psychological distress (F2) by depression
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Measurement point → 1st cycle† 3rd cycle 5th cycle‡ 4 weeks after 12 weeks after 
the last cycle the last cycle 
(n =157) (n =157) (n =135) (n =152) (n =152)
Disease / physical factors
Physical symptom distress 0.68*** 0.64*** 0.74*** 0.62*** 0.70***
Stage of breast cancer 0.11 0.04 0.15* 0.01 0.05
Haemoglobin level¥ -0.06 -0.06 -0.27*** - -
Mental factors
Psychological symptom 
distress 0.31*** 0.28*** 0.41*** 0.40*** 0.57***
Depression¥ 0.25*** 0.42*** 0.43*** 0.47*** 0.56***
Social factors
Everyday social support 0.03 0.00 -0.14* -0.20*** -0.15*
Social support in problem 
situations 0.06 -0.01 0.05 0.08 0.07
Esteem support 0.06 0.07 -0.05 -0.01 -0.07
Coping
Active 0.14* 0.10 0.19** 0.16* 0.16*
Social support seeking 0.03 0.05 0.02 0.02 -0.05
Avoiding 0.11 0.05 -0.01 0.05 0.07
Palliative -0.08 -0.05 -0.13 -0.01 0.02
Treatment factors
Type of chemotherapy¥ - 0.13* 0.17** -0.04 0.08
Operation¥ -0.03 0.00 0.01 -0.01 -0.08
Radiotherapy (1)¥ -0.03 0.06 -0.06 0.03 0.12
Radiotherapy (2)¥ 0.05 -0.03 0.03 -0.07 -0.12
Number of treatments - - - -0.07 -0.17**
Days between operation  
and chemotherapy 0.09 0.09 0.10 -0.04 -0.02
Demographic factors
Age -0.09 -0.05 -0.04 -0.14* -0.10
Marital status¥ -0.06 -0.13* -0.10 -0.13 -0.27***
Children¥ -0.01 0.02 0.01 0.01 -0.02
Job¥ -0.14* -0.19** -0.13 -0.04 -0.03
Education¥ 0.02 -0.02 0.04 0.11 -0.01
† The first three interviews were held directly before, during or after infusion.
‡ Patients receiving only four chemotherapy treatments did not have this interview.
¥ Haemoglobin level: code 0 = mmol/l ? 7.3, code 1 = mmol/l < 7.3; depression: code 0 = no depression,
code 1 = depression; type of chemotherapy: code 0 = CMF group, code 1 = doxorubicin group; operation: code 0
= mastectomy, code 1 = lumpectomy; radiotherapy (1): code 0 = no radiotherapy, code 1 = receiving radiotherapy
at measurement; radiotherapy (2): code 0 = no radiotherapy, code 1 = having finished radiotherapy at
measurement; marital status: code o = alone, code 1 = together; children: code 0 = no, code 1 = yes; job: code 0 =
no, code 1 = yes; education: code 1 = low, code 2 = middle, code 3 = high.
* 0.05 < P < 0.10
** 0.01 < P < 0.05
*** P < 0.01
Table 5. Correlations between the observed variables and fatigue
and psychological symptom distress. Fatigue is now part of or an indicator of the
physical distress. Findings in the study of Hwang et al. [50] supported a symptom-
oriented approach to the assessment of cancer-related fatigue. In this study well-
being of a patient consists of a physical and a psychological part. The two arrows
between F1 and F2 make it possible to estimate at each of the five measurement
points which of the two influences is stronger: psychological on physical (of
which fatigue is an indicator) or vice versa.
The other two variables of the cluster ‘disease/physical factors’ (Hb level and
stage of breast cancer) in Figure 2 are used as predictors of F1. These two variables
are taken together with two variables from the cluster ‘treatment factors’: number
of treatments and chemotherapy regimen. The double-headed arrow to the left of
these four variables signifies that the correlations between them are left
unmodelled.
The remaining five variables of the three clusters ‘social factors’, ‘coping’
and ‘demographic factors’ (every day social support, active, age, marital status
and job) have also been taken together and again here the double-headed arrow
to the left of them means that correlations between these five variables have
been left unmodelled. Correlations between the two clusters of predictors are
assumed zero. Finally, Figure 3a shows that F1 is predicted by all variables and
F2 by age and every day social support.
Estimating the effects on general fatigue
Results are summarised in Table 6. The variables given in the first column of this
table present all those (observed or latent) included in the analysis. In the
corresponding entries of columns two to six, the estimates of the total effects of
the variables on general fatigue are shown for each measurement point. The first
entry of the second column, for instance, shows that there is a very significant
total effect of the latent variable physical distress on general fatigue (0.903). This
total effect is composed of a direct and an indirect effect. The direct effect of
physical distress is calculated as the estimated standardised regression coefficient
(0.790). Because there exists a reciprocal relation between physical and
psychological distress (if a person feels physically not well, this will cause him
to feel mentally not well and vice versa), there is an also an indirect effect of
physical distress (via psychological distress) on general fatigue. This effect is
estimated to be 0.113. The second entry shows that the total effect of
psychological distress on general fatigue is 0.303. In this case this total effect is
composed only of the indirect effect; there is no direct arrow from psychological
distress to general fatigue. The last two rows in the table give the p-value of the
chi-square statistics and the BB-NFI. These two fit-indices show that the model of
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Figure 3a fits the data reasonably well. A possible exception is measurement
two, where the p-value is only 0.013, indicating a low fit. Now that there seems
to be a reasonable fit between model and data, we can interpret the parameter
estimates, i.e. the total effect of the independent variables on general fatigue.
Non-significant (p ≥ 0.05) variables on general fatigue (Figure 3b (inside
cover, right side))
A number of variables do not seem to have any influence at all. First, stage of
breast cancer does not seem to have any effect on general fatigue at any of the
five measurement points. Only during the third measurement point does it
reach the level of 0.073. The same holds for haemoglobin level. Although this
variable is measured only at the first three measurement points, and although
there seems to be a trend during these three periods of increasing strength, its
effect at the third measurement period is still not significant. Thirdly, number of
treatments, measured only at the last two measurement periods, does not reach
significance. Fourthly, there seems to be a negative effect of age on general
fatigue, meaning that older people are less fatigued than younger people, although
the effect seems to disappear over time. During the first two measurements the
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Measurement point → 1st cycle† 3rd cycle 5th cycle‡ 4 weeks after 12 weeks after 
the last cycle the last cycle 
(n =157) (n =157) (n =135) (n =152) (n =152)
Physical (F1) 0.903*** 0.944*** 1.027*** 1.030*** 1.197***
Psychological (F2) 0.303*** 0.382*** 0.412*** 0.516*** 0.688***
Everyday social support -0.005 -0.038 -0.122 -0.227*** -0.162**
Active 0.117 0.117* 0.144* 0.198*** 0.167**
Age -0.152* -0.156* -0.132 -0.107 -0.059
Marital status -0.089 -0.094 -0.096 -0.153** -0.183**
Job -0.222*** -0.265*** -0.155* -0.102 -0.060
Stage of breast cancer 0.030 -0.058 0.073 0.012 0.067
Chemotherapy regimen - 0.107 0.142* -0.021 0.058
Haemoglobin level -0.051 -0.037 -0.078 - -
Number of treatments - - - 0.002 -0.087
P-value 0.098 0.013 0.444 0.207 0.925
BB-NFI 0.902 0.872 0.925 0.920 0.966
† The first three interviews were held directly before, during or after infusion.
‡ Patients receiving only four chemotherapy treatments did not have this interview.
* P < 0.10
** P < 0.05
*** P < 0.01
Table 6. The total effect (sum of indirect effects) of the variables on general fatigue, p-value of
the chi-square statistic and the BB-NFI at each measurement point
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effect is significant (0.05 < p < 0.10). At the third and later measurements the
effect disappears. Finally, chemotherapy regimen did not turn out to be a significant
factor. 
Significant (p < 0.05) variables on general fatigue (Figure 3b (inside cover,
right side))
The effect of psychological and physical distress
In each measurement, psychological and physical distress has a highly significant
positive effect on general fatigue. The authors were wondering whether the
strength of the correlation between physical distress and fatigue might be
artificial because of the fact that two items of the RSCL refer to fatigue (‘tiredness’
and ‘lack of energy’). However, without these items the correlations in each
measurement were as strong as the correlations with the whole list. 
Over the five measurement points, the ratio of the total effects on general
fatigue of physical distress to psychological distress yields the following
sequence: 3.0, 2.5, 2.5, 2.0 and 1.7. Hence, the effect of the physical distress on
general fatigue is monotonically decreasing, or in other words the effect of the
psychological distress is increasing.
The effect of social support
The effect of social support on general fatigue seems to be getting stronger
during the four periods. During the first measurement the relation is virtually
non-existent (-0.005). At the fourth measurement there is a reasonably strong
significant effect (-0.227), meaning that higher social support leads to less
fatigue. During the last measurement the effect is still significant but it is
declining (-0.162).
The effect of coping strategy ‘active’
The pattern of the effect of coping strategy ‘active’ on fatigue seems to be highly
comparable with the pattern of social support, although the sign of the effect is
positive, meaning that high scores on this coping strategy lead to more general fatigue.
The effect of marital status
During the first three measurements there is a small non-significant difference
between respondents living alone being more fatigued than respondents not
living alone. During the fourth and fifth measurements, when respondents have
completed the chemotherapy treatment, the differences become much larger
and also highly significant in favour of living together.
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The effect of having a job
The effect of having a job on general fatigue gradually fades away over the
measurements. During the first two measurements there is a strong significant
difference between patients having a job and those who do not have a job:
patients who do have a job are less fatigued. At the third measurement point the
effect is only slightly significant and at the last two measurement points the
effect has disappeared: at these measurements there is no difference any more.
Direct effect of variables on psychological and physical distress
The direct effect of the variables on psychological and physical distress is similar
to the effect of these variables on general fatigue. No significant effect is found of
the following variables on physical distress: stage of breast cancer, chemotherapy
regimen, haemoglobin level and number of treatments. After completion of the
treatment of chemotherapy, patients living alone experienced significantly more
physical distress than patients not living alone. Patients with a job experienced
significantly less physical distress than those without a job during the first two
measurements. The coping strategy ‘active’ does not have any effect on physical
distress. Directly after the last treatment of chemotherapy (fourth measurement) a
significant negative effect is observed of ‘everyday social support’ on physical
distress, meaning that higher social support leads to less physical distress. On the
other hand, no significant effect is found for this variable on psychological
distress. The only significant effect on psychological distress is of the variable ‘age’
in the first measurement, meaning that older patients experienced less physical
distress than younger patients. 
Reciprocal effects between psychological distress (f1) and physical distress (f2)
In each measurement, psychological distress has a significant positive effect on
physical distress and vice versa (see Figure 3a). 
For each of the five measurements Table 7 shows the estimates of the
parameters of the reciprocal effects between physical distress and psychological
distress. The entries in the third column give the estimates of the effect of
psychological distress on physical distress and the fourth column those of
physical on psychological distress. A comparison of the two columns shows
that during the first four measurements the effect of physical distress on
psychological distress is larger than the reciprocal effect. However, for the last
measurement, taken three months after completion of the chemotherapy
treatment, the opposite holds: the effect of the psychological distress on
physical distress has become larger than the effect vice versa.
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DISCUSSION
This study focuses on the results of general fatigue. The main finding is that
physical and psychological distresses are important predictors of general fatigue.
Other significant predictors of general fatigue are: job, marital status, everyday
social support and an active coping strategy. The direction of the influence of these
variables on psychological and/or physical distress as well as the period of time
that the influence is significant is similar to the effects of these variables on
general fatigue. 
The analysis of the reciprocal effects between physical and psychological
distress shows that during the first four measurements (during adjuvant
chemotherapy as well as four weeks after completion of adjuvant chemotherapy)
the effect of physical on psychological distress is stronger, whereas at the last
measurement (twelve weeks after completion of adjuvant chemotherapy) the
opposite holds. 
Factors relating to general fatigue
Demographic factors
The variables ‘education’ and ‘having children’ were not included in the model.
No relationship between the separate variables and general fatigue was found,
which confirms the findings of the model based on the literature and previous
work of the authors [1]. Age, on the other hand, was adopted in the final model
but did not have any effect on general fatigue. 
After completion of adjuvant chemotherapy, general fatigue was influenced by
marital status: women living alone were more fatigued than women not living
alone. The fact that women with a partner reported less fatigue might be dependent
Measurement point n Effect of f2 (psychological distress) Effect of f1 (physical distress) 
on f1 (physical distress) on f2 (psychological distress)
1st cycle† 157 0.335 0.373
3rd cycle 157 0.405 0.488
5th cycle‡ 135 0.401 0.435
4 weeks after the last cycle 152 0.501 0.543
12 weeks after the last cycle 152 0.575 0.520
† The first three interviews were held directly before, during or after infusion.
‡ Patients receiving only four chemotherapy treatments did not have this interview.
Table 7. The estimates of the parameters of the reciprocal effects between physical distress
and psychological distress at the five measurements
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on whether there is tangible support [1]. It is possible that women living alone
received more support from others during adjuvant chemotherapy than afterwards.
After completion of the treatment with chemotherapy, the support could be
diminished because no treatment was received and therefore help with transport to
the outpatients department as well as support during the visit and afterwards were
not needed anymore. Moreover, patients are normally feeling and looking better
after completion of adjuvant chemotherapy, which could suggest to the social
environment that women living alone need little or no support and therefore they do
not get support. Courtens et al. [51] reported similar findings in a study with different
types of cancer. Here, the expectation towards the patient and/or limited knowledge
about chemotherapy among informal carers could play an important role. 
During the first two measurements patients who did have a job were
significantly less fatigued than those without a job. It is possible that patients
who did have a job were psychologically and physically stronger at the start of
the study, which made the difference in the first measurements. 
Disease/physical factors
Anaemia, multifactorial in origin, is a common occurrence in patients with
cancer, particularly those receiving cytotoxic chemotherapy, that may result in a
decreased functional capacity and quality of life [52-54]. Although, the relationship
between haemoglobin and fatigue is not clear, at the clinical level, its relationship
is universally accepted [55]. In this study no significant effect of the haemoglobin
level on general fatigue is observed. It should be noted that there seems to be a
trend during the first three measurements of increasing strength. Similar findings
were reported in the study of Holzner et al. [56] in cancer patients undergoing
chemotherapy. In this study, correlation between Hb values and fatigue was
moderate with a tendency to increase during chemotherapy. A limitation of the
study is that no haemoglobin levels were measured after completion of
chemotherapy. 
The influence of stage of breast cancer on general fatigue confirms
previous findings: no effect. Note that the results of this study could be caused
by the distribution of the subjects. The majority (80%) had stage II. 
Psychological and physical distress
Both factors separately, psychological and physical distress, do influence
general fatigue in a significant positive way. The influence of these factors was
expected and therefore confirms previous findings [3]. It is still not clear whether
these symptoms cause the fatigue or vice versa. Qualitative research should
give more information. 
During the study, the effect of the physical distress on general fatigue is
decreasing or, put differently, the effect of the psychological distress is increasing.
With this knowledge, health care providers can better tailor their aftercare to
these patients. 
It should be noted that depression is an indicator of psychological distress.
The indicators (physical symptom distress, psychological symptom distress and
depression) acquire a prominent role in the experience of fatigue, which is not
unlikely in the basis of other studies [3, 50]. 
Social factors
The effect of everyday social support on general fatigue seems to be getting stronger
during the study. After completion of chemotherapy there is a strong significant
effect, meaning that higher everyday social support leads to less fatigue. Similar
effects were found by other authors. The author of an early study [57] had reported
that the uncertainties and fears experienced by a person diagnosed with cancer are
likely to result in an enhanced need for social support. Results of another study [58]
among 117 patients with suspected breast cancer, awaiting diagnosis, showed that
patients reported elevated levels of anxiety and high levels of social support. It is not
clear why the effect of everyday social support is significant only after completion
of chemotherapy. According to Van den Akker et al. [30, 31] the social network is
increasingly recognised as a factor in health maintenance and survival. It represents
the web of social relationships that every person maintains, including both intimate
relations with family and close friends and more formal relationships with other
individuals and groups [30]. Following a qualitative study [59], the social network
provides an opportunity to delegate roles, and thus conserves energy. 
Note that esteem support and social support in problem situations, two
other subscales of social support, do not correlate significantly with general
fatigue. Probably this support, a kind of psychological support, does not have
any impact on the experience of fatigue. 
Coping factors
McHaffie [60] reported that how well a person copes is central in determining
his or her well-being, no matter how ill he or she is. The daily lives of almost
every individual are filled with stressful experiences, which require some form of
coping. The impact of each varies, because people switch between their many
roles and because these roles are changing [60]. Individuals with cancer must
deal with the treatment process and its side-effects, the uncertainty of the disease
course and adapt to the changes in physical functioning and other negative life
changes that are inevitably imposed by the disease [61]. In this study a significant
difference is found between an active coping strategy and general fatigue in the
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last two measurements. Patients who are inclined to take an active stance in
problem situations experience more fatigue than those who did not. Van den
Akker et al. [30] found a similar result in their study in primary care subjects,
using the same measurement instrument reporting an association between an
active coping style and the occurrence of multimorbidity. According to the
authors, this is likely to be a result rather than a cause of multimorbidity, subjects
with multiple pathology being more apt to deal actively with problems because
their (health) problems are less easy to avoid [30]. 
The coping strategy ‘seeking for social support’ did not have a significant
influence on general fatigue. According to Manne et al. [61] seeking social
support can be described as efforts to seek either informational, tangible, or
emotional support. The question is whether patients need to seek social support.
It might be that patients are supported naturally in the phase of receiving
chemotherapy and directly afterwards. Moreover, the attention patients received
in the stages of their treatment(s) by professionals (during the study period) may
obviate the need to seek social support. The time after completion of
chemotherapy could be too short for the variable to become significant. 
The internal consistency of the subscales ‘avoiding’ and ‘palliative
coping’ were so low that these were not included in the analysis, which limited
the findings in this study. No complete overview of coping can therefore be
given. 
Treatment factors
As expected, the number of chemotherapy treatments did not have any effect on
general fatigue. It should be mentioned that 77% of all patients received six
treatments of chemotherapy. This might be a reason for not finding an effect. In
this study too, chemotherapy regimen is a non-significant variable on general
fatigue. In another study with the same data [1] a significant influence of
chemotherapy regimen on the course of general fatigue during the study was
found. In the doxorubicin group a significant increase in fatigue was seen during
the initial measurements. The CMF group shows a ‘late effect’ on fatigue. The
reason for not finding very significant effects in this study might be due to the
way the data was analysed, which was separately performed for each of the five
measurements. In addition, the lack of homogeneity in the doxorubicin group, in
which five different chemotherapy regimens are presented, may be a limitation
of this study. 
The variables ‘days between operation and chemotherapy’, ‘radiotherapy’
and ‘operation’ were not entered into the model because these variables were
not significantly correlated with general fatigue. For the first-mentioned variable
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no influence was expected. It should be noted, however, that the expectation is
only based on one study [1]. A similar circumstance arises for the variable
‘radiotherapy’: in several studies [8, 16, 34] no relationship is found between
radiotherapy and fatigue, whereas De Jong et al. [1] reported that receiving
radiotherapy led to an increase in general fatigue. The course of general fatigue
was studied, which might cause the difference in the findings between the
studies. The result in this study are derived from the same database [1], though
the measurement points are studied independently. Probably, radiotherapy does
not influence fatigue of itself, but receiving radiotherapy (in course of time)
does increase the general fatigue level. Type of operation has also an impact on
the course of general fatigue, but was a non-significant variable in this study.
According to the literature, surgery of the breast has a negative impact on body
image [62, 63], which could have an indirect effect on the experience of
general fatigue. The difference in the extent of surgery does not have an impact
on general fatigue either. Results in previous studies [1, 8-10, 13] vary. It is not
exactly clear why these results are incongruous. 
Factors relating to physical and/or psychological distress
The influence of factors on general fatigue is quite similar to the effect on
physical and psychological distress. Only deviant influences are described in
this section. 
For variable ‘age’ no influence on general fatigue was observed, but this
variable has a significant effect on psychological distress at the first measurement
point. The effect is negative, meaning that older women experienced less
psychological distress. Findings in other studies show that younger women with
breast cancer have more severe emotional distress than older women. Schover
[64] reported that the loss of a breast or poor breast appearance would be more
distressing to women whose youth gives them high expectation for physical
beauty. Or probably, younger women had the responsibility of caring for their
families and young children  [12]. It is unclear why the influence of age does not
turn out significant in other measurement points. 
The variable ‘everyday social support’ is only significant for its effect on
physical distress in the fourth measurement. This variable showed significant
effects on general fatigue in all measurements after completion of the treatment
of chemotherapy. An explanation cannot be given.  
Note that not all direct effects on physical and psychological are men-
tioned; only variables which influence general fatigue significantly are entered
into the model. 
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Reciprocal effects between psychological distress and physical distress
In the model developed here physical and psychological distress is reciprocally
connected. Each measurement shows a significant relationship. As in the study
of De Jong et al. [3] it is not unthinkable that several symptoms are interrelated
in a network of symptoms. A limitation of this study is that no separate symptoms
are involved. 
During the first four measurements the effect of physical distress on
psychological distress is larger than the effect vice versa. This is not unlikely,
knowing that chemotherapy affects cells, including healthy cells, in the body.
Patients are busy having treatments, rather than coming to terms with sorrow at
that period of time. For the last measurement, which is taken three months after
completion of the chemotherapy treatment, the opposite holds: the effect of the
psychological distress on physical distress has become larger than the effect vice
versa. The result sounds very plausible, as the body physically rehabilitates after
completion of the treatment of chemotherapy. Besides, patients might have more
time to reflect then. According to the literature, surgery of the breast has a negative
impact on body image [62, 63]. Moreover, the loss of a breast can have important
psychological effects on women [26]. The feelings could be suppressed during the
chemotherapy treatment. It is also possible that patients then realize what they
were going through. Another approach is that many patients experience
ambivalence at the end of chemotherapy. Patients are pleased to be finished, but
they are afraid they should keep doing something to prevent a recurrence [65].
Okamura et al. [66] reported that it is important for all oncology staff to pay
careful attention to the psychological health of patients who have been informed
of their cancer recurrence. Johnson [67] reported in her pilot study that the majority
of women diagnosed with breast cancer expressed moderate fears about recurrence.
She also reported that many women spoke about life circumstances that were
more salient than the possibility of recurrence. Finally the pressure of the society
can also have an influence. After completion of chemotherapy patients are
expected to be healthy again. In an environment that sees things relatively in black
and white terms, complaining about defects is not tolerated anymore. 
The results reported must be considered within the limitations of this
study. It should be noted that the comparability of the results to other studies
might be limited because no study has previously been conducted like the
present one. A model comprising data of breast cancer patients during as well
as after receiving adjuvant chemotherapy is quite unique. An advantage is that
the final model is based on a huge amount of data. On the other hand, patients
had to answer the same question at each interview; this might cause a degree
of habituation. Besides, response shift can affects results. In this study response
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shift refers to a change in the meaning of fatigue over time. This change can be
(a) a change in the respondent’s internal standards of measurement (recali-
bration), (b) a change in the respondent’s values; or (c) a redefinition of the target
construct (reconceptualization) [68]. Additionally, different interview styles
(face-to-face and by phone) were carried out. Moreover, the unpredictable nature
and the unusual character of cancer-related fatigue have been underexposed. De
Jong et al. [69] found a chaotic pattern of fatigue in different women with breast
cancer who receive adjuvant chemotherapy, irrespective of which regimen. They
compared the pattern with a movement of an uncontrolled large marble [69].
Other studies [59, 70] confirm this finding. Another limitation might be that
fatigue is a multidimensional concept [3] and therefore the description of the model
in this study may remain incomplete. The model includes just one of the five
dimensions of fatigue of the measurement instrument used in this study. To
enhance the understanding of fatigue, a complex and subjective phenomenon,
further research should include the different dimensions of fatigue. 
Future research
Improved understanding of the relation between different variables and fatigue in
breast cancer patients receiving adjuvant chemotherapy as well as after completion
of chemotherapy could better equip health care providers to understand and
address the needs of these patients. Future research should include interventions,
based on the model presented in this study, addressing how patients can maintain
or improve their quality of life during as well as after adjuvant chemotherapy. 
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INTRODUCTION
Fatigue is a major concern in patients with cancer [1]. This dissertation has
investigated the extent of fatigue in breast cancer patients experienced during
and after adjuvant chemotherapy. The studies on the course of fatigue are
important contributions to the understanding of fatigue in cancer patients.
Moreover, the influence of variables on fatigue has been examined as well. 
This chapter briefly summarises the main findings and outlines some
methodological reflections. Finally, the chapter presents implications for practice
and recommendations for future research. 
Prevalence of fatigue
Fatigue is highly prevalent both during and after the treatment of chemotherapy
(see Table 1). In the literature, prevalence rates of fatigue between 58 and 94%
were found during treatment of chemotherapy and 56-95% afterwards [2]. Note
that the rates reported depend on the method of classification of patients into
fatigue and non-fatigue groups. It is therefore difficult to compare prevalence
rates of different studies. What is more interesting is that the changes in
prevalence over time, as found in our study, are comparable, regardless of how
the classification was done. As in a previous study by Jacobsen et al. [3], a
significant increase in the prevalence rates of all groups is seen after the start
with chemotherapy. After this increase, as in previous studies [3, 4], a stability in
the prevalence rate is found during chemotherapy treatment. After the treatment
of chemotherapy the prevalence rates seem to decline. 
Measurement point → 1
st cyclea 3rd cycle 5th cycleb 4 weeksc 12 weeksc
n =157 n =157 n =135 n =152 n =152
n % n % n % n % n %
Original data RSCL:
Not at all (1) 56 36 30 19 25 19 27 18 36 24
A little (2) 61 39 59 38 50 37 62 41 69 45
Quite a bit (3) 33 21 49 31 39 29 39 26 31 20
Very much (4) 7 5 19 12 21 16 24 16 16 11
a The first three interviews were held directly before, during or after infusion.
b Patients receiving only four chemotherapy treatments did not have this interview.
c Weeks after the last cycle.
Table 1. Prevalence of fatigue
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Course of fatigue during and after adjuvant chemotherapy 
During adjuvant chemotherapy and after completion of adjuvant chemotherapy
The course of fatigue was studied using five dimensions of fatigue [5]: general
fatigue, physical fatigue, reduced activity, mental fatigue and reduced motivation.
Importantly, the course of general and physical fatigue is different for the
doxorubicin group and CMF group. In the doxorubicin group a direct increase
in fatigue was found. Other studies [3, 6] found similar results. In the CMF
group a moderate direct increase occurred, followed by a delayed, after the last
cycle of chemotherapy, strong increase. The contact with healthcare providers
the women in the CMF group have is probably more intensive than in the
doxorubicin group, because they had to visit the hospital more frequently. The
end of chemotherapy marks the loss of this support system and a change in
routine that might cause this increase of fatigue. The chemical composition of
the CMF regimen could also cause the late effect in the experienced fatigue.
However, no specific data are available. 
Furthermore, we may conclude that no unequivocal pattern of activity
level, mental fatigue and motivation has been observed, though there is a
tendency of stability during the study with a significant improvement of the
activity level, a potential decline in mental fatigue and an increase in motivation
after completion of chemotherapy. Different studies [7-9] show that the trajectory
preceding chemotherapy could influence the experience of fatigue in advance,
which could cause the stability. Anxiety, pain and surgery are mentioned as
predictors. Another reason for the stability could be habituation to the experience
of fatigue. Besides, response shift can affects results. In this study response shift
refers to a change in the meaning of fatigue over time. This change can be (a) a
change in the respondent’s internal standards of measurement (recalibration), (b)
a change in the respondent’s values; or (c) a redefinition of the target construct
(reconceptualization) [10].
In general, the level of each dimension at twelve weeks after completion of
adjuvant chemotherapy did not significantly differ from the pre-chemotherapy
treatment measurement. The time after the last treatment might be too short to
find a change in fatigue that is large enough to result in a significant effect in the
statistical analysis. It might be that patients needed longer to recover from the
treatments or had to cope with the treatment process they had undergone. It is
unknown whether the fatigue at the last measurement can be regarded as normal
fatigue. Probably not, high prevalence rates of fatigue, long after completion of
chemotherapy are evident [11]. 
What is noticeable is that all courses of the dimensions of fatigue are
influenced by type of surgery. Women with a mastectomy operation were at a
disadvantage compared to women who underwent a lumpectomy. The extent of
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the surgery influences physically the experience of fatigue and the loss of a
breast can have important psychological effects on women [12]. 
Supplementary to chemotherapy, 69% of the women received radiotherapy.
Receiving radiotherapy led physically to an increase in fatigue. More specifically,
the longer the duration of radiotherapy (number of days of receiving radiotherapy),
the higher the fatigue, and the longer the time interval between the last
radiotherapy session and the measurement point, the less fatigue was experienced
at that measurement point. The accumulation of radiotherapy treatments
increased the experience of fatigue. This may be partly explained by the trip to the
treatment centre. Women had to go each weekday to the treatment centre during
a period of about five weeks. This could be rather intensive. Besides, daily routine
activities had to be adjusted to the treatments. Finally, it may be the effect of
radiotherapy itself or a combination of the therapies that makes these patients
more fatigued [13]. After the treatment with radiotherapy women recover from
this intensive period, which may explain the normalisation of the extent of fatigue
after the last treatment. Irvine et al. [14]  partially support this reasoning. 
Between two cycles of adjuvant chemotherapy
The pattern of fatigue in women with breast cancer receiving adjuvant
chemotherapy, irrespective of which regimen, appears chaotic, a criss-cross of
lines. Fatigue fluctuates like an uncontrolled large marble. Other studies [15,
16] support this finding. 
Results in this dissertation showed an average highest level of fatigue on
day 3 from the start. For the 28 day regimens another distinct peak was seen
around day 11. As in the study of Richardson et al. [17], the pattern of fatigue
appeared to reflect the drug administration. A relatively larger number of patients
experienced peak fatigue levels before day 5. The first days after treatment with
chemotherapy are the worst [11, 17-20]. The type of chemotherapy has a significant
impact on the course of fatigue. The course of fatigue in the CMF group was
significantly different compared to the doxorubicin regimens. The fatigue peak in
the CMF group was lower. Women taking cyclophosphamide orally experienced
the peak level of fatigue significantly later. 
Impact on daily living activities
In this dissertation a relatively large group, about 15% to 35% of the sample,
reported that fatigue interfered to a large extent with their daily living activities.
Fatigue has a strong impact on daily functioning. This finding is supported by
previous studies [18, 21, 22]. For healthy individuals, fatigue seems to maintain
a healthy balance between rest and activity. It might be a protective, sometimes
even pleasant, regulatory response to physical or psychological stress [23]. For
patients with cancer, fatigue becomes a chronic and unpleasant sensation [24],
which can be a major obstacle to maintaining normal daily activities and quality
of life. The interference with daily functioning is highly important and has been
recognised, also in this dissertation. It is clear that, in our study, for significantly
more patients fatigue interferes to a large extent with their daily living activities
after the first infusion of chemotherapy. During chemotherapy this group grows
significantly. After completion of chemotherapy this group shrinks. At the end of
the study, the group with strong interference is similar in size to the group at the
start of chemotherapy. 
Depressive symptoms and fatigue
This dissertation reports that about 20% of the sample can be classified as suffe-
ring from a depressive syndrome during as well as after adjuvant chemotherapy
treatment. Fatigue and depressive symptoms have a positive relationship during
the whole study period. Visser and Smets [25] found in their study a moderate
relation. Other studies [26-29] in breast cancer patients receiving chemotherapy
showed also a positive relationship between depression and fatigue. That fatigue
and depression are related is beyond doubt, but the interpretation of this relation
is, however, complicated [25]. The symptoms of fatigue and depression overlap.
In addition, fatigue is one of the key symptoms of depression and may be the
result of depressed mood. On the other hand, a person who continuously perceives
his or her energy as insufficient may become depressed. Cancer fatigue and
depression may co-occur without having a causal relationship, because they can
both originate from the same pathology [25].  
Physical and psychological distress
During the first four measurements the effect of physical distress on psycho-
logical distress is larger than the effect vice versa. This does not come as a
surprise, knowing that chemotherapy affects cells, including healthy cells, in
the body. Patients are busy having treatments, rather than come to terms with
sorrow at that same period of time. For the last measurement, which was taken
three months after completion of the chemotherapy treatment, the opposite
holds: the effect of the psychological distress on physical distress has become
larger than the effect vice versa. The result sounds very reasonable, as the body
physically rehabilitates after completion of the treatment of chemotherapy.
Besides, patients might have more time to reflect then. According to the
literature, surgery of the breast has a negative impact on body image [30, 31].
Moreover, the loss of a breast can have important psychological effects on women
[12]. The feelings could be suppressed during the chemotherapy treatment. It is
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also possible that patients then realise what they were going through. Another
approach is that many patients experience ambivalence at the end of
chemotherapy. Patients are happy to be finished, but they are afraid they should
keep doing something to prevent a recurrence [32]. 
Factors relating to general fatigue
A model of variables that influence fatigue in breast cancer patients was developed
based on literature review and previous work of the authors. 
Both physical and psychological distress are important predictors of general
fatigue. The influence of these factors was expected and thus confirms previous
findings [11]. It is still not clear whether the symptoms, such as depression and
anxiety, cause the fatigue or vice versa. Qualitative research should give more
information. 
Treatment factors do not influence general fatigue at all, whereas the social
aspect seems to be of great value. This is observed in the influence of several
variables of demographic or social nature on general fatigue. For example, after
completion of adjuvant chemotherapy general fatigue was influenced by marital
status: women living alone were more fatigued than women living with their
spouse. The fact that women with a partner reported less fatigue might be
dependent on whether there is tangible support [2]. It is possible that women
living alone received more support from others during adjuvant chemotherapy
than afterwards. After completion of the treatment of chemotherapy, the support
could be diminished because no treatment was received and therefore transport
to the outpatients department as well as support during the visit and afterwards
were not needed anymore. Moreover, patients feel normal and look better after
completion of adjuvant chemotherapy which could suggest to the social
environment that women living alone need little or no support and therefore they
do not get support. Courtens et al. [33] reported similar findings in a study with
different types of cancer. Here, the expectation of others with respect to the
patient and/or limited knowledge they have about chemotherapy could play an
important role. The effect of everyday social support on general fatigue seems to
be getting stronger during the study. After completion of chemotherapy there is a
strong significant effect, meaning that higher everyday social support leads to less
fatigue. Similar effects were found by other authors. The author of an early study
[34] had reported that the uncertainties and fears experienced by a person
diagnosed with cancer are likely to result in an enhanced need for social support. 
In our study a significant influence, in the last two measurements, between
an active coping strategy and general fatigue was found. Patients who are
inclined to take an active stance in problem situations experience more fatigue
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than those who did not. Van den Akker et al. [35] found a similar result in their
study in primary care subjects, using the same measurement instrument
reporting an association between an active coping style and the occurrence of
multimorbidity. According to the authors, this is likely to be a result rather than
a cause of multimorbidity, subjects with multiple pathology being more apt to
deal actively with problems because their (health) problems are less easy to
avoid [35]. 
Theoretical reflections regarding the model
In chapter 1, the introduction chapter, an expected simplified model of fatigue
and its related factors was presented. This model was based on a limited number
of studies, including less well specified studies. Chapter 2 described a model of
fatigue and its related factors based on the literature. Only studies on breast
cancer receiving adjuvant chemotherapy were included. In both chapters, 1 and
2, fatigue was presented in the centre of the model. Note that no different
dimensions were taken into account. An addition in the model of chapter 2
compared to the model in chapter 1 is the expected mutual relationship between
physical symptom distress and psychological symptom distress. Noticeably, the
model in chapter 2 shows that in general the separate relationships between
fatigue and the following factors, demographic factors, disease/physical factors,
social factors, coping factors and treatment factors, are unclear or nil. On the
other hand, the relationship between fatigue and physical or psychological
symptom distress seems to be unequivocal. The model based on literature and
previous work of authors, presented in chapter 7, shows similar characteristics.
Note that fatigue in the model which is tested, called general fatigue, is one of
the five dimensions of fatigue of the MFI-20 [5]. The model is therefore restricted
and incomplete. In the final model, Maastricht Fatigue Model (MFM), (general)
fatigue is seen as a part of the physical symptom distress and for that reason is
not a central variable anymore. The well-being of a patient consists of a physical
and a psychological part. In the literature the outcomes of studies indicate that
several symptoms are interrelated in a network of symptoms [11], which is also
seen and expected in the model in chapter 2. By removing (general) fatigue from
the centre, the authors emphasise the relationships between fatigue and physical
distress as well as psychological distress. 
Methodological reflections
Course of fatigue (longitudinal studies)
The literature review (chapter 2) examined different studies with cross-sectional
designs or longitudinal designs on fatigue in breast cancer patients receiving
adjuvant chemotherapy. One of the conclusions is that there is a lack of studies
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on fatigue both during and after receiving adjuvant chemotherapy and between
two cycles of adjuvant chemotherapy. This dissertation determines the course of
fatigue in breast cancer patients during (at the first, third and fifth cycle) as well
as after (4 and 12 weeks after completion) receiving adjuvant chemotherapy
and between two cycles of adjuvant chemotherapy. The longitudinal designs
address the development of fatigue over time. Patients were used as their own
gold standard, which made it possible to show how the fatigue level develops.
A limitation is that it is still unknown whether the fatigue assessed at the time
points can be regarded as normal fatigue. Everyone experiences fatigue on daily
basis. No healthy control group was involved to compare fatigue levels. 
A relatively large sample, 157 patients, was studied for over a half year. The
response rate at the end of the study, 12 weeks after completion of adjuvant
chemotherapy, was very good (97%). Previous studies show that the time span
after completion of chemotherapy considered in our study is most likely too short
[27, 36, 37]. It might be that patients needed longer to recover from the
treatments or had to cope with the treatment process they had undergone. It
should also be noted that women might be fatigued before starting any treatment.
Cimprich [7] found a prevalence of fatigue of 77% before primary surgery. The
increased fatigue in patients before the start of chemotherapy may reflect
lingering physical and psychological stress associated with having recently
undergone breast cancer surgery [3]. The Multidimensional Fatigue Inventory
(MFI-20) was used to assess the course of fatigue [5]. This 20-item questionnaire,
especially designed for cancer patients, consists of five dimensions. The results of
the different dimensions give detailed information regarding fatigue. The fatigue
scores, the MFI-20 scores, could not be compared with other groups (like psychology
students, soldiers) published in the measurement instrument or with other studies,
because no raw fatigue scores were published. Future research should include
this information in their publication. 
The response rate of the study between two cycles of adjuvant chemotherapy
in a relatively large sample (n = 155) is also very high. About 95% of the diaries
returned (97%) were used in the analyses. Patients had to report their experience
of fatigue in a diary, the Shortened Fatigue Questionnaire, on a daily basis
between the third and fourth treatment with adjuvant chemotherapy. Future
research should include measurement points between more cycles to investigate
possible differences. This study on the development of fatigue between two
cycles is one of the first large scale examinations. Fatigue was studied as a
unidimensional concept. To enhance the understanding of fatigue, a complex
and subjective phenomenon, further research should include dimensions of
fatigue. 
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The development of a model (based on data of 5 cross-sectional studies)
A model of variables that influence fatigue in breast cancer patients was
developed based on literature review and previous work of the authors. In a
prospective cohort study the model was tested. The final model, presented in
chapter 7, based on data of 157 breast cancer patients during as well as after
receiving adjuvant chemotherapy, is quite unique. An advantage is that the final
model is based on a huge quantity of data. The data consist of five cross-sectional
studies (the five measurements separately). Moreover, the final model incorporates
information elicited both during and after receiving adjuvant chemotherapy,
giving a broad scope to the model. 
The Utrecht Coping List (UCL) [38, 39], which was used, was not satisfactory.
The internal consistency of the subscales ‘avoiding’ and ‘palliative coping’ were
so low that these were not included in the analysis, which limited the findings in
this study. No complete overview of the effects of coping styles can therefore be
given. Future studies should consider using a different instrument. 
Results of the studies can be generalised, though the lack of homogeneity
of the doxorubicin group, in which five different chemotherapy regimens are
represented, must be mentioned. This may have affected the power to detect
more changes across time in fatigue for this particular group. Additionally, it
should be noted that in our studies many different analyses were executed,
which might enhance the chance of significant results. 
Note that patients were interviewed five times in relatively a short period
of time. They were not interviewed at each treatment of chemotherapy, which
limited the overview of the fatigue pattern during chemotherapy. At each
interview, they had to answer the same questions, which might have led to a
certain habituation. Moreover, different interview styles, face-to-face interviews
and interviews by phone, were executed. The internal consistency of both ways
of administering the questionnaire is good. It is unknown how these methods
may bias the results obtained regarding respondents’ fatigue. 
Implications for practice and future research
Improved understanding of the courses of fatigue in breast cancer patients receiving
chemotherapy will better equip health care providers to understand and address the
needs of these patients. The existing information about fatigue for patients can be
adjusted and specified. Health care providers should pay attention to the possibility
of the patients experiencing depressive symptoms. Recognition and treatment of
these symptoms can influence the course of the chemotherapy treatment as well as
the quality of life during and after the treatment of chemotherapy positively.
The pattern of fatigue is unusual and chaotic. This knowledge must be
included in the education for healthcare providers, like oncologists and oncology
207
General discussion
nurses, which can contribute to a better transfer of information with respect to
the nature of fatigue to patients. Patients who know what they can expect will be
less overwhelmed. Understanding from family members and others can ease the
experience of fatigue. Future research must be combined with qualitative
research to try to clarify the chaotic pattern. Oncology nurses must routinely give
information to patients about a probable peak of fatigue in the first days after an
infusion with chemotherapy. With this knowledge patients can prepare themselves;
for example, they can adjust their activities of daily life. 
Understanding of the relation between different variables and fatigue in breast
cancer patients receiving adjuvant chemotherapy as well as after completion of
chemotherapy could help health care providers to recognise the needs of these
patients. Future research should include interventions, based on the model presented
in this study, addressing how patients can maintain or improve their quality of life
during as well as after adjuvant chemotherapy. Health care providers should
detect psychological distress in an early stage. For example, health care providers
could incorporate a short depression list as a standard part of their anamnesis to
give a quick indication if a patient suffers from depressive symptoms. Moreover,
an intervention for diminishing psychological distress should be developed. 
The model presented in chapter 7 should be tested in patients with other
types of cancer. Note that the model can also be tested in men or in mixed groups.
Finally, the model can be tested in other patients groups such as rheumatic patients
and patients with chronic fatigue syndrome. 
Further research, in which an assessment at the last treatment of chemotherapy
is included, needs to conclude whether there is really a late effect in the CMF
group. In addition, future studies should include a comparison group of healthy
women. Fatigue tends to decline after completion of chemotherapy, but whether
the fatigue levels can be regarded as ‘normal’ is not yet clear. Moreover, research
involving the trajectory preceding adjuvant chemotherapy and a longer study
period afterwards needs to be executed. 
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Fatigue is a major concern in patients with cancer. Little is known about fatigue
in cancer, despite the high prevalence and its profound effects on patients’ quality
of life. It is recognised that cancer patients frequently become fatigued when
undergoing treatment, notably chemotherapy. Because breast cancer is the most
frequently occurring malignancy in women in the Netherlands and adjuvant
chemotherapy is part of the standard treatment in a large subset of these patients,
we analysed fatigue in relation to chemotherapy in breast cancer patients. 
Chapter 2 introduces the concept of fatigue, and presents a literature review on
prevalence and course of fatigue in breast cancer patients receiving chemotherapy.
Fatigue is one of the most common side-effects of chemotherapy. In the literature
high and fluctuating prevalence rates of fatigue have been described not only
during but also after adjuvant chemotherapy. The intensity of fatigue seems to be
stable throughout the treatment cycles, despite the general perception that more
chemotherapy treatment leads to greater fatigue. The first two days after a
chemotherapy treatment seem to be the worst period. In addition, factors relating
to fatigue are described. Symptom distress, whether it is physical or psychological,
plays a crucial role in experiencing fatigue. The outcomes of the studies indicate
that several symptoms are interrelated in a network of symptoms. Stage of
disease seemingly does not have significant impact on fatigue. The influence of
type of surgery is debatably. Factors such as changes in weight, menopausal
symptoms, coping, social support, and biochemical changes have been mentioned
in the literature as potentially contributing to fatigue. Results are conflicting and
need further study. 
There is a lack of studies that investigate fatigue in breast cancer patients
during as well as after receiving adjuvant chemotherapy. It is obvious that breast
cancer patients experience fatigue, but the course of fatigue during and after
adjuvant chemotherapy is unclear. Besides, it is uncertain which determinants
influence fatigue during this course. Moreover, the nature of ‘chemotherapy-
related fatigue’ is less well studied. 
Chapters 3, 4 and 5 focus on the course of fatigue in 157 breast cancer patients
during the first, third and fifth cycles of adjuvant chemotherapy and four and
twelve weeks after the last cycle. The chemotherapy the patients received was
either a doxorubicin-containing schedule, or cyclophosphamide, methotrexate
and 5-fluorouracil (CMF). The Multidimensional Fatigue Inventory (MFI-20) was
used to assess the course of fatigue. This questionnaire consists of five subscales
based on different dimensions: general fatigue, physical fatigue, reduced
activity, reduced motivation and mental fatigue. In each of the chapters 3, 4 and
5, one or two dimension(s) are described, each assessed in separate studies. 
Chapter 3 determines the prevalence of fatigue and the courses of general and
physical fatigue as a function of chemotherapy. The prevalence of fatigue increases
significantly after the start of chemotherapy, whereas after the end of treatment
with chemotherapy it seems to decline. The courses of general and physical
fatigue are to a large extent similar. A different impact of the chemotherapy
regimen on the course of fatigue is found. In the doxorubicin group a direct
increase in fatigue is found. In the CMF group a moderate direct increase occurs,
followed by a delayed strong increase. An increase in fatigue is associated with a
decrease in daily functioning. At all measurements fatigue is affected by type of
operation, such that women with a mastectomy are more fatigued than women who
had undergone a lumpectomy. Receiving radiotherapy also leads to an increase in
fatigue. 
Chapter 4 elaborates on the course of fatigue with respect to cognitive symptoms
(scale ‘mental fatigue’) as well as the motivation to start any activity (scale ‘reduced
motivation’), as a function of chemotherapy. The course of mental fatigue and
motivation is not affected by the type of chemotherapy. The course of mental fatigue
and motivation varies, but seems to be stable during the treatment of chemotherapy.
After the completion of chemotherapy a weak improvement is seen. 
The Center for Epidemiological Studies Depression Scale (CES-D) was
used to measure depressive symptoms. Many patients experienced depressive
symptoms during the study. These symptoms correlate with both dimensions of
fatigue. Health care providers should be aware of the high numbers of patients
experiencing depressive symptoms during and after the treatment of chemotherapy. 
At all assessment points mental fatigue was influenced by type of
operation where women with a mastectomy are significantly more mentally
fatigued than women that have undergone a lumpectomy, but nevertheless they
are significantly more motivated to start any activity. 
Further research should include the trajectory preceding adjuvant chemotherapy
and a longer study period afterwards. Moreover, the exact influence of the
variables ‘age’, ‘marital status’, ‘number of treatments’ and ‘the interval between
the operation and the first treatment of chemotherapy’ on fatigue is unclear and
needs further study. 
Chapter 5 reports the course of the activity level, perceived as a dimension of
fatigue, as a function of chemotherapy within the breast cancer population
receiving adjuvant chemotherapy. In addition, the course of the interference of
fatigue with daily activities in this population is determined. The activity level
seems to be rather stable during the treatment with chemotherapy. After completion
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of chemotherapy an improvement is observed. The activity level reported at the
first and the last measurement does not differ significantly. The course of the
activity level is not affected by type of chemotherapy regimen. Age, having
children and the stage of breast cancer seem to be important determinants of
the course of the activity level. At all measurement points women with a
mastectomy are significantly more hampered in their activity level than women
that had undergone a lumpectomy. The longer the duration of radiotherapy, the
less active, and the longer the time interval between the last radiotherapy session
and the assessment point, the more active patients are at that assessment point.
A phenomenon not easy to explain is that the activity level in women who had
received in total more chemotherapy treatments was significantly less diminished
than those who had received fewer treatments. 
The revised Piper Fatigue Scale is used to examine the behavioural changes
in the interference of fatigue with activities of daily living. During the study
period, in about 15% to 35% of the patients in the sample, fatigue interferes
considerably with their daily living activities. Furthermore, the interference of
fatigue with activities in daily life first increases after the start of chemotherapy
and decreases after completion of chemotherapy.
With this knowledge health care providers can inform patients about what
they can expect. Further research should include the trajectory preceding
chemotherapy as well as a healthy control group. 
Chapter 6 describes the course of fatigue in patients with breast cancer between
two cycles of adjuvant chemotherapy, from the day of administration until the
day of the next infusion. One hundred and fifty-one patients reported their
experience of fatigue in a diary, the Shortened Fatigue Questionnaire, on a daily
basis between the third and fourth treatment with adjuvant chemotherapy.
Patients were treated with either a doxorubicin containing schedule or with
CMF. Depending on the chemotherapy regimen, patients filled in 21 or 28 days
of the diary. In the 28-day regimens, infusions were given on day 1 and day 8.
The days after completion of the third and the start of the fourth treatment with
chemotherapy were analysed statistically. The hypothesis that the maximum
fatigue score occurs in the first four days after treatment was tested. 
A chaotic pattern of fatigue between the two cycles of chemotherapy
emerges. Smooth curves (splines) show the average highest level of fatigue on
day 3 from the start. For the 28-day regimens another distinct peak is seen
around day 11. 
A relatively larger number of patients experience peak fatigue levels before
day 5. Most of these patients report day 3 as the worst day. The course of fatigue
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in the CMF group is significantly different compared to the doxorubicin regimens.
The fatigue peak in the CMF group is lower. Women taking cyclophosphamide
orally experience the peak level of fatigue significantly later. Influences of other
variables were not observed in any chemotherapy group. 
Improved understanding of the nature and course of fatigue can enable
health care providers to better inform patients about what they may expect. Future
research should include interventions aimed at reducing or coping with fatigue. 
Chapter 7 outlines a model of variables that influence fatigue in breast cancer
patients based on literature review and the previous chapters. In this chapter the
model is tested in a sample of 157 breast cancer patients. One model (for general
fatigue) for all five time points is developed using EQS, a computer program for
linear structural equation modelling. In the identifiable and testable model two
latent variables, (1) physical distress (measured by two observed indicators: general
fatigue and physical symptom distress), and (2) psychological distress (measured
by two observed indicators: depression and psychological symptom distress), 
are included. Physical distress is predicted by the variables: every day social 
support, active as coping strategy, age, marital status, job, stage of breast cancer,
chemotherapy regimen, Hb level and number of chemotherapy treatments.
Psychological distress is predicted by age and everyday social support. 
Physical and psychological distresses are important predictors of general
fatigue. General fatigue imbedded in a network of symptoms is not unlikely
anymore. The social aspect seems to be of great importance as well. This is
observed through the influence of several demographic or social variables on
general fatigue. 
The knowledge that chemotherapy affects cells, including healthy cells, in the
body could explain that the physical distress compared to psychological distress is
larger during the first four assessment points. Time to reflect and cope with the
whole situation occurred after completion of chemotherapy, which could account
for the larger effect of psychological distress at the last measurement point. 
Improved understanding of the relation between different variables and
fatigue in breast cancer patients receiving adjuvant chemotherapy as well as
after completion of chemotherapy can better equip health care providers to
understand and address the needs of these patients. Future research should
include interventions, based on the model presented in this study, addressing
how patients can maintain or improve their quality of life both during and after
adjuvant chemotherapy.
Chapter 8 discusses the main findings of the various studies and presents some
methodological reflections. The main findings focus on the prevalence of fatigue,
course of fatigue and the influence of variables on fatigue during and after
adjuvant chemotherapy. Methodological criticism may include the absence of a
healthy control group, time span of the study, the assessment points and the
different chemotherapy regimens in the doxorubicin group. The chapter ends by
discussing implications of our findings for practice and providing topics for
future research. 
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Vermoeidheid is een grote zorg voor kankerpatiënten. Weinig is bekend over
vermoeidheid bij kanker ondanks de hoge prevalentie en haar diepgaande
effecten op de kwaliteit van leven van patiënten. Het wordt erkend dat
kankerpatiënten frequent vermoeid worden wanneer zij een behandeling onder-
gaan. Dit geldt voornamelijk voor chemotherapie. Nu in Nederland borstkanker
één van de meest voorkomende kwaadaardige tumoren bij vrouwen is en
adjuvante chemotherapie voor het grootste gedeelte deel uitmaakt van de
standaardbehandeling, hebben we vermoeidheid bij borstkankerpatiënten in
relatie tot chemotherapie onderzocht. 
Hoofdstuk 2 introduceert het concept ‘vermoeidheid’. In dit hoofdstuk wordt
bovendien een literatuurstudie naar de prevalentie en het verloop van vermoeid-
heid bij borstkankerpatiënten die chemotherapie ondergaan, weergegeven.
Vermoeidheid is één van de meest voorkomende bijwerkingen van chemo-
therapie. In de literatuur worden niet alleen tijdens adjuvante chemotherapie
hoge en variërende vermoeidheidsprevalentie cijfers gevonden, maar ook na
afloop van de adjuvante chemotherapiebehandeling. De intensiteit van
vermoeidheid lijkt stabiel tijdens de chemokuren, hoewel men in het algemeen
ervan uitgaat dat meer chemokuren leiden tot meer vermoeidheid. De eerste
twee dagen na de chemokuur lijkt de slechtste periode te zijn. Bovendien
worden factoren gerelateerd aan vermoeidheid beschreven. Klachten, of deze
nu fysiek of psychisch van aard zijn, spelen een belangrijke rol in het ervaren
van vermoeidheid. De resultaten van studies wijzen er op dat verscheidene
symptomen met elkaar in verband staan, in een netwerk van symptomen. Het
stadium van de ziekte lijkt geen significante invloed te hebben op vermoeidheid.
De invloed van de type operatie wordt bediscussieerd. Factoren, zoals
gewichtsveranderingen, menopausale symptomen, coping, sociale steun en
biochemische veranderingen worden in de literatuur als mogelijke bijdragen aan
de vermoeidheid gezien. De resultaten zijn tegenstrijdig en moeten verder
worden onderzocht. 
Aan studies over borstkankerpatiënten tijdens en na afloop van adjuvante
chemotherapiebehandeling bestaat een tekort. Het is duidelijk dat borstkanker-
patiënten vermoeidheid ervaren, maar hoe het verloop van vermoeidheid is
tijdens en na afloop van een adjuvante chemotherapie-behandeling is onduidelijk.
Bijvoorbeeld: welke determinanten beïnvloeden het verloop van vermoeidheid?
De aard van chemotherapie gerelateerde vermoeidheid is bovendien onvoldoende
onderzocht. 
De hoofdstukken 3, 4 en 5 richten zich op het verloop van vermoeidheid bij
157 borstkankerpatiënten tijdens (bij de eerste, derde en vijfde chemokuur) en
na afloop (4 en 12 weken na de laatste chemokuur) van een adjuvante
chemotherapiebehandeling (doxorubicinegroep of CMF (cyclofosfamide,
methotrexate en 5-fluorouracil) groep). De Multidimensionele Vermoeidheids
Index (MVI-20) wordt gebruikt om het verloop van vermoeidheid vast te stellen.
Deze vragenlijst bestaat uit vijf subschalen en is gebaseerd op verschillende
dimensies: algemene vermoeidheid, lichamelijke vermoeidheid, reductie in
activiteit, reductie in motivatie en mentale vermoeidheid. In elk hoofdstuk (3, 4
en 5) worden één of twee dimensies, die elk in afzonderlijke studies zijn
onderzocht, beschreven. 
Hoofdstuk 3 beschrijft de prevalentie van vermoeidheid en het verloop van
algemene en lichamelijke vermoeidheid als functie van chemotherapie. De
prevalentie van vermoeidheid neemt na de start van de chemotherapie-
behandeling significant toe. Na afloop van de chemotherapiebehandeling
lijkt de prevalentie te dalen. Het verloop van algemene en lichamelijke
vermoeidheid is voor een groot deel hetzelfde. Een verschillende invloed van
de chemokuren op het verloop van vermoeidheid wordt aangetroffen. In de
doxorubicine groep is een directe toename van vermoeidheid gevonden. In de
CMF groep werd na de start een gemiddelde toename gevonden, die gevolgd
werd door een vertraagd sterke toename. Een toename van vermoeidheid wordt
geassocieerd met een afname in het dagelijks functioneren. In elke meting
wordt vermoeidheid beïnvloed door het type operatie: vrouwen die een
mastectomie hebben ondergaan zijn meer vermoeid dan vrouwen die een
lumpectomie hebben ondergaan. Behandeld zijn met radiotherapie leidt ook
tot een toename van vermoeidheid. 
Hoofdstuk 4 gaat over het verloop van vermoeidheid dat refereert aan zowel
cognitieve symptomen (subschaal ‘mentale vermoeidheid’) als de motivatie om
een activiteit te beginnen (subschaal ‘reductie in motivatie’) als functie van
chemotherapie. Het verloop van mentale vermoeidheid en motivatie wordt niet
beïnvloed door het type chemokuur. Het verloop van mentale vermoeidheid en
motivatie varieert, maar lijkt stabiel te zijn tijdens de chemotherapiebehandeling.
Na afloop van de chemotherapiebehandeling is een lichte verbetering te zien. De
‘Center for Epidemiological Studies Depression Scale’ (CES-D) wordt gebruikt om
depressieve symptomen te meten. Veel patiënten ervaren depressieve symptomen
tijdens de studie. Deze symptomen zijn gecorreleerd met beide dimensies van
vermoeidheid. Gezondheidswerkers moeten zich bewust zijn van het hoge aantal
patiënten dat depressieve symptomen tijdens en na afloop van de chemotherapie-
behandeling ervaart. In elke meting wordt mentale vermoeidheid beïnvloed
222
Samenvatting
223
Samenvatting
door het type operatie: vrouwen die een mastectomie ondergaan zijn
significant meer mentaal vermoeid dan vrouwen die een lumpectomie hebben
ondergaan, maar niettemin zijn zij significant meer gemotiveerd om een activiteit
te starten. 
Vervolgonderzoek zou het traject vóór adjuvante chemotherapie-behandeling
moeten omvatten en een langere periode na afloop. Bovendien is de invloed
van leeftijd, burgerlijke staat, aantal kuren en het interval tussen de operatie en
de eerste chemokuur op vermoeidheid onduidelijk en moet dit verder onderzocht
worden. 
Hoofdstuk 5 rapporteert het verloop van het activiteitsniveau, dat als een
dimensie van vermoeidheid wordt gezien, als een functie van chemotherapie
binnen de borstkankerpopulatie die chemotherapiebehandeling ondergaat.
Daarnaast wordt het verloop van de belemmering van vermoeidheid op
dagelijkse activiteiten in deze populatie vastgesteld. Het activiteitenniveau blijkt
stabiel tijdens de chemotherapiebehandeling. Na afloop van de chemotherapie-
behandeling wordt een verbetering geconstateerd. Het activiteitenniveau van 
de eerste en laatste meting verschilt niet significant. Het verloop van het
activiteitenniveau wordt niet beïnvloed door het type chemokuur. Leeftijd, 
het hebben van kinderen en het stadium van borstkanker blijken belangrijke
determinanten van het verloop van het activiteitenniveau. In elke meting worden
vrouwen die een mastectomie hebben ondergaan significant meer gehinderd in
hun activiteitenniveau dan vrouwen die een lumpectomie hebben ondergaan.
Hoe langer men radiotherapie krijgt, hoe minder actief men is en hoe langer de
tijd tussen de laatste radiotherapie sessie en de meting, hoe actiever patiënten
zijn. Een fenomeen dat niet gemakkelijk te verklaren is dat het activiteitenniveau
van vrouwen die in totaal meer chemokuren hebben gekregen significant
minder afnam dan zij die minder chemokuren kregen. 
De gereviseerde ‘Piper Fatigue Scale’ wordt gebruikt om gedrags-
veranderingen door de belemmeringen van vermoeidheid op dagelijkse activiteiten
te onderzoeken. Tijdens de onderzoeksperiode is ongeveer 15 tot 35 procent van
de steekproef aanzienlijk door vermoeidheid belemmerd in haar dagelijks leven
activiteiten. Bovendien neemt de belemmering van vermoeidheid op dagelijks
leven activiteiten eerst toe na de start van de chemotherapiebehandeling en
neemt deze af na afloop van de chemotherapie-behandeling. Met deze kennis
kunnen gezondheidszorgmedewerkers patiënten informeren over wat ze kunnen
verwachten. Vervolgonderzoek zou het traject vóór de chemotherapiebehandeling
en een gezonde controle groep moeten omvatten. 
Hoofdstuk 6 beschrijft het verloop van vermoeidheid van borstkankerpatiënten
tussen twee adjuvante chemotherapie cycli, van de dag van de toediening tot de
dag van het volgende infuus. Een steekproef van 151 patiënten rapporteerde
dagelijks hun ervaring van vermoeidheid tussen de derde en vierde adjuvante
chemokuur in een dagboekje, de ‘Shortened Fatigue Questionnaire’. Patiënten
werden behandeld met een doxorubicine bevattende kuur of met CMF.
Afhankelijk van de chemotherapiebehandeling vulden patiënten 21 of 28
dagen van het dagboekje in. De infusen van de kuren van 28 dagen werden op
dag 1 en op dag 8 gegeven. De dagen na afloop van de derde chemokuur tot
aan de start van de vierde kuur werden statistisch geanalyseerd. De hypothese
dat de maximum vermoeidheidsscore in de eerste vier dagen na de chemokuur
plaats vindt werd getest. 
Er doet zich een chaotisch vermoeidheidspatroon tussen de twee chemo-
kuren voor. Gladde (splines) curves laten een gemiddeld hoogste niveau van
vermoeidheid zien op dag 3 vanaf de start. Voor de kuren met 28 dagen wordt
een andere top rond dag 11 gevonden. Een relatief groot aantal patiënten ervaart
de vermoeidheidspiek vóór dag 5. De meeste patiënten rapporteren dag 3 als de
slechtste dag. Het verloop van vermoeidheid in de CMF groep is significant
verschillend vergeleken met de doxorubicine kuren. De vermoeidheidspiek in de
CMF groep is lager. Vrouwen die cyclofosfamide oraal nemen, ervaren de
vermoeidheidspiek significant later. Invloeden van andere variabelen zijn niet
geobserveerd in geen van de chemotherapiegroepen. Verbeterd begrip van de
aard en verloop van vermoeidheid kan gezondheidsmedewerkers beter uitrusten
om patiënten te informeren over wat ze zouden kunnen verwachten.
Vervolgonderzoek zou interventies moeten bevatten met als doel vermoeidheid te
verminderen of er mee om te kunnen gaan. 
Hoofdstuk 7 schetst een model met variabelen die vermoeidheid bij borstkanker-
patiënten beïnvloeden en dat gebaseerd is op een literatuurstudie en voorafgaand
werk van de auteurs. In dit hoofdstuk wordt het model getest in een steekproef
met 157 borstkankerpatiënten. Eén model (voor algemene vermoeidheid) voor
alle vijf de metingen is ontwikkeld waarbij EQS werd gebruikt, een computer-
programma voor het schatten van lineaire structurele vergelijkingen met latente
variabelen. In het model waarvan de parameters identificeerbaar en schatbaar
zijn, worden twee latente variabelen verondersteld: (1) fysieke klachten (gemeten
door twee geobserveerde indicatoren: algemene vermoeidheid en lichamelijke
klachten), en (2) psychische klachten (gemeten door twee geobserveerde
indicatoren: depressie en psychische klachten). Fysieke klachten worden voorspeld
uit de variabelen: elke dag sociale steun, actief zijn als coping strategie, leeftijd,
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burgerlijke staat, werk, stadium van borstkanker, type chemokuur, haemoglobine
niveau en het aantal chemokuren. Psychische klachten worden voorspeld uit
leeftijd en dagelijkse sociale steun. Fysieke en psychische klachten zijn
belangrijke voorspellers van algemene vermoeidheid. Het is niet meer
onwaarschijnlijk dat algemene vermoeidheid deel uitmaakt van een network
van symptomen. Het sociale aspect is ook van grote waarde. Dit wordt
uitgedrukt door de invloed van verscheidene demografische variabelen of
sociale aard op algemene vermoeidheid. De fysieke klachten vergeleken met
psychische klachten zijn groter tijdens de eerste vier metingen. Dit zou kunnen
worden verklaard door de wetenschap dat chemotherapie cellen in het lichaam
aanvalt, ook gezonde cellen. Tijd om te reflecteren en om te gaan met de hele
situatie krijgen patiënten na afloop van de chemotherapiebehandeling. Dit zou
het grotere effect van psychische in de laatste meting kunnen verklaren. Door
een verbeterd begrip van de relatie tussen verschillende variabelen en
vermoeidheid van borstkankerpatiënten die adjuvante chemotherapie ondergaan,
alsook na afloop van de chemotherapiebehandeling, kunnen gezondheidszorg-
medewerkers zich beter uitrusten deze patiënten te begrijpen en zich te richten
naar hun behoeftes. Vervolgonderzoek zou interventies moeten omvatten die op
het model van deze studie zijn gebaseerd en aangeven hoe patiënten hun kwaliteit
van leven kunnen handhaven of verbeteren tijdens en na afloop van adjuvante
chemotherapiebehandeling. 
In hoofdstuk 8 worden de belangrijkste resultaten van de verschillende studies
besproken en worden methodologische kanttekeningen gemaakt. De belangrijkste
resultaten richten zich op de prevalentie van vermoeidheid, verloop van
vermoeidheid en de invloed van variabelen op vermoeidheid tijdens en na afloop
van adjuvante chemotherapiebehandeling. Methodologische kanttekeningen
betreffen de afwezigheid van een gezonde controle groep, de tijdspanne van de
studie, de meetpunten en de verschillende chemokuren in de doxorubicine groep.
Het hoofdstuk eindigt met een discussie over aanbevelingen voor de praktijk. Verder
worden onderwerpen voor vervolgonderzoek gegeven.
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